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Abstract 
 
The misuse of anabolic androgenic steroids in sports remains a significant concern. 
They are exploited to enhance physical performance, and as a result, they are listed as 
prohibited substances by the world anti-doping agency (WADA). Detection of steroids is 
important to maintain fair play in sports and to ensure that athletes are not jeopardising 
their long-term health.  
The human phase II steroid metabolites are mainly excreted in urine as 
glucuronide or sulfate conjugates. The routine screening methods require 
deconjugation of the phase II conjugates to produce the free steroids. The hydrolysis of 
steroid glucuronides is efficiently achieved by using E. coli β-glucuronidase enzyme. 
However, there is no robust method for hydrolysing steroid sulfates. Acid catalysed 
solvolysis is a general method of hydrolysis of steroid conjugates. However, this method 
is often unsuitable for routine anti-doping screening since it can degrade analytes of 
interest and generate a more complicated analytical matrix. Steroid sulfates are 
emerging as highly useful markers to detect AAS abuse, importantly as long-term 
markers that have the potential to improve the sensitivity and the retrospectivity of 
steroid screening. However, their routine detection would benefit from a robust steroid 
sulfatase for deconjugation, in a manner analogous to the β-glucuronidase enzyme. The 
arylsulfatase from Pseudomonas aeruginosa (PaS) is an enzyme capable of hydrolysing 
steroid sulfates and represents a good starting point for engineering a steroid sulfatase. 
However, this enzyme requires improvement in hydrolytic activity and substrate scope 
in order to be useful in an anti-doping context.  
This study aimed to improve the catalytic rate of PaS for the hydrolysis of steroid 
sulfates such as testosterone sulfate (TS) and to improve the substrate scope while 
maintaining the stability of the enzyme. These improvements were sought by applying 
semi-rational design to mutate amino acid residues neighbouring the enzyme active site 
by taking use of the crystal structure of PaS (1HDH) and the binding modes suggested 
by computational ligand protein docking. Mutagenesis was implemented on single 
residues and multiple residue sites and finally shuffling all the beneficial mutations. 
Screening was performed to test the steroid sulfate hydrolysis activity of these mutant 
libraries by employing LC-MS.  
 vii 
 
These libraries revealed the steroid sulfate binding pocket of PaS and screening of 
>10000 variants resulted in three mutants that showed an improvement in the catalytic 
efficiency (Vmax/ KM) of more than 150 times that of wild type PaS for TS hydrolysis. In 
addition, the substrate scope of steroid sulfates for PaS enzyme was increased and a 
modest improvement in thermostability was observed. The mechanistic involvement of 
E74 as a catalytic residue was proposed with the observation of mutants created on this 
residue.  
To apply the enzyme on real world samples, an untargeted screen was performed 
on pre- and post-administration testosterone propionate (TP) horse urine samples 
which identified three metabolites that could be potential markers for TP 
administration. This also revealed that PaS is compatible with urine matrices under the 
reaction conditions analogous to β-glucuronidase treatment in the anti-doping screens, 
making it a valuable steroid sulfatase for anti-doping applications. 
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Chapter 1:                              Introduction 
 
1.1 Anabolic androgenic steroids 
 
Steroids are a class of natural products that share a characteristic tetracyclic fused 
ring system with three cyclohexane rings (rings A, B and C) and one cyclopentane ring 
(ring D). The steroid structure usually contains methyl groups at C-10 and C-13 positions 
and may contain an alkyl side chain at C-17 position 1. Unless stated otherwise the 
stereochemistry of the substituents at the ring junction positions is 8β, 9α, 10β, 13β and 
14α with the stereochemistry at C-5 being variable. The structure of steroids is typified 
by testosterone in Figure 1.1. The steroids may contain various functional groups 
differing in stereochemistry and position and also the degree of unsaturation.  
 
 
 
 
 
 
 
Figure 1.1: Structure of testosterone (17β-hydroxyandrost-4-en-3-one) showing the 
IUPAC recommended atom and ring labelling 
 
Anabolic androgenic steroids (AASs) are substances that mimic testosterone (T), a 
naturally occurring steroid. They mediate their effects by binding to and activating the 
androgen receptors, that will facilitate muscle gain and strength (anabolic effects) and 
develop male sexual characteristics in both males and females (androgenic effects). The 
AASs are used clinically to treat wounds, burns, many forms of anaemia and steroid 
deficiency conditions such as delayed puberty 2, 3. They are also used to stimulate growth 
in the treatment of chronic wasting conditions such as cancers and AIDS where a rapid 
muscle gain is desired. However, the misuse of AASs can also result in adverse effects 
like permanent organ damage, reduced fertility, hypertension, psychiatric and 
behavioural disorders 3, 4.  
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Exploitation of steroids by athletes to enhance their physical performance, 
commonly known as doping, is a concern that has attracted increased attention in the 
past few decades. Administration of steroids can build muscle mass, reduce fatigue 
levels, increase the rate of recovery and consequently enhance the performance of the 
athlete. They have been classified as prohibited substances by the World Anti-Doping 
Agency (WADA) 5. The WADA classifies a substance as prohibited when it meets two of 
the three criteria listed as: a substance which has the potential to enhance or enhances 
sport performance, represents an actual or potential health risk to the athlete, or 
violates the spirit of sport. In addition to AASs, peptide hormones, growth factors, 
related substances and mimetics, hormone and metabolic modulators, diuretics and 
masking agents, are drug classes that could change the endogenous steroid profile or 
mask AAS abuse and which are also prohibited by WADA 5. As a result AASs have been 
outlawed by the major sporting organizations including the International Olympic 
Committee (IOC) 6. Anabolic steroids were added to the list of IOC’s banned substances 
in 1975 as a test considered reliable was developed based on radioimmunoassay 
techniques,4 and steroid testing was first conducted at the Montreal Olympics in 1976. 
Detection of steroid abuse in athletes frequently results in severe penalties such as 
retrospective disqualifications and the removal of medals or records.  
 
1.2 Steroid metabolism  
 
Steroids undergo a number of metabolic changes primarily in the liver but also in 
other tissues. These metabolic reactions are grouped into two phases, phase I and phase 
II, where both phases involve enzymatically controlled reactions that typically increase 
the polar nature of the steroid and facilitate excretion from the body. The two phases 
can occur in turn or independently from one another. Phase I metabolism involves 
oxidation, reduction or hydroxylation reactions that increase the hydrophilicity of the 
steroid. It is followed by phase II metabolism that involves conjugating the steroids or 
their metabolites with glucuronic acid, sulfate, amino acids, glutathione or methyl 
groups. These moieties typically serve to further increase the hydrophilicity 7, 8. The 
major human phase II metabolites are glucuronate and sulfate conjugated steroids. 
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Figure 1.2 shows representative metabolic pathways for testosterone leading to the 
formation of androsterone 3-glucuronide and epiandrosterone 3-sulfate. 
Glucuronylation in humans is catalysed by uridine 5’-
diphosphoglucuronosyltransferases (UGTs) and uses uridine-5’-diphosphoglucuronic 
acid (UDPGA) as the glucoronyl donor. Sulfation reactions are catalysed by 
sulfotransferases (SULTs) where 3′-phosphoadenosine 5′-phosphosulfate (PAPS) is used 
as the sulfate donor. Conjugation typically reduces the biological activity and the toxicity 
of the steroid and facilitates excretion. Nevertheless, cholestatic activities, that is the 
stagnation of bile flow and toxicities for some D-ring glucuronide conjugates such as the 
glucuronides of 17β-hydroxyestrogens, testosterone and dihydrotestosterone have 
been reported 9, 10.  Not all the steroids and their metabolites are excreted as conjugates, 
but it has been reported that the unconjugated fraction of steroids is less than 3% of the 
total amount of steroids excreted and therefore conjugation plays an important role in 
steroid metabolism and excretion 11.  
 
 
 
 
 
 
 
 
 
 
 
 
*Phase I metabolism reactions shown consist of enzymatically controlled multiple steps 
Figure 1.2: An exemplary metabolic pathways of testosterone. 
 
Different steroids follow different metabolic pathways. The main urinary 
metabolites after ingestion of T have been reported as the glucuronylated and sulfated 
conjugates of testosterone, androsterone, etiocholanolone, 5α-androstane-3α,17β-
UGT 
SULT 
Testosterone 
Sulfation 
Glucuronylation 
Androsterone 3-glucuronide 
Phase I 
Metabolism* 
Phase II 
Metabolism 
Epiandrosterone 3-sulfate 
Androsterone  
Epiandrosterone  
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diol, 5β-androstane-3α,17β-diol and epiandrosterone 12, 13. A recent study of 
testosterone metabolism by Piper et al. 12 has been performed by administration of 
deuterium labelled testosterone to four male volunteers and monitoring the deuterated 
metabolites over a period of eight days by hydrogen isotope ratio mass spectrometry 
(HIRMS). These results revealed some new insights to testosterone metabolism, 
including an unprecedented methylation, and importantly epiandrosterone 3-sulfate 
was identified as a long-term marker of testosterone administration. In addition to 
urinary excretion products, steroid sulfates such as dehydroepiandrosterone-3-sulfate 
(DHEAS) can also be found in plasma and endocrine tissues 14. Both DHEAS and DHEA 
are secreted in the human adrenal cortex and they act as pro-androgens involved in the 
biosynthesis and regulation of testosterone, a potent endogenous androgen 15, 16. 
Surveillance of steroid metabolism is important in the testing of doping in sports, 
as the starting steroids will be excreted in a modified inactivated form. For instance, 
testosterone administered by an athlete will be excreted in multiple forms after 
metabolism, such as the conjugated forms of androsterone, etiocholanolone, 
androstanediol, epiandrosterone and other metabolites in addition to the starting 
testosterone 12, 14.  
 
1.3 Detection of steroids 
 
The detection of the parent compound or at least one metabolite of the synthetic 
steroids such as methyltestosterone, stanozolol or oxandrolone provides evidence for 
doping 4, 17, 18 19. However, the situation is different for endogenous steroids such as 
testosterone. A number of markers to detect the illicit use of testosterone have been 
reported 11, 12, 20-22. A well-known biomarker for testosterone doping is the testosterone 
(T) to epitestosterone (ET) ratio (T/ET) of the glucuronylated fractions in urinary 
excretion. The secretion of epitestosterone, an inactive epimer of testosterone, is 
typically unchanged by the administration of T or other AASs and hence this increases 
the ratio of T/ET, which is usually around 1:1 otherwise. This ratio was first introduced 
in 1983 23 with a threshold at 6.0 which was later brought down to 4.0. According to the 
WADA criteria, a ratio of ≥ 4.0 is considered suspicious and further testing will be carried 
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out as this ratio is also affected by the ethnicity, sex or age of the athlete 14. Other criteria 
indicating endogenous steroid abuse includes concentrations of T or ET being greater 
than 200 ng/mL in males and 50 ng/mL in females, or concentrations of A or EC being 
greater than 10 µg/mL combined with a ratio of A/EC lower than 0.4 in males (in the 
absence of 5α-reductase) or greater than 4 in males or females 23. 
 
1.3.1 Athlete Biological Passport (ABP) 
 
Recently the WADA together with medical experts introduced the concept of the 
Athlete Biological Passport (ABP). It is an electronic record of the athlete’s biological 
values, composed of two modules 23; i) the haematological module that aims to identify 
the enhancements of oxygen transport including erythropoiesis-stimulating agents and 
any form of blood transfusion or manipulation; ii) the steroid module or the steroid 
profile aims to identify the administration of endogenous AAS. 
The testing of the steroid profile is performed on a longitudinal basis where the 
values from a series of steroid profiles from an individual are compared over time. The 
markers that compose the steroid profile are listed as, testosterone (T), epitestosterone 
(ET), androsterone (A), etiocholanolone (EC), 5α-androstane-3α,17β-diol (5αAdiol), 5β-
androstane-3α,17β-diol (5βAdiol) and the testosterone to epitestosterone ratio (T/ET). 
In addition to these markers, other steroidal ratios such as A/T, A/EC, 5αAdiol/5βAdiol, 
5αAdiol/E are useful in evaluating the steroid profile. These markers are detected in the 
free steroid form as a sum of the free steroid fraction and the hydrolysed products of 
the steroid glucuronides. 
 Where an unusual steroid profile is detected, conformation is carried out as a 
second step that will distinguish the endogenous steroids from the exogenous. Gas 
chromatography combustion isotope ratio mass spectrometry (GC-CIRMS) is used as a 
confirmation technique as the ratio of stable carbon isotopes 13C/12C allows 
discrimination between natural and synthetic steroids. Since exogenous testosterone or 
precursors contain less 13C than their endogenous homologues, it is expected that 
urinary steroids with a low 13C/12C ratio originate from pharmaceutical sources 4, 14.  
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1.3.2 Analytical approaches 
 
Most commonly, the urinary steroids are analysed in the anti-doping screens as 
urine can be acquired in noninvasively large volumes 11, 20. Gas chromatography-mass 
spectrometry (GC-MS) is the method conventionally used for the detection of steroids, 
which are then confirmed by comparison with reference materials. In comparison to the 
full scan MS or single ion monitoring (SIM) techniques used for detection in GC-MS 
methods, the gas chromatography tandem mass spectrometry (GC-MS/MS) includes a 
range of scan types to identify the metabolites with greater selectivity and sensitivity. 
This includes full scan MS, SIM, or MS/MS techniques such as precursor ion, product ion 
and neutral loss scans, and selected reaction monitoring (SRM) techniques such as 
multiple reaction monitoring (MRM). This technique being more sensitive and specific 
than GC-MS typically enables detection over an increased time period post drug 
administration. The detection by GC-MS method requires sample processing steps such 
as conjugate hydrolysis, pre-concentration and derivatization to enhance stability, 
volatility, ionization efficiency and detection limits (Figure 1.3).  
 
 
Figure 1.3: The important sample processing steps required for GC-MS detection with 
an example metabolite of testosterone 
 
The hydrolysis of steroid glucuronides, a major class of human metabolites, is 
achieved by using E. coli β-glucuronidase. However, the efficiency of the hydrolysis 
depends on a number of factors 10, 14, 22 such as enzyme inhibitors present in the urine 
Enzyme 
hydrolysis 
Enol-TMS derivatization 
GC-MS analysis 
Detection 
Phase II metabolite Phase I metabolite 
TMS derivative 
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matrix, the presence of contaminants in different enzyme preparations, and also the pH, 
temperature, and incubation time. Despite the application of optimised conditions, 
some steroid glucuronides such as 6β-hydroxyandrosterone glucuronide or 6β-
hydroxyetiocholanolone glucuronide 10 are resistant to hydrolysis on treatment with β-
glucuronidase and so remain undetected in the subsequent GC-MS screens. 
Nevertheless, the completeness of the hydrolysis by β-glucuronidase is tested by 
hydrolysing a known sample of an isotopically labelled steroid glucuronide such as 
androsterone glucuronide 23.    
In addition to the steroid glucuronides, steroid sulfates also contribute to a 
significant fraction of steroid metabolites although may not be routinely analysed in the 
anti-doping screens, as there is no standard method for hydrolysing steroid sulfates. 
Solvolysis is a general method of acid-catalysed hydrolysis of steroid conjugates that has 
been used in equine anti-doping analysis. This method is considered unsuitable by many 
for routine anti-doping screening since it can degrade analytes of interest 24 and 
generate a more complicated matrix 10, 22, 25-28. Hence, enzymatic methods are preferred 
over chemical means due to their specificity and the mild conditions used that would 
have a lower capacity to degrade steroid analytes. As a result, an enzyme preparation 
from Helix pomatia is used in anti-doping. However, this enzyme preparation is a crude 
mixture that contains alternative activities that could lead to steroid conversion, 
degradation and artefact formation 29-31 . The enzyme preparations from Patella vulgate 
or Haliotis rufescens are also occasionally used 22, 29, 32 even though they exhibit weak 
sulfatase activity. Failure to hydrolyse steroid sulfates leads to an incomplete steroid 
profile and could result in imprecise conclusions. Therefore, these enzyme preparations 
are not suitable for routine analysis.  
In contrast to GC-MS, liquid chromatography mass spectrometry (LC-MS) enables 
direct analysis of steroid conjugates (Figure 1.4) and has the advantage of avoiding the 
sample preparatory steps so enabling higher throughput in sample analysis 25, 33. 
Nevertheless, LC-MS has the difficulty in detecting some analytes such as saturated 
steroids and steroid diols due to poor ionization properties 8, 28. 
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Figure 1.4: Direct detection of phase II metabolites by LC-MS 
 
Followed by detection, confirmation is carried out by comparison with reference 
materials. Unfortunately, many reference materials of phase II metabolites that are 
required for confirmation purposes are unavailable. This makes hydrolysis of phase II 
metabolites necessary to liberate phase I metabolites or free steroids which can then be 
confirmed against the more widely available reference materials developed for anti-
doping applications 28. Therefore, hydrolysis of the steroid conjugates plays an 
important role in the anti-doping testing irrespective of the technique used for 
detection. 
The recent advancements in mass spectrometry (MS) techniques such as 
quadrupole time-of-flight (QTOF), quadruple orbitrap (Q Exactive™) mass spectrometers 
used in conjunction with ultrahigh pressure liquid chromatography (UHPLC) are gaining 
popularity in the anti-doping arena. The UHPLC techniques provide higher 
chromatographic resolution while maintaining similar elution times compared to 
conventional LC. The QTOF, orbitrap devices enable data acquisition over a broad mass 
range, accurate mass measurements and high sensitivity 34.  
These technological breakthroughs have assisted in implementing untargeted and 
open screening methods in anti-doping analysis. These methods scan for characteristic 
fragments or fragmentation modes of the metabolite class, instead of the individual 
metabolite itself. This allows detection of families of metabolites regardless of the minor 
structural changes they possess, hence would also be useful in identifying new 
metabolites derived from previously unknown substances. Metabolomics approaches 
enable the simultaneous detection of a broad range of small metabolites in biological 
samples that is performed in an untargeted mode 35, 36. This approach is attracting 
Detection 
LC-MS analysis 
Phase II metabolite 
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attention in doping control analysis as it is useful for the discovery of new metabolites 
or changes in the profile of endogenous metabolites in response to drug administration.  
 
1.4 Importance of sulfate metabolites in anti-doping  
 
The growing importance of the detection of sulfate metabolites in anti-doping 
screens has been extensively discussed in previous literature 12, 18, 27, 37, 38. The study of 
sulfate metabolites is important for the detection of both exogenous and endogenous 
steroids. Dehydroepiandrosterone (DHEA), the most abundant circulating steroid 
hormone in humans 39, interconverts in the forward and reverse sense with its sulfate 
conjugate (DHEAS), catalysed by sulfotransferase or sulfatase enzymes. Both DHEA and 
DHEAS are predominant precursors for androgens and estrogens where approximately 
50% of androgens in men and 75% of estrogens in pre-menopausal and 100% post-
menopausal women originate from DHEA and DHEAS 16, 40, 41. Together DHEA and DHEAS 
form the largest steroid reservoir in the body and the DHEAS concentration is 103 - 104 
times greater than estradiol and around 100 - 500 times greater than testosterone 42. 
Moreover, the concentration of DHEAS in blood is about 300 times higher than free 
DHEA and could therefore affect the concentration of DHEA glucuronide conjugate 
(DHEAG). This will also be contingent on the rate of inter-conversion between DHEA and 
DHEAS 15, 37 compromising the effectiveness of the screening method that detects the 
free steroid by the deconjugation of the glucuronide fraction alone.  
A study performed by Dehennin et al. 39 on DHEA metabolism detected the 
metabolites of DHEA before and after administration of an oral dose of DHEA. This study 
revealed that before DHEA administration, the sulfate conjugated DHEA and 3β-diols of 
DHEA were observed in abundance compared to their glucuronide equivalents. Whereas 
the other metabolites had similar levels of sulfate and glucuronide excretion or greater 
glucuronide conjugation. However, post-administration, the exogenous DHEA was 
preferentially converted into sulfate conjugated metabolites such as the sulfates of 
androsterone, etiocholanolone, epiandrosterone, the 3β-diols of DHEA, 5α-androstane-
3α,17β-diol and 5β-androstane-3α,17β-diol. These were observed in high excess relative 
to the glucuronide metabolites. 
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Several previous studies highlight the importance of steroid sulfates as long-term 
markers that can be used to improve the retrospectivity of the AAS misuse. A recent 
WADA funded study performed by Gomez et al. 18 following an oral administration of 
methyltestosterone (MT) detected three diol mono-sulfate metabolites out of which 
17β-methyl-5α-androstan-3α,17α-diol 3-sulfate (Figure 1.5) was identified as the 
metabolite with the longest detection window of up to 21 days after MT administration. 
This was an improvement in the retrospectivity of between 2 to 3 times compared to 
the previously reported long-term metabolite of MT, 17α-hydroxy-17β-
methylandrostan-4,6-dien-3-one (up to 9 days).  
 
 
 
 
 
 
 
 Figure 1.5: Methyltestosterone and its long-term sulfate metabolite 
 
A separate study 43 conducted by the same group on the oral administration of 
metandienone detected seven sulfate metabolites where 18-nor-17β-hydroxymethyl-
17α-methylandrost-1,4,13-triene-3-one sulfate (Figure 1.6) was detected up to 26 days 
after metandienone administration. This improved the detection window compared to 
the previously reported long-term metabolite, 18-nor-17β-hydroxymethyl-17α-
methylandrost-1,4,13-triene-3-one glucuronide (14 days) that is used to identify 
metandienone misuse.  
 
 
 
 
 
 
 
 
Figure 1.6: Metandienone and its long-term sulfate metabolite 
methyltestosterone                 17β-methyl-5α-androstan-3α,17α-diol  
3-sulfate 
        metandienone                       18-nor-17β-hydroxymethyl-17α-   
               methylandrost-1,4,13-triene-3-one sulfate 
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A similar study by Liu et al. 44 on oral administration of 1-testosterone identified a 
sulfate metabolite, 3α,6β-dihydroxy-5α-androstan-17-one 3-sulfate (Figure 1.7), as a 
long-term marker that could be detected up to 15 days after administration of 1-
testosterone. This provided five times greater retrospectivity compared to the 
alternative long-term metabolites, 1-testosterone (<2 days), 5α-androst-1-ene-3α,17β-
diol (up to 3 days) and 5α-androst-1-ene-3,17-dione (up to 3 days) identified as 
unconjugated metabolites in this study. 
 
 
 
 
 
 
 
Figure 1.7: 1-testosterone and its long-term sulfate metabolite 
 
Studies on 19-nor-steroids 27, 45-47 (Figure 1.8) also suggest that the sulfate 
conjugated metabolites are eliminated at a slower rate than the glucuronide conjugates 
during excretion. Once the excretion of glucuronides declines, the sulfate metabolites 
can become predominant. Further, the high levels of 19-nor-androsterone sulfate 
observed compared to the glucuronide counterpart over a longer period of time makes 
it a potential target for discrimination between metabolites of an endogenous and 
exogenous nature by the IRMS technique 46. 
 
 
 
 
 
Figure 1.8: 19-nor-androsterone sulfate 
 
A recent study performed by Piper et al. 12 on testosterone metabolism showed 
that the sulfated conjugates of the main urinary testosterone metabolites, have longer 
excretion times than their glucuronylated counterparts. While the metabolites of 
1-testosterone
  
3α,6β-dihydroxy-5α-androstan-17-one 
3-sulfate 
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glucuronide conjugates were observed up to two days after drug ingestion, only the 
sulfate conjugates were observed after eight days.  Therefore, the sulfate metabolites 
can be used as long-term markers in the anti-doping screens. Moreover, this study 
shows that epiandrosterone, that is only excreted in its sulfated form, may serve as a 
useful target for IRMS to detect the administration of exogenous testosterone.  
A recent WADA funded study of oral administration of methenolone 48 (Figure 1.9) 
identified four major sulfate metabolites including methenolone 17-sulfate and 3α-
hydroxy-1-methylidene-5α-androstan-17-one 3-sulfate that had detection windows 
comparable with the hydrolysed glucuronide analogues. Another WADA funded study 
of the oral administration of boldenone 49 (Figure 1.9) identified two sulfate metabolites, 
boldenone sulfate and epiboldenone sulfate in minor concentrations. These sulfate 
metabolites were detected mainly after exogenous administration of boldenone. Hence 
these sulfate metabolites can be used as additional markers to identify the exogenous 
origin of boldenone that could reduce the requirement to analyse samples by IRMS.  
 
 
 
 
                  
Figure 1.9: Methenolone and boldenone 
 
An untargeted study by Boccard et al. 50 on steroidomics using UHPLC-QTOF-MS 
upon testosterone undecanoate administration revealed that the performance indices 
of the metabolites such as area under the curve and sensitivity are notably higher for 
androsterone sulfate (AS) and etiocholanolone sulfate (ECS), than for their glucuronide 
counterparts. Hence, they suggested that AS, ECS and an unidentified steroid sulfate, an 
isomer of ECS, AS or dihydrotestosterone sulfate, possibly epiandrosterone sulfate, 
could be used as additional markers for the detection of testosterone administration.  
Therefore, including the sulfate metabolites is important to circumvent false 
negative results in the steroid profiles of the athletes and also to increase the 
retrospectivity for the detection of the misuse of some AASs. However, harsh acidic 
conditions used to deconjugate the sulfates is not suitable for routine analysis. Further, 
methenolone    boldenone 
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confirmation techniques such as GC-CIRMS that differentiates the endogenous form 
exogenous steroids require careful sample clean-up prior to analysis. This could be 
challenging for sulfate metabolites that require severe acidic conditions for hydrolysis. 
Due to the emerging importance of sulfate metabolites in anti-doping and the need for 
mild methods for sulfate hydrolysis, attention is drawn toward suitable sulfatase 
enzymes as candidates for steroid sulfate hydrolysis.    
 
1.5 Sulfatase family (EC 3.1.6) 
 
The sulfatases catalyse the hydrolysis of a diverse range of sulfate ester substrates 
ranging from small steroids such as estrogen sulfates to complex cell surface 
carbohydrates such as glycosoaminoglycans. They are divided into different enzyme 
sub-classes 51 according to the type of substrate they can hydrolyse or sequence 
similarity to other known sulfates enzymes. For example; EC 3.1.6.1: arylsulfatases; EC 
3.1.6.2: steryl-sulfatases (arylsulfatase C); EC 3.1.6.8: cerebroside-sulfatase 
(arylsulfatase A and E); EC 3.1.6.12: N-acetylgalactosamine-4-sulfatase (arylsulfatase B). 
Arylsulfatases (EC 3.1.6.1) are present in all kingdoms of life and catalyse the hydrolysis 
of sulfate esters. The historical nomenclature likely reflects the relative ease with which 
aromatic sulfate esters are hydrolysed. However, alkyl sulfate esters such as saturated 
steroid sulfates are also substrates for this enzyme family.  
The bacterial and human sulfatases share a high degree of sequence and structure 
homology which consist of a globular monomer with a mixed α/β topology, however the 
human sulfatases are membrane anchored. The core polypeptide motif C/S-X-P-X-R is 
conserved throughout the entire enzyme class. It directs a post-translational 
modification of the conserved cysteine or serine residue to α-formyglycine (FGly). This 
residue is a unique feature observed in the sulfatases and some closely related enzyme 
families that is essential for the catalytic activity 52, 53.  
Seventeen human sulfatase proteins and their corresponding genes have been 
identified 54, some of which were uncovered through the study of diseases 52, 55, 56 . The 
biological importance of sulfatases has been reported in relation to human diseases such 
as: leukodystrophy that can contribute to movement problems and developmental 
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delay, ichthyosis that results in dark scaly skin or scoliosis that results in abnormal 
curvature of spine due to a condition known as multiple sulfatase deficiency (MSD). The 
MSD is a rare autosomal disorder occurring in humans due to a mutation in the sulfatase 
modifying factor 1 (SUMF1), the gene that encodes the formylglycine generating enzyme 
(FGE). 
 
1.5.1 Post-translational modification 
 
A unique type of post-translational modification of a cysteine (Cys-type sulfatases 
in eukaryotes and some prokaryotes) or a serine (Ser-type sulfatases in some 
prokaryotes) to formylglycine (FGly) is a crucial functional feature for the catalytic 
activity of sulfatases. The cysteine or serine residue included in the signature sequence, 
C/S-X-P-X-R 52, 57-60 forms the recognition sequence for the generation of FGly in 
sulfatases. The Cys-type modification takes place in the cytoplasm whereas the Ser-type 
modification takes place in the periplasm. In eukaryotes, FGly generation occurs during 
or immediately after the translocation of sulfatase into the endoplasmic reticulum. 
Conversion of serine to FGly is merely an oxidation while that of cysteine goes through 
a presumed  thio-aldehyde intermediate that requires an additional hydrolytic step to 
form FGly 53 (Figure 1.10).  
 
Figure 1.10: Post-translational modification in Cys-type and Ser-type sulfatases 
 
The modification of cysteine to FGly by the formyl glycine generating enzyme (FGE) 
has been reported in previous literature 38, 52, 54. It uses molecular oxygen and is a 
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cofactor independent catalysis. The FGly modification of the Ser-type sulfatases in 
prokaryotes is mediated by AtsB gene which is an iron-sulfur protein 61. Studies by Dierks 
et al. 60, 61 reveal that it is unlikely that the Cys-type sulfatases undergo hydrolysis to 
serine prior to oxidation, as mutation of the critical cysteine to a serine in Pseudomonas 
aeruginosa arylsulfatase abolished the FGly generation. These studies also suggest that 
the modifying machinery for generation of FGly from cysteine and serine is distinct and 
highly specific for the respective residue. Nevertheless, having an essentially identical 
sequence neighbouring FGly makes it intriguing that the post-translational modification 
for FGly in bacteria has two separate modification machineries.  
 
1.6 The arylsulfatase from Pseudomonas aeruginosa (PaS) 
 
Pseudomonas aeruginosa is a common Gram-negative pathogenic bacterium 
found in many natural and artificial environments, not only in normal atmospheres but 
also in low oxygen atmospheres.  The arylsulfatase from P. aeruginosa (PaS) (EC 3.1.6.1) 
is one of the most widely studied enzymes in the sulfatase family. Suppression of 
arylsulfatase expression in P. aeruginosa is observed in the presence of good sulfate 
sources such as inorganic sulfate, and its expression under sulfate starved conditions is 
reported 53, 62. This shows its important role in bacterial growth under different sulfur 
regulated conditions. It has been suggested that the substrate specificity of such 
enzymes expressed in response to sulfur starved conditions could be quite broad, 
allowing flexibility in scavenging sulfur from the environment 53.  
The promiscuity of PaS has been broadly discussed in previous literature 63-65 
which is an important feature in steering enzyme evolution.  Although the native 
substrate of PaS is unknown, the enzyme has been studied in relation to its hydrolytic 
activity of phosphate and phosphonate esters and small aromatic sulfates such as para-
nitrophenyl sulfate (PNPS), para-nitrocatechol sulfate (PNCS) to show its catalytic 
promiscuity. However, the hydrolytic activity of PaS in relation to steroid sulfates had 
not been discussed widely. Studies by Stevenson et al. 32 revealed that WT-PaS could 
hydrolyse sulfate groups with a β configuration such as testosterone 17-sulfate, 
epiandrosterone 3-sulfate etc., however, under the screening conditions employed it 
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did not show detectable activity with α-configured steroid sulfates such as 
epitestosterone 17-sulfate, androsterone 3-sulfate and etiocholanolone 3-sulfate.  
 
1.6.1 Structure of PaS 
 
The crystal structure of native PaS has been determined at 1.3 Å by Boltes et al. 66. 
It essentially comprises of two domains with a monomeric structure of 536 amino acids. 
The overall dimensions of the globular PaS are 55 x 55 x 50 Å with a molecular weight of 
59 kDa. The C-terminal domain is the smaller of the two domains and contains a four 
stranded anti-parallel β sheet and a solvent exposed terminal α helix (Figure 1.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Crystal structure of PaS (PDB Code: 1HDH 66) (blue cylinders: α helices, 
magenta arrows: β-sheets) characterized by two domains. Calcium ion (light green) is 
shown that is located in the substrate binding pocket. 
N-terminal domain 
C-terminal domain 
N 
C 
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The N-terminal domain has an α/β topology that contains a ten stranded β sheet 
flanked by several α helices. The active site is located at the end of a narrow cleft 
between the C terminal β-sheet and a number of N terminal α-helices 52, 66. The structure 
contains no disulfide bridges and no cysteine residues as the only one expressed (Cys51) 
is post-translationally modified to FGly which is present in its hydrated form (FGH). A 
metal cation was located in the crystal structure in the vicinity of FGH and that was 
determined to be calcium (by comparison of B values and bond valence calculations). 
The crystal structure contained a sulfate anion in the active site that was non-covalently 
bound to the protein and eight more sulfate anions located on the surface of the protein 
originated from the precipitation reagent ((NH4)2SO4) used for crystallization. 
Three other x-ray crystal structures of sulfatases have been solved to date. They 
are: human arylsulfatase A (HARSA, cerebroside-sulfatase: EC 3.1.6.8) at 2.1 Å resolution 
67, human arylsulfatase B (HARSB, N-acetylgalactosamine-4-sulfatase: EC 3.1.6.12) at 2.5 
Å resolution 68, arylsulfatase C (HARSC, steryl-sulfatase: EC 3.1.6.2) at 2.6 Å resolution 
69. All these sulfatases show strikingly similar structure with a superimposable catalytic 
domain and a high degree of sequence similarity 52, 70. However, none of the structures 
were solved with a native substrate bound.  
 
1.6.2 The functional residues and the sulfate ester hydrolysis mechanism 
 
The substrate binding pocket is made up of ten highly interconnected residues and 
a Ca2+ ion (Figures 1.12 and 1.13). The ten residues in PaS comprise five basic residues: 
Lys113, Lys375, His115, His211, Arg55; three acidic Asp residues: Asp317, Asp14, Asp13; 
and two polar residues: Asn318 and the FGly51. It was observed that FGly was present 
in its hydrated form (FGH), which is believed to be essential for sulfatase activity. The 
residues Lys113, Lys375, His211 and the divalent calcium ion are involved in binding the 
anionic sulfate and by extension, sulfate ester substrates. These interactions of the 
positively charged residues with sulfate group make the sulfur center more electrophilic 
by withdrawing the electron density. These residues are also suggested to orient the 
tetrahedral sulfate ester for an in-line nucleophilic substitution by FGH.  
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Figure 1.12: The functional residues of PaS enzyme as observed in the crystal 
structure (1HDH) with the bound sulfate, the FGH residue (pink) and Ca2+ ion (green). 
The residues interacting with sulfate and/or FGH are coloured in orange and the 
interactions are shown by yellow dashed lines.  
 
The Ca2+ ion plays an important role in the active site by coordinating to both FGH 
and the substrate sulfate group and allowing sufficient proximity for the nucleophilic 
substitution to take place. The Ca2+ ion is coordinated by seven-fold ligands including 
the substrate, and holds a distorted pentagonal bipyramid with the Asp13 and Asn318 
coordinating in the axial directions while the oxygen atoms of Asp 317, Asp14, FGH and 
sulfate coordinating in the equatorial directions. Besides FGH, the three aspartate 
residues and the asparagine residue are bound to the metal cation, which helps define 
the catalytic pocket. In addition to the Ca2+ ion, the residues Lys113, Arg55, His115 are 
involved in FGH stabilization.  
 
His115 
Lys113 
His211 Lys375 
Arg55 
FGH 
Asp317 
Asn318 
Asp13 
Asp14 
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Figure 1.13: A 2D view of the active site residues of PaS enzyme with the interactions 
(dashed lines) with the substrate, Ca2+ ion and FGH. The distance measurements are 
displayed in Å (brown). 
 
              Two mechanisms for sulfate ester hydrolysis have been proposed 52, 67, 68. The 
first involves an addition-hydrolysis (AH) mechanism and was proposed based on the 
HARSB crystal structure 68 that contains a covalently bound sulfate unit. The negatively 
charged sulfate ester oxygen adds to the electrophilic aldehyde group of FGly to form a 
sulfate di-ester, which is then hydrolysed through nucleophilic substitution by a water 
molecule to release the product. It is followed by the regeneration of the aldehyde 
group, releasing sulfate and completing the catalytic cycle (Figure 1.14). The crystal 
structure of HARSB assumed the FGH-sulfate ester to be the resting state that led to the 
proposal of the AH mechanism.   
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Figure 1.14: Addition hydrolysis mechanism of sulfate esters by FGly in the form of 
an aldehyde. 
 
The second mechanism involves a transesterification-elimination-hydration (TEH) 
67 sequence that was proposed based on the HARSA crystal structure. In the crystal 
structure, the post-translationally modified cysteine residue was observed as 
formylglycine hydrate (FGH) in the resting state of the enzyme that led to proposing TEH 
mechanism. This mechanism is illustrated in Figure 1.15 in relation to the residue 
numbering in PaS enzyme. The residues Lys375, His211, His115, Asp13 together with the 
Ca2+ help in coordinating to FGH, sulfate moiety or both. This helps orient FGH and 
substrate for an in-line nucleophilic substitution. The four residues also assist in the 
proton exchange acting as general acids or bases. In this mechanism, the FGly is first 
hydrated to produce a geminal-diol (FGH). The Asp13 residue acts as a general base 
where it abstracts a proton from one of the hydroxyl groups from the geminal-diol of 
FGH. This leads to the nucleophilic substitution where the oxygen of FGH acts as a 
nucleophile and substitutes (SN2) at the sulfur atom of the sulfate ester. This results in 
the hydrolysis of the sulfate ester S-OR bond, releasing the free alcohol, which abstracts 
a proton from His211 that acts as a general acid. Next His115 abstracts a proton from 
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the second hydroxyl group of the sulfated FGH intermediate that helps to reform FGly 
by eliminating the sulfate completing the catalytic cycle 52 (Figure 1.15).  
 
Figure 1.15: Transesterification elimination mechanism of sulfate esters by FGly in 
the form of an aldehyde hydrate. 
 
Evidence in support of the second mechanism includes a study on a mutational 
change performed on the crucial cysteine residue to a serine that blocks the FGly 
generation71. This progressed the reaction as far as the elimination of ROH to form a 
serine sulfate ester intermediate. However, it does not release HSO4- to complete the 
catalytic cycle.  This study reveals the importance of the second hydroxyl group of FGH 
to eliminate the sulfate group. A similar mutational study 72 performed with [35S]-p-
nitrocatechol sulfate revealed that the serine mutants had the radioactive sulfate group 
trapped in the active site while the unmutated enzyme did not show traces of 
radioactivity. These studies also discourage the addition-hydrolysis mechanism, as it is 
highly unlikely a nucleophilic addition occurs at the saturated serine residue by the 
oxygen atom of sulfate. Moreover, the crystallographic structure of PaS has revealed 
that the FGly residue is present in its hydrated form rather than the unsaturated FGly 
form in the resting state that is near to but independent from the sulfate moiety. These 
observations support the transesterification elimination mechanism.  
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1.7 Previous work  
 
The PaS enzyme has been previously investigated in the McLeod laboratory at the 
Australian National University. The hydrolytic activity of WT-PaS had been compared to 
four other commercially available crude enzyme preparations over a range of substrates 
representing a diversity of structure and stereochemistry (Figure 1.16).  
 
Figure 1.16: Substrates tested on native PaS 
β-Configured steroid sulfates 
α-Configured steroid sulfates 
Epitestosterone 
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17-sulfate (TS) 
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Epiandrosterone 
3-sulfate (EAS) 
Etiocholanalone 
3-sulfate (ECS) 
Boldenone  
17-sulfate (BS) 
Dehydroepiandrosterone 
3-sulfate (DHEAS) 
para-Nitrophenyl 
sulfate (PNPS) 
Estrone  
3-sulfate (ES) 
     Model aromatic sulfate             Aromatic steroid sulfate 
Nandrolone  
17-sulfate (NS) 
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This study reported by Stevenson et al. 32 shows that PaS has comparable activity 
with the commercially available sulfatase from Helix pomatia (HpS). However, the 
sulfatase from Helix pomatia is a crude enzyme preparation that can also exhibit 
additional activities such as oxidase, reductase or glucuronidase activity. The other 
commercial sulfatases studied: sulfatases from Haliotis rufescens (HrS), Klebsiella 
pneumonia (KpS), or Patella vulgata (PvS), have shown a narrower substrate range and 
lower activity per gram of protein. Of these sulfatase preparations, only KpS has a known 
gene sequence but none has structural information.  In this study, PaS was found to 
show activity towards the hydrolysis of model aryl sulfates, such as para-nitrophenyl 
sulfate (PNPS), used for its chromogenic properties, and some steroid sulfates, such as 
estrone 3-sulfate (ES), epiandrosterone 3-sulfate (EAS) and testosterone 17-sulfate (TS). 
However, the maximum hydrolytic activity (Vmax) for testosterone 17-sulfate is five 
orders of magnitude lower than that observed for PNPS. The enzyme kinetics of native 
PaS for PNPS, ES, EAS and TS were measured and compared with that of the crude 
enzyme preparation of HpS. 
The previous studies demonstrate that PaS requires further improvements to be 
used in an anti-doping context. However, engineering efforts are not straightforward 
because the orientation of steroid sulfates in the cleft leading to the catalytic site is 
unknown. Crystallographic studies to determine substrate binding would be challenging 
due to potential substrate turnover, and the high concentration of sulfate used in known 
crystallization conditions that would be difficult to displace. Therefore, analysis of PaS 
with specific mutations could be of use to determine important residues for substrate 
binding and thereby to identify the binding site. Nevertheless, the promiscuity of PaS 
makes it a good candidate for improvement and this is possible since the sequence is 
known and the gene can be readily modified. The enzyme can be expressed from a 
recombinant gene with a His-tag for affinity purification therefore can be easily purified, 
in a stable and soluble form. The observed expression of native PaS under sulfur starved 
conditions makes it a better candidate as it is likely to have evolved for a broad substrate 
range. In addition, the crystal structure of PaS has been determined by X-ray 
crystallography 66. For these reasons, PaS was selected as the suitable candidate for 
protein engineering. 
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Chapter 2:                   Engineering of PaS     
              for improved TS hydrolysis,  
and characterization of the  
PaS mutants 
2.1 Introduction 
 
The growing importance of a robust steroid sulfatase for anti-doping applications 
was discussed in Chapter 1. The arylsulfatase from Pseudomonas aeruginosa (PaS) was 
selected as a suitable candidate as it exhibited some necessary activity. However, due 
to the limitations discussed, PaS requires modifications to be used in an anti-doping 
context. This chapter aims to improve PaS by enzyme engineering that would bring 
together protein chemistry, molecular biology, enzymology and analytical chemistry. 
 
2.1.1 Enzyme engineering 
 
Enzymes are biological catalysts that can dramatically increase the rate of specific 
chemical reactions, and their properties and characteristics have been studied for well 
over a century. Subtilisin, a type of alkaline protease is an early example 1 of an enzyme 
that was isolated and characterized (1967) 2. Some enzymes such as the glucose 
dehydrogenase from Thermoproteus species 3 or dipeptidyl peptidase from 
Porphyromonas gingivalis 4 have evolved with apparent strict specificity for their natural 
substrates while some enzymes accept a broader range of substrates such as the 
arylsulfatase from Pseudomonas aeruginosa 5. Modification of these enzymes or 
enzyme engineering to accomplish faster reaction rates for alternative substrates or to 
enhance the stability has great significance, mainly for industrial and synthetic 
applications 6, 7.  The first commercialized enzyme expressed in a genetically modified 
organism was a lipase called LipolaseR introduced for detergents in 1988 1.  
Evolution of enzymes can follow several pathways. Directed evolution 8-11 involves 
random mutagenesis of the whole gene, where in-depth understanding of the structure-
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function relationships is not crucial. This process mimics natural selection, which 
involves iterative rounds of randomly distributed mutations introduced into the gene of 
interest, selection for mutants that contain the desired property and amplification of 
the gene as the template to be used in the next round. Error prone PCR and DNA 
shuffling are the methods commonly used for library generation in directed evolution. 
This technique requires screening of large libraries and hence developing a high-
throughput method to isolate the desired property is often a major constraint in 
directed evolution 12-14.  
Rational design on the other hand uses prior detailed knowledge to predict the 
best amino acid substitution that results in a desired property 14, 15. Where available, 
comprehensive analysis of structure-function relationships of the catalytic residues can 
lead to mutating targeted residues to a single or a few selected amino acids of interest 
(site directed mutagenesis, SDM). Despite this technique being less laborious in terms 
of screening, the significant complexity and incomplete understanding of the enzyme 
structure-function relationships is a limiting factor for rational design. Hence semi-
rational approaches are more often used by protein engineers upon the availability of 
enzyme structure 6, 15.  
Semi-rational approaches are combinations of random mutagenesis and rational 
design where some prior knowledge on structure and function is required. The balance 
of random and rational approaches depends on the amount of information available 
regarding the structure-function relationship 15. If structural details are available with 
vague functional information, then the selection of residues to be mutated could be 
rational while the amino acids investigated could be chosen randomly. In such instances, 
the targeted residues can be saturated (site saturation mutagenesis, SSM) to all 
possibilities with selection of the best variants. Whereas, if there is limited information 
on both structure and function, this could lead to random mutagenesis on a few residues 
by saturating the sites simultaneously 15-17 (combinatorial active-site saturation testing, 
CASTing) or in turn. If the required functionality (such as hydrophilicity or aromaticity) is 
known, then the amino acid alphabets could be restricted to a smaller group to achieve 
the desired property in a single site or multiple sites (multiple site mutagenesis, MSM). 
Such restricted amino acid libraries reduce the level of screening required to fully 
investigate the mutants generated. 
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The work described in this chapter takes the semi-rational approach and 
employed two techniques for mutagenesis. First, all possible residues were introduced 
at a single position by site saturation mutagenesis (SSM). Second, multiple positions 
were altered simultaneously with only a subset of the possible residues by multiple site 
mutagenesis (MSM).  
 
2.1.2 Previous mutagenesis of PaS enzyme 
 
A related mutagenesis study on PaS performed by Li et al. 18 revealed two 
beneficial mutants with greater Vmax for TS and NS hydrolysis. The two mutations 
performed based on site directed mutagenesis were arginine at position 155 mutated 
to glycine (R155G) and lysine at position 330 mutated to alanine (K330A).  
 
Table 2.1: Mutations found by Li et al. 18 in comparison with wild type (WT)-PaS 
 
 
 
 
 
 
 
 
 
 
These two residues were selected based on the hypothesis that bulky and charged 
residues near the proposed substrate binding pocket may restrict access for steroid 
sulfates. These two mutations show that replacing the bulky charged arginine and lysine 
to glycine and alanine respectively resulted in an improvement of activity (Vmax) as 
shown in Table 2.1. Particularly the R155G mutant showed a ~2-fold improvement for 
TS hydrolysis. However, the catalytic efficiency (Vmax/KM) of the hydrolysis of above 
substrates have slightly decreased compared to WT-PAS. Yet, these two sites provide 
scope for further improvement by performing site saturation mutagenesis.  
Mutation 
Kinetic 
parameter 
TS hydrolysis NS hydrolysis 
R155G 
Vmax 1.71 x WT 1.83 x WT 
KM 2.75 x WT 1.89 x WT 
Vmax /KM 0.62 x WT 0.97 x WT 
K330A 
Vmax 0.96 x WT 1.29 x WT 
KM 3.10 x WT 2.06 x WT 
Vmax /KM 0.68 x WT 0.62 x WT 
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2.1.3 Project goals and hypothesis 
 
In view of the long-standing interest in a sulfatase for anti-doping applications, PaS 
is a possible solution that requires some improvement. Testosterone sulfate (TS) that 
represents a challenging substrate for PaS, was selected as the preferred substrate for 
the engineering of PaS. Further, TS plays a vital role in anti-doping and starting the 
enzyme engineering with a substrate that shows at least a little activity is important. The 
primary goals of this project were to: identify the steroid binding site of PaS, improve 
the catalytic efficiency of PaS for the hydrolysis of testosterone sulfate by 10-100 fold, 
characterise the mutants, improve the substrate scope of PaS, and to develop the 
enzyme for the hydrolysis to take place at 37 °C, pH 7.5. These hydrolysis conditions are 
analogous to those used with β-glucuronidase from Escherichia coli bacteria for the 
hydrolysis of steroid glucuronide metabolites in anti-doping laboratories. 
The hypothesis generated is that the native activity of PaS can be improved by 
protein engineering: mutating bulky and/or charged residues around the substrate 
binding pocket to smaller hydrophobic residues that will facilitate substrate entry to, 
and product release from, the binding pocket by opening it up. Such an approach could 
also lower the substrate specificity providing a broader substrate scope.  
 
2.2 Engineering of PaS enzyme for improved TS activity 
 
In the course of engineering PaS for improved TS activity, site saturation 
mutagenesis, was performed on single residues and then small groups of residues were 
mutated simultaneously. Finally, the beneficial mutations from all libraries were 
shuffled to search for further improvements. 
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2.2.1 The recombinant E. coli 
 
 
Figure 2.1: The pJExpress404 vector map with the AtsA gene inserted at the NdeI, 
EcoRI restriction sites. 
 
The recombinant AtsA gene with the C-terminal hexa-histidine tag was expressed 
in the pJExpress404 vector (Figure 2.1) that carries the ampicillin resistance gene (ampR) 
and also the T5 promotor and LacI repressor.  The AtsA gene was sub cloned to the 
pJExpress404 vector at the NdeI and EcoRI restriction sites. This expression system was 
used in all aspects of work in this project hosted in the E. coli DH5α strain. 
 
2.2.2 Medium throughput screen 
 
The sorting step is probably the most labour intensive yet the most crucial step in 
enzyme engineering 19 that identifies the desired mutants from a large mutant library. 
This could be of two types: selection and screening. Selection identifies mutants based 
on a phenotype such as antibiotic resistance, visual inspection of growth on minimal 
media or zones around colonies 14 that will select the variants with the desired property. 
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In occasions where the desired property cannot be linked with a phenotype, screening 
is employed. Screening involves a random selection of the variants that are usually 
cultured and tested in a 96-well or 384-well format and typically rely on a chromophore 
released from a chromogenic substrate. Despite selection offering a higher throughput 
in a shorter time, it is often performed on solid media plates and can be hard to set-up 
with optimized conditions to favour a particular phenotype. In contrast, the random 
screening systems blindly select mutants but require a discriminating assay 14, 19. Due to 
the difficulties in generating a distinguishable selection method, random screening was 
selected as the method of choice for the sorting of the variants. 
Mutating the whole gene of PaS by error-prone PCR with an error rate of two 
nucleotide mutations per sequence would require screening a library of a magnitude of 
107 20. A library of this size would most suitably be best screened by a higher throughput 
colourimetric assay with a commercially available model substrate like para-nitrophenyl 
sulfate (PNPS) which releases a yellow chromophore upon hydrolysis by PaS enzyme 
(Figure 2.2). 
 Figure 2.2: Hydrolysis of PNPS by PaS enzyme at alkaline pH 
 
The colourimetric assay with PNPS, however, is not appropriate as a primary assay 
to engineer improved steroid sulfate hydrolysis, as the hydrolytic activities displayed by 
the PaS mutants could be contrasting for the two different substrates and could even 
follow different enzyme mechanisms. Therefore, performing a colourimetric screen with 
PNPS was not adopted as it was thought unlikely to lead to improved mutants for steroid 
sulfate hydrolysis. Hence, a medium throughput LC-MS assay that directly monitored 
testosterone sulfate hydrolysis was adopted for this study. Instead of directed evolution 
of the PaS gene with error-prone PCR, a few sites neighbouring the catalytic site were 
selected for mutagenesis that was performed in turn or simultaneously.  
Yellow 
λ = 405 nm 
Colourless 
Hydrolysis by PaS 
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The practical limitations of LC-MS such as the long run time per sample 
(approximately 5 hours per 96-well plate compared to 10 seconds on a plate reader), 
necessity of a periodic system clean-up at least every 200 samples, the use of HPLC grade 
solvents, and the extra steps required to ensure no cell debris pass through the system 
make the process time consuming and costly. These reasons limited the library size to a 
maximum of a few thousands a library. This was achieved by targeting a few residues 
for mutagenesis at a time and trimming the library size by mutating them to selected 
amino acids of interest. However, screening of such focused libraries has previously 
been reported to have resulted in the discovery of beneficial mutations. In a study 
performed by Reetz et al. 21 to improve the enatioselectivity of a Baeyer-Villiger 
monooxigenase, a loop of four residues were selected as targets for mutagenesis. Using 
greatly reduced amino acid alphabets at each position significantly reduced the required 
screening effort to 2587 transformants to achieve 95% coverage as compared to over 
three million transformants in saturation mutagenesis. Yet, the screen was arbitrarily 
further restricted to 1700 clones even in which outstanding results were obtained. More 
studies have shown that focused libraries have resulted in improved mutants while 
reducing the screening effort 22, 23.  
The primary screening of the mutagenesis libraries involved several hundreds to 
several thousands of samples and was performed by LC-MS in 96-well microtiter plates. 
A microtiter plate based screening was employed as it is simple and easy for liquid 
handling when coupled with multi-channel pipetting. However, the main problem is that 
the uneven environment it provides to samples. This is often observed as an ‘edge 
effect’ where greater aeration during culture growth or evaporation during reactions 
occurs for wells at the edges of the plate. This can result in false positive ‘hits’ arising 
from elevated production of enzyme during culturing or increased concentration of 
reagents during reaction.   
Precautions were taken to minimize errors on sample treatment, edge effects and 
in selection of the active hits. Culturing, setting up reactions and screening for the 
beneficial mutants were the three steps involved and at most eight plates were 
subjected to these steps in a single session. Sample pipetting was performed in an 
orderly staggered manner so as to minimize variations in the time provided between 
samples for reaction. All steps were performed under tape sealed (culturing and 
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reactions) or thin film sealed (screening) conditions to reduce evaporation. Each plate 
included one or more control samples (WT-PaS for the single SSM libraries and an 
improved PaS mutant for MSM and shuffling libraries) for comparison of clones between 
plates. Instead of the product (testosterone, T) alone, the product/substrate (T/TS) 
response ratio was considered for the selection of hits of the initial libraries (libraries 1-
6) to overcome the difficulties encountered in selection due to sample evaporation, as 
the responses for both substrate and product would be enhanced due to sample 
evaporation. Each half plate was considered separately by placing control samples in 
each half and also in an edge well. However, the T/TS ratio does not result in a precise 
quantification as the changes in the ratios may not reflect the actual improvement or 
drop of activity. While TS was analysed in negative mode T was analysed in positive 
mode and the efficiency of ionization and detection did not appear to be well correlated. 
In addition, because TS eluted very early, it was prone to matrix effects that T was not 
exposed to. Further, the TS concentration being roughly two orders of magnitude 
greater than the testosterone produced, the T/TS ratio could lead to less precise 
interpretations. For these reasons, an internal standard was introduced in the latter 
libraries that would be detected in positive mode, would be eluted after the water 
soluble components and would not interfere with the reaction or product analysis. 
Nandrolone (N) was the internal standard of choice and was included in the buffer of 
the reaction where the response ratio between the product/internal standard (T/N) was 
taken into consideration. Since the nandrolone concentration is more comparable with 
the testosterone concentration, the T/N ratio would be an accurate measure for 
quantification.  This ratio of each sample was plotted plate wise and was compared with 
the activity of the control on each plate. Depending on the distribution of the plot from 
the primary screen, samples that displayed improved activity from each library were 
selected for a secondary screen. 
 The secondary screens were performed in biological triplicates. The culturing and 
the reactions of the secondary screens of the SSM libraries and the tertiary screens of 
the MSM libraries were performed in 1.5 mL Eppendorf tubes and screening in closed 
HPLC vials. This helped in treating all samples in an equal environment, thus minimizing 
the errors due to sample evaporation.  
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2.2.3 Site saturation mutagenesis libraries (libraries 1-5) 
 
The NNS (N=A/T/G/C, S=C/G) codon degeneracy was used in the primer design to 
randomly alter the sites of interest to any of the other possible 19 amino acids with 1/32 
probability of introducing a stop codon. However, multiple codons translating the same 
amino acid increase the probability of those amino acids being over-represented in a 
library. 
 
2.2.3.1 Overview of library generation and screening 
 
With the crystallographic structure in hand, a semi-rational approach was followed 
to create PaS variants. The prudently selected residues were mutated by site saturation 
mutagenesis (SSM) and the libraries were expressed in E. coli. The choice of E. coli strain 
used throughout the course of this work was DH5α, as it is known for its high 
transformation efficiency, relatively simple preparation, and easy storage.  
 
Figure 2.3: An overview of the library generation and screening of the site 
saturation mutagenesis libraries 
 
 
The selected clones were screened for testosterone sulfate (TS) hydrolysis. The 
primary screen was conducted in 96-well plates with a pre-determined library size to 
screen all possible variants with more than 95% probability. The beneficial mutants from 
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the primary screen or the ‘hits’ were carried forward for a secondary screen where 
thorough sealed conditions were used for culture growth, TS reactions and screening 
that was performed as biological triplicates. When they were confirmed as hits, the 
expressed proteins were purified for further characterization. All hydrolysis reactions 
were monitored by liquid chromatography-mass spectrometry (LC-MS).  
 
2.2.3.2 Selection of residues 
 
The efforts to generate an enzyme with improved catalytic efficiency for the 
hydrolysis of testosterone sulfate (TS) were based on the crystallographic structure 
resolved by Boltes et al. 24. Two possible binding modes of TS were identified in silico by 
Dr. Thomas Balle (Faculty of Pharmacy, University of Sydney). The modelling was 
preliminary and introduced simplifications such as using a carboxylate in place of a 
formylglycine hydrate (FGH) nevertheless provided useful insights. 
Inspection of each predicted pose (Figure 2.4) indicates several residues that could 
be restricting catalytic site access for bulky substrates. As depicted in pose I (Figure 
2.4A)), the three phenylalanine residues surrounding the binding pocket at positions 
328, 331 and 463 could be hindering the substrate entry to, and the product release 
from, the binding pocket. For pose II (Figure 2.4B)), the positively charged arginine and 
lysine at 155 and 330 respectively could be disfavouring the interactions with the 
hydrophobic steroid skeleton. The two residues (R155 and K330) that obstruct the 
binding pocket depicted in pose II have been previously investigated by Li et al. 18 with 
modest improvements to Vmax on hydrolysis of some steroid sulfates.  
 
 
 
 
  
 
 
 
Figure 2.4: The two binding modes suggested by computational ligand protein 
docking. The substrate (DHEAS) is shown in dark blue. A) Pose I. B) Pose II 
F463 
F328 
F331 
K330 
R155 
A) B) 
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The substrate docking in pose I aligns well for an inline nucleophilic substitution to 
take place with an angle of 164.0° between the nucleophilic oxygen of FGH, and the S—
O bond of the sulfate ester. In contrast, this angle in pose II is 113.6° making the pose II 
poorly arranged for the proposed inline nucleophilic substitution (Figure 2.5).  
 
Figure 2.5: FGH (magenta) and docked DHEAS substrate (dark blue) showing 
the angle between the nucleophilic oxygen of FGH, and the S—O bond of the sulfate 
ester in A) pose I and B) pose II. Selected catalytic residues in PaS active site are 
shown: residues activating and stabilizing FGH (yellow), residues that facilitate 
substrate binding, activation and leaving group protonation (orange). 
 
Hence, the residues corresponding to pose I were targeted first for mutagenesis 
despite the improvements observed for steroid sulfate hydrolysis with respect to the 
mutagenesis of the corresponding residues of pose II by Li et al. 
 
2.2.3.3 Library generation and screening 
 
Site saturation mutagenesis was first performed using the Stratagene 
QuickChangeTM PCR method 25 with the wild type gene as the template. This method 
employs a set of complementary primers containing the mutation which is introduced 
in a single PCR. Although a DpnI digestion was carried out to digest the methylated sites 
of the parent DNA, observing 80-90% of wild type contamination was one problem 
encountered. This method also included introducing silent mutations to incorporate 
restriction enzyme cleavage to reduce wild type contamination when generating the 
164.0° 
FGH 
113.6° FGH 
A) B) 
H115 H115 
H211 H211 
K375 
K375 
D13 
D13 
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SSM libraries at 328 (BpmI site) and 463 (SphI site) positions. However, due to inefficient 
digestion, this technique was not successful. 
Therefore, an alternative method, the megaprimer (MP) approach 26 (see section 
2.6.5.1) was employed to overcome this problem. This is a two-stage process where the 
first PCR introduces the mutation and the product of it serves as a megaprimer for the 
second PCR to create the full-length gene. A subsequent gel purification of the final 
product diminished the wild type contamination to 10-20%. A schematic representation 
of the library generation is shown in Figure 2.6. 
 
Figure 2.6: Reaction scheme for library generation by the megaprimer PCR 
method. 
 
The three phenylalanine residues shown in Figure 2.4 A), F328, F463, F331, were 
mutated in turn as described in section 2.6.5.1 using the primers listed in Table A1 (see 
Appendix), to produce three site-saturation mutant libraries (SSM 1,2,3 respectively). 
Before performing the primary screening, a small-scale library (10-15 colonies) for 
each site was subjected to a colony PCR to check for the presence of the correct size of 
the insert, and the samples with the correct insert were DNA sequenced to check for 
wild type contamination, after which the library size was determined. The number of 
mutants to be screened or the library size for TS hydrolysis from each library was 
calculated such that each of the possible mutant codons had more than 95% probability 
Gel purification 
X 
X 
X 
X 
X 
X 
X 
X PCR 1 
PCR 2 
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of being tested by substituting to the equation used by Patrick et al.20, L = -V ln (-ln Pc / 
V); where L= library size; V= possible sequence variants; Pc= probability every variant is 
represented. The activity profiles of the primary screen of SSM 1, SSM 2 and SSM 3 are 
shown in Figure 2.7. 
 
Figure 2.7: The activity profiles of the primary screens of SSM 1, 2 and 3 ordered by 
increasing activity from left to right. The red lines represent WT controls and the blue 
lines represent the test samples. The x-axis represents the clone number screened. 
 
Mutating the three Phe residues did not result in beneficial mutations. The 
samples that showed better activity in the primary screen were tested with DNA 
sequencing and resulted as wild type. Therefore, the residues corresponding to binding 
mode II were investigated despite the angle measured from substrate docking being 
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poor for an in-line nucleophilic substitution. As a result, K330 and R155 were mutated 
and screened similarly to the three phenylalanine residues, which resulted in two 
libraries, SSM 4 and 5 respectively.  
 
Figure 2.8: The activity profiles of the primary screens of SSM 4 and 5 ordered by 
increasing activity from left to right. The red lines represent WT controls and the blue 
lines represent the test samples. The x-axis represents the clone number screened. 
 
The activity profiles of SSM 4 and SSM 5 (Figure 2.8) are quite dissimilar when 
compared to that of SSM 1-3 with more variants resulting in better activity than the wild 
type control used. Upon subsequent secondary screening and DNA sequencing of all 
variants selected for the secondary screen (12 and 18 variants from SSM 4 and SSM 5 
libraries respectively), these two libraries resulted in three improved mutants: proline 
or threonine at position 155 (R155P or R155T) or valine at 330 (K330V).  In contrast to 
the residues at 155 and 330, mutating the phenylalanine residues did not yield any 
beneficial mutants.  
Each of the improved mutants (R155P/T, K330V) discovered in the site saturation 
mutagenesis (SSM) introduced smaller residues that would help accommodate bulky 
steroid sulfate substrates more easily. It is interesting to note that the crystal structure 
of PaS 24 has several regions that cannot be refined due to a lack of electron density and 
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presumably conformational flexibility. The side chain of K330 is one of these regions and 
could be impeding the substrate entry or product release. Valine at this position should 
reduce the obstruction. Additionally, R155P not only allows a larger opening around the 
putative entrance to the catalytic site, but also restricts movement of the protein 
backbone. This occurs where a single turn of alpha-helix is flanked by the proline at 154. 
This proline-proline unit forms a trans conformation during folding and provides rigidity 
due to the conformationally restricted five membered rings.   
 
2.2.3.4 Comparison of TS and PNPS hydrolysis  
 
The TS and PNPS hydrolysis were tested with ten randomly picked colonies in two 
libraries representing the two binding modes as described in section 2.6.7.3. A wild-type 
colony was used as a control and the results shown in Figure 2.9 are normalized with 
respect to the WT control. The test was not replicated as it aimed to compare the 
mutants of two libraries against a model substrate, PNPS, and a steroid sulfate, TS, and 
to test the aptness of using PNPS as the substrate when engineering PaS for TS. 
 
 
 
 
 
 
 
 
Figure 2.9: The activity profiles for 100 µM TS and 100 µM PNPS hydrolysis by crude 
lysates of a 10-colony random library in SSM 1 and SSM 4. The connected lines 
between discrete data points is for clarity. 
 
 
The comparative loss of function for both substrates by different mutations at 328 
position is similar; this could reflect other enzyme characteristics such as stability, and 
expression. It could also be due to the mutations on the 328 residue having minimal 
impact on substrate specificity. The colony 6 in SSM 1 was confirmed as WT after 
sequencing. In contrast, the variations at the 330 residue affects the hydrolytic activity 
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of the two substrates differently and reflects genuine improvement or detrimental 
effects in the catalytic activity.  
The colony 3 in the SSM 4 library represents an example for improved activity for 
TS but suppressed activity for PNPS. This validates the use of TS as the substrate in 
screening despite its longer reaction time and more extensive sample preparation 
compared to the use of PNPS as the substrate. 
 
2.2.4 Combined mutants 
 
Site saturation mutagenesis identified two sites that can be mutated for improved 
TS hydrolysis. The combination of mutations at these sites were then investigated to 
determine if the benefits were additive. Two PaS variants were prepared by combining 
the beneficial mutations, R155P/K330V (PV-PaS) and R155T/K330V (TV-PaS) by double 
digestion of the three single mutants from the two sites followed by ligation (Figure 
2.10)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Combination of the three single mutants to produce two double mutants 
 
The resulting double mutants were sequence verified, purified and used for 
further characterization.  
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2.2.4.1 Enzyme kinetics of the beneficial mutants  
 
Enzyme kinetics of the purified proteins of the beneficial mutants obtained from 
the SSM libraries and the combined mutants together with wild type PaS (WT-PaS) were 
studied for the hydrolysis of TS as described in section 2.6.8.1. The final concentration 
of the enzymes used was 0.4 µM. The results were fitted to the Michaelis Menten model 
(Figure 2.11).  
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2.11: Substrate saturation kinetics, at 37 °C, pH 9 (50 mM Tris acetate), fitted 
to the Michaelis-Menten model: Vo = Vmax*[S]/(KM +[S]) by using KaleidaGraph 4.5 
software. Initial velocity (Vo, µmol min-1 (g protein)-1) of PaS mutants, 0.4 µM, is 
plotted against TS concentration ([S], µM). The error bars correspond to the standard 
deviation between triplicates. 
 
All PaS variants exhibit a significant increase in Vmax with the two double mutants 
exhibiting more than three times wild type Vmax (Table 2.2). In terms of substrate affinity, 
there was no significant change in KM as a result of single mutations at 155, whereas 
K330V significantly increased KM. Mutations of both sites together showed that their 
effects on TS hydrolysis kinetics were not independent; they are synergistic in 
accordance with their close proximity in the crystal structure 24. The PV-PaS mutant 
shows a significant improvement in substrate affinity with 62% of the wild-type KM, 
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whereas TV-PaS is the opposite with about twice the KM of wild-type. Overall, PV-PaS 
offered the best result from the first set of mutations with the highest Vmax/KM: 5.6 times 
that of wild-type. Therefore, PV-PaS double mutant was selected as the best mutant to 
be carried forward for the next rounds of engineering.  
 
Table 2.2: Kinetic parameters of the beneficial PaS variants from SSM libraries and of 
combined mutants over an initial TS concentration from 2.5 – 320 µM, pH 9 (50 mM 
Tris acetate), 37 °C. See section 2.6.8.1. 
*The errors are the standard deviation between triplicates. 
 
With regard to enzyme substrate interactions, if pose I reflects the steroid sulfate 
binding site then the mutational analysis suggests Phe is optimal at each position. Given 
this, improvements arising from mutation at R155 and K330 must operate at a distance 
to improve affinity and catalytic activity. Conversely, if pose II is the steroid sulfate 
binding site then the R155P/T and K330V mutations introduce smaller uncharged 
residues that would help to accommodate the bulky substrates. In this case, mutation 
to each of the three Phe residues perturb enzyme performance through attenuated 
substrate binding, reduced enzyme activity, lower PaS stability or a combination of these 
factors. Thus, this early evidence suggested pose II as the likely steroid sulfate binding 
site. The pose II showing a poor geometry for an in-line nucleophilic substitution could 
therefore be an artifact of the modelling, as in the enzyme, the substrate can 
presumably adopt a more productive binding mode. Despite the modelling performed 
being preliminary it provided the initial guidance to target the residues to mutate by 
introducing the binding poses. However, a comprehensive modelling is currently being 
PaS enzyme Mutation Library 
Kinetic parameters* 
KM / µM 
Vmax / 10-2 
µmol min-1 g-1 
(Vmax/KM) / 
10-3 L g-1 min-1 
WT-PaS - - 35.1 ± 4.6 9.72 ± 0.40 2.77 ± 0.38 
V-PaS K330V SSM 4 52.5 ± 4.1 16.3 ± 0.4 3.10 ± 0.25 
P-PaS R155P SSM 5 35.6 ± 4.4 29.3 ± 1.1 8.23 ± 1.16 
T-PaS R155T SSM 5 36.7 ± 2.7 24.0 ± 0.6 6.54 ± 0.51 
PV-PaS R155P/K330V - 21.7 ± 1.4 35.3 ± 0.6 15.6 ± 1.0 
TV-PaS R155T/K330V - 87.5 ± 10.0 47.1 ± 1.7 5.38 ± 0.64 
 47 
 
carried out by Professor Lynn Kamerlin and her team (University of Uppsala, Sweden) to 
further characterize enzyme-substrate interactions. Irrespective of the precise location 
of substrate binding site, next it was sought to investigate additional mutations on and 
around the PV-PaS template in order to further improve PaS.  
 
2.2.5 Multiple site mutagenesis (MSM) 
 
Further efforts to improve PaS for TS hydrolysis aimed to build on finding optimal 
combinations of mutations. The success of mutagenesis lies in obtaining and screening 
sufficient amino acid diversity at the targeted site so that sequence space is adequately 
covered. Therefore, for the MSM libraries, reduced amino acid alphabets were 
employed (NYS randomization, N=A/T/G/C, Y=C/T, S=G/C) to limit the library size for 
screening. Assuming full coverage, this degeneracy allowed for all hydrophobic residues 
except tryptophan and glycine. Tryptophan was not of interest as it is a bulkier residue 
than the original residues. However, the option for glycine was sacrificed in order to use 
a simple degenerate codon for library preparation.  
The residues for MSM 1 and MSM 2 were selected based on an online tool for ‘hot 
spot’ identification called HotSpot Wizard reported by Pavelka et al. 27. This web server 
helps in identifying residues of a protein that could be mutated for improved enzymatic 
properties such as catalytic activity, substrate specificity and enantioselectiviy. When 
the PDB code or the structure is uploaded, the server predicts the hot spots by 
integration of several bioinformatics databases such as RCSB PDB, UniProt, PDBSWS, 
Catalytic Site Atlas and nr NCBI and computational tools such as CASTp, CAVER, BLAST, 
CD-HIT, MUSCLE and Rate4Site. The mutability of each amino acid is determined by their 
level of conservation within the enzyme family. The server first extracts the residue 
annotations from UniProt fields that determine the amino acids crucial for the catalytic 
function and collect information about mutagenesis and naturally occurring variants. 
Other databases such as Catalytic Site Atlas and PDBSWS are also used to acquire 
information about catalytic site residues. The CASTp tool helps in finding all the pockets 
in the structure and with the available information on catalytic site residues, the active 
site pockets are selected. Then, a point in the active site is calculated such that a sphere 
around it does not intersect any atom in the structure and the distance to the centre of 
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the structure is minimal. Next, the CAVER tool is used to identify tunnels connecting this 
point with the outside solvent. Finally, a BLAST search is carried out to obtain similar 
sequences to the query. They are clustered with CD-HIT and aligned with MUSCLE 
computational tools. The evolutionary rates obtained for each amino acid position from 
Rate4Site program are converted to a conservation score which is used to assign 
mutability to individual residues of the query enzyme and outputs an annotated 
structure with the mutable residues.  
Apart from the residues previously mutated by SSM, the HotSpot Wizard assisted 
in identifying more mutable residues. Amongst these, the residues forming the short 
alpha helix flanked by R155 are predicted to accommodate mutations (Figure 2.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: The functional residues and the neighbouring residues of the PaS 
catalytic pocket. The mutable residues or the hot spots (sticks) and functional 
residues (lines) are coloured by mutability according to the rainbow spectrum; from 
red having the highest mutability to violet having the lowest mutability. The initially 
mutated residues by SSM are labelled.  
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2.2.5.1 Multiple site mutagenesis 1 (MSM1)  
 
The first set of residues selected for multiple site mutagenesis (MSM1) were: I156, 
L325, and F331. They were selected as neighbours of the successfully mutated sites 
(R155 and K330), because they appear to project into the substrate binding pocket 
(Figure 2.13) and have a high mutability as depicted by the red sticks in Figure 2.12.  
These traits suggested that they would have some influence over substrate 
specificity. The best mutant in hand, PV-PaS, was used as the template for this library of 
variants. One residue, F331, had already been mutated in isolation without success and 
it was hypothesised that simultaneous mutations at neighbouring residues and the 
mutations in PV-PaS might support a useful change that would otherwise be unstable.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Pose II and the residues selected for mutagenesis in MSM 1 (orange 
sticks). The mutational locations of the template, PV-PaS (in pink), the Ca2+ ion 
(green) and DHEAS docked (blue) are shown. 
 
The primary screening of 1728 clones was performed with 100 µM TS and cultures 
that gave rise to greater testosterone release than PV-PaS were selected for further 
testing. A typical activity profile of a single plate (Figure 2.14) contained approximately 
5 % beneficial mutants compared to the template (PV-PaS) used. A total of 92 clones 
from the primary screen were subjected to a secondary screen to confirm the activity 
by comparing with that of PV-PaS. The secondary screen was performed in 96-well 
plates in biological triplicates.  
I156 
F331 
L325 
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Figure 2.14: Activity profile of crude lysates of a single plate of the primary screen of 
MSM 1 with the tested samples (blue) in comparison to the PV-PaS control samples 
(red). See 2.6.7.1. 
 
The tests with purified PaS variants confirmed that four beneficial PaS variants had 
greater activity than PV-PaS, as outlined in Table 2.3. All beneficial mutants observed in 
this library had the F331 unmutated.  
 
Table 2.3: The beneficial mutants found in MSM 1 library and the initial hydrolysis 
rates of TS (20 µM) hydrolysis by the purified mutants (0.4 µM) relative to PV-PaS (0.4 
µM). 
 a The initial hydrolysis rates measured for 1 hr reactions at 37 °C, pH 9 (50 mM Tris acetate). The errors 
represent the standard deviation between triplicates. 
 
The kinetic parameters of the best mutant (No. 4 or PVFV-PaS, Table 2.3) show a 
significant improvement in TS hydrolysis compared to the template used, PV-PaS (Figure 
2.15). The improvement in catalytic efficiency, Vmax/KM, of PVFV-PaS compared to WT-
PaS is approximately 33 times greater (Table 2.8). The PVFV-PaS mutant has two 
additional mutations (I156V and L325F). The mutation at 156 essentially removes a 
single methyl group from the sidechain and may create more space for the substrate.  
 
No. Mutations Initial hydrolysis rate relative to 
PV-PaSa 
1 I156/L325V/F331 1.1 ± 0.05 
2 I156L/L325V/F331 1.7 ± 0.15 
3 I156/L325F/F331 2.1 ± 0.07 
4 I156V/L325F/F331             (PVFV) 3.0 ± 0.23 
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Figure 2.15: Substrate saturation kinetics, at 37 °C, pH 9 (50 mM Tris acetate), fitted 
to the Michaelis-Menten model: Vo = Vmax*[S]/(KM +[S]) by using KaleidaGraph 4.5 
software. Initial velocity (Vo, µmol min-1 (g protein)-1) of PVFV-PaS mutant, 0.4 µM 
(blue) and WT-PaS, 0.4 µM (black) are plotted against TS concentration ([S], µM). The 
error bars correspond to the standard deviation between triplicates. The kinetic 
parameters for each plot are tabulated beside the chart. 
 
2.2.5.2 Multiple site mutagenesis 2 (MSM 2) 
 
The second round of MSM targeted I156, L157, K158 and T160 (Figure 2.16) with 
PV-PaS as the template. These residues are on the short helix where two other beneficial 
mutations (R155P and I156V) were found and they are offered as highly mutable 
residues (Figure 2.12). When the residues of the short α-helix were considered, the G159 
was disregarded to limit the library size, as it is originally a small hydrophobic residue. 
The PVFV-PaS was not selected as the template in the MSM 2 because it was not 
confirmed as the best mutant from the MSM 1 library by kinetic analysis by the time 
MSM 2 was commenced. Hence, the three residues at 156 position (isoleucine, valine 
and leucine) identified as beneficial from the secondary screen of the purified proteins 
in the MSM 1 library (Table 2.3) were included for randomization in the MSM 2 library 
using VTT degenerate codon at this position and NYS at other positions.  
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Figure 2.16: Pose II and the residues selected for mutagenesis in MSM 2 (cyan sticks). 
The mutational locations of the template, PV-PaS (in pink), the Ca2+ ion (green) and 
DHEAS docked (blue) are shown. 
 
Having a mutant with ~33-fold improvement in hand, more stringency was applied 
for the screening of the MSM 2 library by using 20 µM TS; one fifth the previous 
concentration. This brought the substrate concentration below the wild-type KM so as 
to discover mutants with greater affinity for TS; necessary for the samples encountered 
in the anti-doping screens. A typical activity profile of a single plate is presented in Figure 
2.17 and on average a plate contained approximately 10 % beneficial mutants compared 
to the template (PV-PaS) used.  
 
 
 
 
 
 
 
 
Figure 2.17: Activity profile crude lysates of a single plate of the primary screen of 
MSM 2 with the tested samples (blue) in comparison to the PV-PaS control samples 
(red) 
 
From the primary screen of 4800 clones, 118 clones that resulted in greater 
testosterone release than PV-PaS were tested in the secondary screen and a subsequent 
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tertiary screen (20 clones). The secondary and the tertiary screens were performed in 
biological triplicates. The 20 clones were confirmed as 13 distinct mutants (some being 
replicated) from gene sequencing out of which three mutants that showed standout 
activity were purified and their initial TS hydrolysis rates were tested (Table 2.4).  
 
Table 2.4: The beneficial mutants found in MSM 2 library and the initial hydrolysis 
rates of TS (20 µM) hydrolysis by the purified mutants (0.4 µM) relative to PV-PaS (0.4 
µM). 
No. Mutations Initial hydrolysis rate 
relative to PV-PaSa 
1 I156V/L157A/K158V/T160P 2.0 ± 0.06 
2 I156L/L157V/K158V/T160S                 (PLVVSV) 5.7 ± 0.17 
3 I156/L157V/K158I/T160                            (PVIV) 8.5 ± 0.28 
a The initial hydrolysis rates measured under 1 hr reactions at 37 °C, pH 9 (50 mM Tris acetate). The errors 
represent the standard deviation between triplicates. 
 
Enzyme kinetics was performed on the best mutant discovered from the initial 
hydrolysis rates (Table 2.4: No 3 or PVIV-PaS). This mutant shows a remarkable 
improvement in the catalytic efficiency for TS hydrolysis compared to the previously 
discovered mutants (Figure 2.18). The improvement of Vmax/KM is approximately 167 
times greater than that of WT-PaS (Table 2.8).  
Discovering a mutant with remarkably improved substrate affinity in MSM 2 
library was achieved by modifying the screening conditions. As lower substrate 
concentrations are more relevant to the low concentration samples encountered in the 
anti-doping screens, a substrate concentration lower than the KM of WT-PaS was 
deliberately used that resulted in sighting PVIV-PaS mutant with a KM of 4.5 µM 
compared to 35 µM for WT-PaS. 
The two additional mutations in PVIV-PaS distinct to PV-PaS template are L157V 
and K158I. Presumably the loss of the positive charge and the introduction of a smaller 
hydrophobic residue in the K158I mutation accounts for the enhanced substrate affinity 
resulting from the increased interactions with the hydrophobic steroid skeleton. 
Alternatively, both mutations to smaller residues ease interactions between the α-helix 
and adjacent loops potentially leading to an opening of the pocket. 
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Figure 2.18: Substrate saturation kinetics, at 37 °C, pH 9 (50 mM Tris acetate), fitted 
to the Michaelis-Menten model: Vo = Vmax*[S]/(KM +[S]) by using KaleidaGraph 4.5 
software. Specific activity (Vo, µmol min-1 (g protein)-1) of PVIV-PaS mutant, 0.08 µM 
(blue) and WT-PaS, 0.4 µM (black) are plotted against TS concentration ([S], µM). The 
error bars correspond to standard deviation between triplicates. The kinetic 
parameters for each plot are tabulated beside the chart. 
 
2.2.5.3 Multiple site mutagenesis 3 (MSM 3) 
 
An additional site, MSM 3 focused on two residues, M72 and E74 (Figure 2.19), on 
the opposite side of the binding pocket compared with previous sites. Research by 
Kintses et al. 28, used directed evolution to improve PaS for hydrolysis of a bulky 
phosphonate ester. This resulted in beneficial mutations of residues 72-75 that are in 
close proximity to the binding site. The results of this study were taken into 
consideration when the residues for mutagenesis of MSM 3 were selected. These 
residues are in close proximity to the catalytic residues and were of interest because 
they provide some bulk to the substrate binding pocket. In this case PVFV-PaS (from 
MSM 1) was used as the template and included screening of the possible variations with 
NYS degeneracy of >95% probability being tested.  
 
 
WT-PaS 
Vmax 0.0972 ± 0.0039 
KM 35.1 ± 4.6 
χ2 7.5673e-5 
R2 0.99419 
PVIV-PaS 
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Figure 2.19: Pose II and the residues selected for mutagenesis in MSM 3 (green 
sticks). The mutational locations of the template, PVFV-PaS are shown in pink and 
orange. The Ca2+ ion (green) and DHEAS docked (blue) are shown. 
 
Unlike the positive results obtained by Kintses et al. here a library of inactive PaS 
variants was obtained for TS hydrolysis suggesting that the steroid sulfate hydrolysis 
could proceed via a different catalytic pathway to the phosphonate ester hydrolysis by 
PaS. Importantly, as the NYS degenerate codon allowed methionine to be coded, but 
not glutamate, suggesting the deleterious mutation must occur at E74 rather than at 
M72. The results suggest that E74 is involved in the catalytic process. A typical activity 
profile of a single plate is shown below (Figure 2.20), which profiles the substantially 
reduced activity of the mutants.  
 
 
 
 
 
 
 
 
Figure 2.20: Activity profile of crude lysates of a single plate of MSM 3 with the 
tested samples (blue) in comparison to the PVFV-PaS control samples (red). 
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2.2.6 Shuffled library 
 
The beneficial mutations found from all the libraries were recombined (shuffled) 
to test for further improvements in catalytic activity. In addition to the mutations from 
the best mutants discovered from each library, the mutations from PLVVSV-PaS mutant 
from MSM 2 library was also included for shuffling as the initial hydrolysis rate of this 
mutant was greater than that of PV-PaS or PVFV-PaS and also because the mutant 
provides a range of additional mutations.  
 
Table 2.5: Randomization for the shuffling library 
PaS variant 155 156 157 158 160 325 330 
WT R I L K T L K 
PV P - - - - - V 
PVFV P V - - - F V 
PVIV P - V I - - V 
PLVVSV P L V V S - V 
Degenerate codon* CST VTT STG RWA WCC TTS - 
Expected AA’s R/P I/V/L L/V K/I/V/E T/S L/F K/V 
*S=C/G; V=A/C/G; R=A/G; W=A/T 
The shuffle involved mutations at seven residues, as outlined in Table 2.5, with 
WT-PaS or PV-PaS used as the template. Suitable degenerate codons were available at 
all positions with the exception of position 158. Here, in addition to the targeted amino 
acids, a glutamate (E) residue was included for randomization in order to use a simple 
degenerate codon (RWA) for library preparation. 
Variation at codon 330 was not introduced by oligonucleotide primers, instead 
two templates (WT-PaS and PV-PaS) were used to obtain the required residues (K or V) 
at this position while randomizing the other positions with the designed primers. An 
equal number of clones with both templates was screened with the same low TS 
concentration (20 µM) used in MSM 2. From a primary screen of 1152 clones, 30 samples 
were selected for the secondary screen that was performed in triplicates out of which 
22 samples that had comparable activity were sequenced resulting in 14 unique mutants 
(Table 2.6). The entries 1 and 10 were found three times and entries 3, 6, 13 and 14 were 
found two times in the 22 samples identified by the secondary screen.  
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Table 2.6: The mutations of the beneficial mutants observed at each mutated position.  
         
Sample 155 156 157 158 160 325 330 Frequency 
observed no. R/P I/V/L L/V K/V/I/E T/S L/F K/V  
1 R I L K T F K 3 
2 R I V I T L K 1 
3 R L L E S F K 2 
4 R L L E T F K 1 
5 R V V I T L K 1 
6 P I V V T L V 2 
7 P L V I S L V 1 
8 P V V I T L V 1 
9 R I V I S L V 1 
10 R I V I T L V 3 
11 R I V V T L V 1 
12 R L V I T L V 1 
13 R V V I T L V 2 
14 R V V V T L V 2 
The expected residues at each position is shown (blue) underneath the residue number.  
The mutations are highlighted in grey.  
 
 
Interesting mutational patterns were observed among the beneficial mutations. 
From the four possible combinations with residues 157 and 325, L157V/L325 or 
L157/L325F were the only combinations observed in all the beneficial mutants while 
L157V/L325 was dominant (79 %).  The L157V/L325 combination always occurred with 
the mutants that contained K330V while the L157/L325F combination was present in 
three of the five unique mutants with K330. Furthermore, R155 was always unmutated 
when K330 was also unmutated while the K330V mutation was present with both R155 
and R155P variants. The wild-type residues were more frequently observed than the 
mutations at the 155, 156, 160 and 325 positions occurring in 11, 6, 11 and 11 mutants 
respectively. In contrast, the 158 position was unmutated only in a single mutant. This 
suggests that 158 residue could be mutated by SSM to test the optimum residue at this 
position. However, the combination of R155P/K330V mutations used as the template 
for the generation of MSM 1 and MSM 2 libraries was observed only in three out of 14 
mutants. These observations support the importance of incorporating the wild-type 
residues into the shuffle.  
Given the rare occurrence of the R155P/K330V combination, the previously 
identified best mutants, PVFV, PVIV or PLVVSV based on this template were not 
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observed in the shuffled library. However, entry No 7 has a similar sequence to PLVVSV 
with a K158I mutation instead of K158V and entries No 6 and 10 are similar to PVIV with 
a single change at 158 and 155 positions respectively. Interestingly and unexpectedly, 
K158E mutation was observed in two beneficial mutants that always occurred with 
R155, I156L, L157, L325F and K330.  
Six PaS variants that showed the greatest crude lysate activity were purified and 
the initial hydrolysis rates for TS hydrolysis were tested (Table 2.7) for confirmation.  
 
Table 2.7: The beneficial mutants found in shuffled library and the initial hydrolysis 
rates of TS (20 µM) hydrolysis by the purified mutants (0.04 µM) relative to PV-PaS 
(0.4 µM). 
No.* Mutations Initial hydrolysis 
rate relative to 
PV-PaSa 
11 R155/I156/L157V/K158V/T160/L325/K330V 11.1 ± 0.49 
8 R155P/I156V/L157V/K158I/T160/L325/K330V 11.9 ± 0.06 
10 R155/I156/L157V/K158I/T160/L325/K330V 13.6 ± 0.14 
13 R155/I156V/L157V/K158I/T160/L325/K330V    (VVIV) 15.3 ± 0.27 
4 R155/I156L/L158/K158E/T160/L325F/K330          (LEF) 30.6 ± 1.19 
3 R155/I156L/L158/K158E/T160S/L325F/K330 31.5 ± 1.11 
* Mutant numbers from table 2.6 
a The initial hydrolysis rates measured under 1 hr reactions at 37 °C, pH 9 (50 mM Tris acetate). The errors 
correspond to the standard deviation between triplicates. 
 
Surprisingly, the two mutants incorporated the unexpected K158E substitution 
(No. 3 and No. 4) exhibited the greatest initial rates for TS hydrolysis. These two mutants 
were found as equally beneficial for TS hydrolysis having similar rates with T or S at 160 
position. 
Two mutants, one without K158E substitution VVIV-PaS (No. 13) and one with 
K158E substitution LEF-PaS (No. 4) were selected for further characterization. Kinetics 
studies were performed on these mutants at pH 9 and both showed a similar 
improvement in Vmax/KM of ~154 times (Table 2.8) with a compensation between the 
Vmax and KM. Figure 2.21 shows the substrate saturation kinetics fitted to the Michaelis-
Menten model of the two shuffled mutants in comparison to the previously identified 
best mutants in each round and WT-PaS. 
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Figure 2.21: Substrate saturation kinetics, at 37 °C, pH 9 (50 mM Tris acetate), fitted 
to the Michaelis-Menten model: Vo = Vmax*[S]/(KM +[S]) by using KaleidaGraph 4.5 
software. Initial velocity (Vo, µmol min-1 (g protein)-1) of PaS variants (WT, PV and 
PVFV at 0.4 µM, PVIV, VVIV and LEF at 0.08 µM) is plotted against TS concentration 
([S], µM). The error bars correspond to the standard deviation between triplicates. 
The kinetic parameters for LEF-PaS and VVIV-PaS are tabulated beside the chart 
 
The discovery of K158E mutation in LEF-PaS was serendipitous. The original 
positive charge at the residue is converted to a negative charge upon mutation. This 
mutation may allow a salt bridge to form with R155; the α-carbons of residues 155 and 
158 are 4.9 Å apart (Figure 2.22). Since both residues are solvent exposed they are 
expected to be conformationally flexible, but a salt bridge could restrict flexibility and 
alter the opening to the substrate binding pocket. 
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Figure 2.22: Pose II and proposed salt bridge formation between R155 and the K158E 
mutation imposed on the model derived from the crystal structure (1HDH) 24. 
 
The K158I mutation observed in the PVIV-PaS (KM of ~4.5 µM) of MSM 2 library 
recurred in the VVIV-PaS mutant discovered from the shuffled library that also has a 
significant improvement in substrate affinity with a KM of ~9.6 µM compared to WT-PaS 
(KM of ~35 µM). The loss of the positive charge and the introduction of a small 
hydrophobic residue could be among reasons for the greater TS affinity observed. In 
addition, K158 had a mutation in all the beneficial mutants that were purified and tested 
in the shuffled library (Table 2.7), suggests that this position is worth being mutated by 
SSM.  
 
2.2.7 Summary of enzyme kinetics of the beneficial mutants 
 
The enzyme kinetic parameters of the best mutants identified from each round of 
enzyme engineering in comparison to WT-PaS are summarized in Table 2.8.  The final 
concentrations of the enzymes used to study the enzyme kinetics were 0.4 µM for WT-, 
PV-, PVFV-PaS and 0.08 µM for PVIV-, VVIV- and LEF-PaS.  
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Table 2.8: The respective mutations, the library they were found in, template used, 
and kinetic parameters of beneficial mutants over an initial TS concentration from 2.5 
– 320 µM, pH 9 (50 mM Tris acetate), 37 °C. See section 2.6.8.1. 
PaS 
enzyme 
Library Template 
Kinetic parameters* 
KM / µM Vmax / 10-2 
µmol min-1 g-1 
(Vmax/KM) / 
10-3 L g-1 min-1 
WT-PaS - - 35.1 ± 4.6 9.72 ± 0.40 2.77 ± 0.38 
PV-PaS - - 21.7 ± 1.4 35.3 ± 0.60 15.6 ± 1.0 
PVFV-PaS MSM 1 (No. 3) PV-PaS 37.7 ± 2.4 343 ± 28 91.0 ± 9.4 
PVIV-PaS MSM 2 (No. 7) PV-PaS 4.5 ± 0.2 207 ± 6.8 463 ± 25.6 
VVIV-PaS Shuffling (No. 11) WT- or PV-PaS 9.6 ± 0.5 411 ± 19 427 ± 29.7 
LEF-PaS Shuffling (No. 13) WT- or PV-PaS 17.4 ± 1.0 743 ± 35 427 ± 31.7 
*The errors correspond to standard deviation between triplicates. 
 
2.2.8 Alterations in the screening protocols 
 
During the enzyme engineering work, several variations to the evolution protocol 
were investigated in an effort to improve the screening process. Although these proved 
ultimately fruitless, they are briefly described below. 
 
2.2.8.1 Minimal media selection 
 
To reduce the amount of screening, a minimal media selection was attempted in 
the MSM 2 prior to screening as described in section 2.6.11. This protocol was developed 
by Dr. Bradley Stevenson of McLeod group, ANU and then deployed in the current work. 
The E. coli was grown on minimal growth media (MMTS) without any other sulfates but 
testosterone sulfate. In theory, considerable growth of colonies should be observed if 
they could release sulfate by the hydrolysis of testosterone sulfate, which is the only 
source of sulfur available in the media. Agarose was used instead of agar due to the 
presence of sulfur in agar. Glycerol was used as a carbon source as it has previously been 
shown in the laboratory that glycerol affords higher sulfatase expression in comparison 
with glucose. The chloride salts of Mg2+ and Ca2+ were used to avoid sulfates from the 
original recipe. Despite IPTG being a sulfur-containing additive, it is not metabolized by 
E. coli but it induces the expression of the sulfatase via the lac promoter.  
Pin-prick colonies were observed in 3 days on incubation at 30 °C and the plates 
were transferred to 37 °C. Distinguishable sizes of clones for PVFV-PaS and PV-PaS used 
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as controls were identified within a week of plating.  However, the sizes of library clones 
were not discernible for an appropriate selection even after 10 days of growth. From a 
challenging selection, 10 clones were re-grown on LBA, out of which eight did not grow, 
as they were false positives, or could have been dead clones due to prolonged 
incubation. Hence, the usual screening protocol was continued in place of selection on 
minimal media plates, as this technique needs further optimization to be used for PaS 
selection for steroid sulfate hydrolysis.  
 
2.2.8.2 Four-substrate screen 
 
The need of PaS to be evolved for other steroid sulfates led to efforts to perform 
the simultaneous evolution on different steroid sulfates of interest. As a first step the 
variants selected from the primary screen of MSM 1 as beneficial for TS hydrolysis were 
subjected to a secondary screen that included a mixture of β-configured steroid sulfates 
(TS and NS) and α-configured steroid sulfates (ECS and ETS).  
An LC-MS method was developed to detect the steroids and their sulfates by 
changing the eluting solvent. An isocratic solvent system was used with 58 % MeOH to 
achieve a better separation with a run time of 8 minutes (Figure 2.23).  
 
 
 
 
 
 
 
Figure 2.23: The overlay of the chromatograms from the positive mode ESI single ion 
monitoring (SIM) of the four expected product peaks with three different m/z values.  
 
The reaction times were extended to obtain measurable hydrolytic activity with 
the α-configured steroid sulfates (ET and EC). Incubating the crude cell lysates with the 
four substrates in one pot for 21 hours made the variants less distinguishable for the β-
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configured steroid sulfates and yet no detectable activity was observed for the 
hydrolysis of α-configured steroid sulfates. Therefore, the secondary screen was moved 
back to screening and confirming the mutants against TS hydrolysis only.  
 
2.2.9 Validation of libraries 
 
The completeness and the coverage of the screened libraries were validated 
theoretically and experimentally immediately after preparation.  
 
2.2.9.1 Completeness of the libraries 
 
Table 2.9: Completeness of the libraries in DNA and amino acid diversities. 
Library  
Codon 
degeneracy 
Screened 
library 
size 
DNA 
completeness (%) 
(GLUE) 
Amino acid 
completeness (%) 
(GLUE-IT) 
SSM 1 NNS 355 100 100 
SSM 2 NNS 361 100 100 
SSM 3 NNS 189 100 100 
SSM 4 NNS 278 100 100 
SSM 5 NNS 284 100 100 
MSM 1 NYS 1728 34 81 
MSM 2 NYS, 156-VTT 4800 32 79 
MSM 3 NYS 768 95 99 
Shuffled See Table 2.5 1536 98 98 
 
The completeness of the libraries screened was calculated (Table 2.9) as described 
by Firth et al.29, 30. The two online tools used to estimate the completeness were GLUE 
for DNA completeness and GLUE-IT for amino acid completeness. The GLUE tool helps 
in finding the expected DNA sequence completeness when the number of equally 
probable variants within the screened library size is used as input. The GLUE tool is 
applicable when the gene variants have an equal probability of occurring in the library 
as with targeted mutagenesis. The GLUE-IT (GLUE - Including Translation) tools calculate 
the amino acid completeness of the library when the codon degeneracy and the 
screened library size is used as input.  
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The expected completeness of the SSM libraries, the MSM 3 library and the 
shuffled library have achieved a complete coverage (≥ 95 %) whereas one third 
completeness is achieved by the MSM 1 and MSM 2 libraries in DNA level. At the amino 
acid level considering degenerate codons for the same amino acid, the SSM, MSM 3 and 
shuffled libraries have ≥ 98 % completeness. The completeness of the MSM 1 and MSM 
2 libraries improves to ~ 80 %. 
 
2.2.9.2 Quality control of libraries 
 
Three SSM libraries (SSM 1 (F328), SSM 4 (K330) and SSM 5 (R155)), all the MSM 
libraries and the shuffled library were validated experimentally for completeness. 
Several variants were randomly picked (small-scale library) and their diversities were 
evaluated by DNA sequencing as a check of adequate coverage of sequence space. The 
DNA of 32 randomly picked clones from three SSM libraries were sequenced and the 
presence of nucleotide bases is depicted in the pie charts in Figure 2.24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.24: Degeneracies of small-scale libraries of SSM 1 (328), SSM 4 (330) and 
SSM 5 (155). The four colours represent the four nucleotide bases: A (adenine): blue; 
T (thiamine): red; G (guanine): green; C (cytosine): purple 
SSM 1 
SSM 4 
SSM 5 
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Although 32 clones from each library were sequenced, the numbers of complete 
sequences obtained were 18, 32 and 31 samples from the SSM 1, SSM 4 and SSM 5 
libraries respectively. The presence of thiamine (T) as the third base in SSM 5 is an 
unexpected observation, which could be a result of wild-type contamination. Whereas 
the absence of guanine (G) as the second base in the SSM 1 library would result in the 
absence of cysteine, tryptophan, arginine, and glycine that are only coded by a G as the 
second base. However, the complete SSM 1 library being approximately 20 times the 
small-scale library evaluated for completeness has a greater chance of these residues 
being tested. The amino acid residues observed in each of the small-scale libraries are 
shown in Table 2.10. Assuming a 100 % coverage of all 20 amino acids from 32 clones, 
the representation of amino acid coverage in the small-scale libraries of SSM 1, SSM 4, 
and SSM 5 are 62 %, 65 % and 67 % respectively.  
 
Table 2.10: Mutations observed from the small-scale libraries of SSM 1, SSM 4 and 
SSM 5. The amino acids are represented by their single letter code.  
x: Presence of mutation 
Grey highlights: wild-type residue 
 
Over-representation of some codons in the libraries was observed. However, most 
of the small hydrophobic residues were observed in the small-scale library. The primary 
screen that was 8-20 times larger than this sample library has a greater probability of 
having screened all the mutations of interest. The lesser number of mutations observed 
in the SSM 1 reflects the low number of successful sequencing results acquired in the 
particular library.  
 
G A V L I M W F P S T C Y N Q D E K R H 
SSM 1   x x    x x x x  x        
SSM 4 
 
x x x x x 
 
x x x x 
 
x x x 
   
x 
 
SSM 5 
 
x x x x 
   
x x x x x 
  
x 
 
x x x 
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Figure 2.25: Degeneracies of small-scale libraries of MSM 1, MSM 2 and MSM 3. The 
four colours represent the four nucleotide bases: A (adenine): blue; T (thiamine): red; 
G (guanine): green; C (cytosine): purple. 
 
MSM 1 
MSM 2 
MSM 3 
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For each of the MSM libraries and each half of the shuffled library (with WT- or 
PV-PaS template) 10 clones were randomly selected for sequencing. The presence of the 
nucleotide bases of the small-scale MSM libraries (Figure 2.25) and the presence of the 
amino acids in the shuffled library are presented in pie charts (Figure 2.26). 
The MSM 2 and MSM 3 libraries introduced the mutations through synthetic 
duplex oligonucleotide inserts with the required codon degeneracy whereas the 
introduction of mutations in the SSM libraries and MSM 1 was PCR based. Hence, a 
biasing of the mutagenesis towards the template codon in the SSM libraries was 
observed in certain occasions such as in the first and third bases of SSM 1, the first base 
of SSM 5 and the first and second bases at the 156 position of MSM 1 library. However, 
a critical bias based on the template codon was not observed in the MSM 2 and MSM 3 
libraries. Template contamination of a single colony each was observed in the MSM 1 
and MSM 2 libraries. The SSM 4 and MSM 3 small-scale libraries exhibit a reasonable 
representation of the codon degeneracy.  
 
Table 2.11: Mutations observed from the small scale MSM libraries. The amino acids 
are represented by their single letter code.  
 
  
A V L I M F P S T 
MSM 1 156 
 
x x x 
 
x 
  
x 
325 
 
x x 
 
x x 
 
x x 
331 
 
x x x x x 
 
x x 
MSM 2 156 
 
x x x 
     
157 x 
 
x 
  
x x x 
 
158 
 
x x 
 
x 
 
x 
 
x 
160 x x 
 
x x x x x x 
MSM 3 72 x x x 
   
x 
 
x 
74 x x x x 
  
x x 
 
 
Out of the nine amino acids that are expected to be observed in the MSM libraries 
with the NYS codon randomization, isoleucine, methionine, and phenylalanine have the 
least probability of being observed (1/16) while leucine has the highest probability 
(3/16). Valine, serine, proline, threonine, and alanine have equal probability of being 
observed (1/8). The absence of alanine (codon: GCN) or proline (codon: CCN) in the small 
scale library of MSM 1 is due to the under-representation of a cytosine (C) as the second 
base. However, the mutations that were absent in the small scale library of the MSM 2 
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library were observed in the beneficial mutants of this library such as V, I and M at 157 
position, A, I and F at position 158. This indicates the probable presence of all amino 
acids in the complete library despite the absence in the small-scale library.  
The presence of the mutations in the small-scale shuffled library shows a good 
representation at all positions except the 325 position where leucine is over-
represented exhibiting 90 % presence (Figure 2.26). The dominant representation of 
L325 in the beneficial mutants observed (Table 2.6) therefore could possibly be 
reflecting the library rather than the fitness. The degenerate codon used to randomize 
leucine and phenylalanine was TTS (S=C/G), selected because TTG and TTC both show 
high expression levels in E. coli 31. However, there could have been bias towards primers 
with codons that are more similar to the WT codon (CTG for 325) during the annealing 
phase of PCR. Leucine’s codon (TTG) causes only one mismatch with the template DNA 
whereas phenylalanine’s (TTC) causes two. Using the TTW degenerate codon could have 
avoided this bias.  
 
 
 
 
 
 
 
Figure 2.26: Expected and observed amino acids in the shuffled library at each 
mutated position. The legend below the chart represents the codes for different 
amino acids. 
 
Overall, the expected quality was observed from the SSM 4, MSM 3 and shuffled 
libraries while SSM 5, MSM 1 and MSM 2 exhibit some template contamination. The 
SSM 1, SSM 5, MSM 1 and MSM 2 show considerable bias towards some nucleotides. 
Importantly, a fair representation of amino acids was observed in all libraries as 
expected in the theoretical calculations (section 2.2.9.1). However, with the actual 
library screens being 8-20 times in the SSM libraries and 77-480 in the remaining 
libraries, there would be a higher chance of observing the completeness specified in 
Table 2.9. 
Shuffled 
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2.3 Characterization of the PaS variants 
 
2.3.1 The pH dependence  
 
The optimum pH for PaS hydrolysis was determined with respect to two different 
substrates, TS and PNPS, in a pH range as described in section 2.6.8.2. The test was 
performed at two different substrate concentrations (Figure 2.27). 
  
Figure 2.27: The pH profiles of PVFV-PaS and WT-PaS for hydrolysis of two different 
substrates performed in TMA buffer (50 mM Tris, 25 mM MES and 25 mM acetic 
acid) at 37 °C. The error bars correspond to the standard deviation between 
triplicates. A) Hydrolysis of 20 µM or 300 µM TS by 0.4 µM enzyme concentration, 
from pH 4-9 at increments of 0.5 pH units. The results are presented as relative 
activities with respect to the activities observed at pH 7. B) Hydrolysis of 20 µM or 50 
µM PNPS by 10 nM enzyme concentration from pH 6-9 at every half pH, the data 
series is not normalized. 
 
The pH profile for TS hydrolysis appears almost bell shaped. The pH optimum for 
TS hydrolysis, an alkyl steroid sulfate, at approximately at pH 6 could be explained in 
terms of the local ionisable residues in the active site that are responsible for enzyme 
catalysis. The general acid catalysed protonation of the departing steroidal oxygen 
(Figure 2.28) is required for the release of the product. According to the previously 
reported 32 transesterification-elimination-hydration sequence (Figure 2.28), the sulfate 
ester oxygen (O1) forms hydrogen bonding with the protonated forms of H211 and 
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K375. Upon hydrolysis, oxygen will abstract a proton from H211 that acts as a general 
acid as the sulfate ester substitution occurs. The pKa of the ionisable side chain of 
histidine is near 6 and would be expected to exist in its deprotonated form under basic 
conditions. Hence at high pH, impaired general acid catalysis and lower rates of catalysis 
would be expected. Nevertheless, the bell shaped dependence is more prominent with 
the hydrolysis at the low substrate concentration (20 µM) profiles as at higher TS 
concentration (300 µM) the release of product does not decrease as drastically as pH 
increases.  
 
 
 
 
 
 
Figure 2.28: The proposed mechanism of transesterification step in the 
transesterification-elimination-hydration sequence.  
 
The activity drop in the acidic pH range could be due to the D13 (pKa = 3.65) or 
H115 (pKa = 6) being protonated and the inability to activate the FGH (formyl glycine 
hydrate) by abstracting the proton from a –OH group for the nucleophilic substitution 
at sulfur to occur. Hence a decrease of activity is also observed when the pH is lowered.  
 
 
 
 
 
 
Figure 2.29: The leaving groups following TS and PNPS hydrolysis. 
 
The pH profiles of PNPS hydrolysis by PaS enzymes, however, follows a different 
pattern to TS hydrolysis. The release of a phenolate ion (Figure 2.29) does not essentially 
require a general acid catalyst for protonation 5 as the para-nitrophenolate ion is 
stabilized by delocalization. Hence alkaline pHs would be best suitable for the hydrolysis 
Testosterone leaving group para-Nitrophenolate leaving group 
 71 
 
of PNPS. The activity is expected to plateau at high pH, however, the pH dependence 
was not tested above pH 9 as other factors such as enzyme instability would become 
then prominent. Further, since PNPS was not the target substrate this study was not 
pursued on a broader pH range. The shift in the acidic limb to a higher pH for PNPS 
hydrolysis suggest a change in the role of the general base or even a different base 
involved in the hydrolysis of PNPS, possibly due to a change in the rate determining step 
for this substrate. 
 
2.3.1.1 PaS hydrolysis in a range of buffers 
 
The hydrolytic activity of WT-PaS and PVFV-PaS was tested on a range of buffers 
(50 mM) at two pH values for each buffer differing by one pH unit. The buffers and their 
corresponding pHs (measured at 50 °C) are tabulated (Table 2.12).  
 
Table 2.12: The buffers used with their corresponding pHs measured at 50 °C 
 
   
 
 
 
 
 
 
 
 
 
The hydrolytic activity was tested against TS at 37 °C or 50 °C. It should be noted 
that the pH values are recorded at 50 °C, hence the actual pH at 37 °C could be slightly 
varied for some buffers. The results presented are the average of duplicates (Figure 
2.30).  
Buffer Abbreviation pH at 50 °C 
Ammonium 
acetate 
A 
8.1 
7.2 
Bis-tris 
propane-HCl 
B 
8.4 
7.4 
Sodium HEPES H 
7.7 
6.7 
Sodium 
phosphate 
P 
8.0 
7.0 
Tris-HCl T 
8.3 
7.3 
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Figure 2.30: The activity profiles by WT-PaS (0.4 µM) and PVFV-PaS (0.4 µM) on TS 
(20 µM) hydrolysis in different buffers (50 mM) at different pHs. The error bars 
represent standard deviation of the duplicate measurements.  
 
 The results exhibit a general trend of a greater release of testosterone at the 
lower pH for each buffer across the range that is consistent with the pH optimum 
previously observed in TMA buffer. The phosphate buffer (pH 5.8 – 8.0) is exceptional 
showing low activity for PaS and lower activity at pH 7 compared to pH 8 and is not 
recommended for future studies. Despite Tris (pH 7.5 – 9.0) buffer used in most of the 
experimental work in this thesis, bis-tris propane (pH 6.3 – 9.5) shows comparatively 
greater hydrolysis rates and has been used in the previous PaS related studies 33 hence 
can be deemed suitable for PaS enzyme studies. Ammonium acetate (pH 6.0 – 8.0) and 
HEPES (pH 6.8 – 8.2) buffers with the useful pH range close to pH 7 will be suitable for 
the studies performed close to neutral pH.   
 
2.3.2 Effect of temperature on enzyme activity and stability 
 
The thermostability of WT-PaS and the best variants from each library was tested 
in two ways: determining the temperature that causes 50% irreversible inactivation 
after 5 min (apparent melt temperature, Tmapp) at pH 7.5 or pH 9, or by measuring the 
half-life at 50 °C (T1/2 50 °C ) at pH 9.  
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2.3.2.1 The determination of apparent melt temperatures  
 
The Tmapp of the PaS variants in comparison to WT-PaS was determined by 
incubation of the enzymes for 5 minutes at temperatures ranging from 30 °C - 80 °C at 
pH 9, and 20 °C – 65 °C at pH 7.5 as described in section 2.6.8.3. Figure 2.31 shows the 
residual activity of the enzymes as a function of temperature. 
 
 
 
 
Figure 2.31: Effect of temperature on enzyme stability fitted to a modified form of 
the Hill equation: a= a0 – (a0.Th)/(T1/2h + Th), where the residual activity (a) of the heat 
treated samples are compared to the activity (a0) of the non-heat treated samples 
and plotted against temperature (T)  using KaleidaGraph 4.5 software. The 
temperature (T1/2) at which PaS had 50% of its initial activity is considered the 
apparent melting temperature and h is the Hill coefficient. The figure shows the 
melting curves of the PaS mutants (20 µM and PVFV-PaS at 80 µM) compared to WT-
PaS (20 µM) at A) pH 7.5 (Tris HCl, 50 mM); B) pH 9 (Tris acetate, 50 mM). The error 
bars represent the standard deviation of biological triplicates.  
 
The PaS mutants and WT-PaS show higher Tmapp at pH 9 compared to that at pH 
7.5. Two mutants, PVFV-PaS and LEF-PaS, show greater thermostability compared to 
that of WT-PaS with approximately 4 °C improvement in Tmapp at pH 9. However, only 
PVFV-PaS retains improved thermostability at pH 7.5 (approximately 3 °C higher than 
WT-PaS). 
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2.3.2.2 The determination of half-life at 50 °C 
 
The half-life of the PaS variants in comparison to WT-PaS was determined by 
incubation of the enzymes at 50 °C for 0 – 9.5 hours and measuring the enzyme activity 
at different time points as described in section 2.6.8.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.32: Half-life of PaS variants at 50 °C fitted to exponential decay equation: 
a=100*(m1+(m2*exp(-t*m3))), where the residual activity (a) of the heat treated 
samples are plotted against the heat treated time (t) using KaleidaGraph 4.5 
software. The time at which PaS had 50% of its initial activity (where a=50%) is 
considered the half-life (t1/2) and is calculated using the final value (m1), initial value 
(m2) and the initial slope (m3). The figure shows the half-life curves of the PaS 
mutants (20 µM and PVFV-PaS at 80 µM) compared to WT-PaS (20 µM) at 50 °C, pH 9 
(Tris acetate, 50 mM). The error bars represent the standard deviation of biological 
triplicates.  
 
The half-life curves (Figure 2.32) of the PaS variants show that PVFV-PaS has a 
remarkably greater half-life of ~5.8 hours compared to the other variants and WT-PaS 
(Table 2.13). 
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Table 2.13: Thermal parameters for PaS mutants 
 
The PVFV-PaS and LEF-PaS mutants exhibit greater thermostability compared to 
WT-PaS. The mutation of leucine to phenylalanine at 325 position introduces an 
aromatic cluster with the neighboring aromatic residues, W212, F328 and F331 as 
depicted in Figure 2.33. The increased aromatic pi-stacking interactions upon the 
introduction of L325F could lead to the improvement in thermostability 34-36 of the PVFV-
PaS and likewise in the LEF-PaS mutants as outlined in Table 2.13. The improved stability 
of these mutants could be a feature credited to the improved activity in long reactions.  
 
 
 
 
 
 
 
 
Figure 2.33: The location of L325 (orange) with the neighbouring aromatic residues 
 
However, the K158E mutation of the LEF-PaS could be lowering the 
thermostability compared to the original lysine. Because, the adjacent loop containing 
D150 and E151 could form salt bridges with K158 that would enhance the 
thermostability 37, are removed upon the introduction of K158E mutation. The PV-PaS 
mutants is the least thermostable variant tested. The reduced thermostability of this 
mutant could be due to the hydrophobic mutations introduced to solvent exposed 
residues thereby decreasing the polar surface area 36.  
 WT-PaS PV-PaS PVFV-PaS PVIV-PaS VVIV-PaS LEF-PaS 
Tmapp , pH 7.5 (°C) 51.2 ± 0.3 45.4 ± 0.7 54.3 ± 0.3 48.8 ± 1.4 47.9 ± 0.9 51.4 ± 0.2 
Tmapp , pH 9 (°C) 56.0 ± 0.1 50.2 ± 0.2 59.4 ± 0.2 53.3 ± 0.2 52.7 ± 0.2 59.5 ± 0.2 
T1/2 50 °C ,pH 9 (hrs) 0.67 ± 0.04 0.12 ± 0.01 5.76 ± 0.14 0.57 ± 0.22 0.30 ± 0.04 1.15 ± 0.13 
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2.3.3 Substrate scope at pH 7.5  
 
The hydrolytic activity of the best mutants from each level of mutagenesis were 
tested over four steroid sulfates, with the sulfate group varying in stereochemistry and 
position. The four substrates tested were TS, EAS, ECS and ETS (Figure 2.34). They were 
tested at pH 7.5 as the enzymes exhibit faster turnover closer to neutral pH for the 
hydrolysis of steroid sulfates (Figure 2.27), and were quantified against the standards of 
free steroids. The reaction conditions used are described in 2.2.1. It is noteworthy that 
the enzyme concentration, substrate concentration and the reaction time used for the 
hydrolysis of α-configured steroid sulfates is greater, considering the low turnover of 
these substrates by PaS enzyme.   
 
 Figure 2.34: range of substrates tested 
 
All mutants exhibit improved hydrolytic activity for TS, the substrate employed in 
enzyme engineering for improved activity. However, the best mutant for TS may not 
necessarily be the best for the other substrates. WT-PaS hydrolyses EAS one order of 
magnitude greater than TS which agrees well with the published results 35. The EAS 
hydrolysis varies but does not dramatically change over the course of protein 
engineering. Considering the low turnover of α-configured steroid sulfates, higher 
enzyme and steroid sulfate concentrations were required to observe detectable activity, 
as a result the relative activities of α- and β-configured steroid sulfates may not be 
directly compared in Figure 2.35.  Apart from TS hydrolysis showing remarkable 
improvements, ECS hydrolysis too shows enhanced activity with all mutants compared 
to WT-PaS particularly PVFV-PaS. The large errors associated with ETS hydrolysis for all 
but PVFV-PaS suggest that the signals are within the level of noise.  
Testosterone 
17-sulfate (TS) 
Epiandrosterone 
3-sulfate (EAS) 
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Figure 2.35: The activity profiles of WT-PaS and PaS mutants. The error bars 
correspond to standard deviation between triplicates. 
 
Amongst the beneficial mutants discovered for TS hydrolysis, LEF-PaS exhibits the 
highest activity (Vmax) for TS hydrolysis and PVFV-PaS shows the broadest substrate 
range. The substrate range improved early in the screening process, but continued 
screening for a single substrate was detrimental to substrate range, as stated by You and 
Arnold 39 ‘you get what you select for’. This has often been observed in directed 
evolution.  
 
2.3.4 Level of post-translational modification by Ellman’s assay 
 
In PaS, the only cysteine at 51 position (C51) is post-translationally modified to 
formylglycine (FGly). The level of post-translational modification for each enzyme was 
tested by performing Ellman’s assay that assesses the amount of remaining cysteine in 
the enzyme that has not undergone post-translational modification to FGly. A similar 
study performed by Bojarova et al. 33 reported that 97% of the cysteine residues of PaS 
is modified to FGly. This is a simple spectrophotometric assay that is used for rapid thiol 
quantification that uses 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) commonly known as 
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Ellman’s reagent. The Ellman’s reagent is an aromatic disulfide that reacts with thiol 
groups to form a mixed disulfide and 2-nitro-5-thiobenzoate (TNB2-) that produces an 
intense yellow colour and a strong absorbance at 412 nm. One mole of TNB2- is produced 
per one mole of protein sulfhydryl group (Figure 2.36). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.36: Scheme for the reaction of cysteine with Ellman’s reagent to produce the 
dianionic yellow species (TNB2-). 
 
The preparation of standards and protein samples and the absorbance 
measurements were performed as described in section 2.6.8.5. The path length was 
considered as 0.57 cm considering the total volume of a well as 350 µL and the volume 
of a reaction as 200 µL. The extinction coefficient was calculated by dividing the slope 
of the calibration plot (Figure 2.37) by the path length and was 12295 M-1 cm-1. The 
published values for the molar extinction coefficient of TNB2- varies between 11400 to 
14150 M-1 cm-1 40.  
  
 
 
 
 
 
 
 
 
Figure 2.37: A) The calibration plot for the standard series of TNB2-. B) The levels of 
post-translational modification as a percentage. The error bars correspond to 
standard deviation between triplicates.  
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By subtracting the amount of cysteine present, the amount of FGly formed in each 
enzyme is presented as a percentage. The amount of FGly present in each enzyme is 
nearly the same with a value ranging from 90-95% for all the enzymes. The range 
observed could be due to systematic errors in the experiment rather than incomplete 
post-translational modification. These results suggest that the mutations introduced in 
each of the PaS variants do not impact on the level of post-translational modification 
and the improvements observed in hydrolysis activity cannot be attributed to changes 
in post-translational modification.    
 
2.4 Testing the involvement of E74 residue in catalysis 
 
In the MSM 3 library (2.2.5.3), it was observed that mutating the E74 residue led 
to a dramatic loss in PaS activity. It is possible that the negative charge on E74 is 
polarizing H115 where the two residues form an in-line interaction that facilitates 
activation of the formyl glycine hydrate (FGH) for the nucleophilic substitution (Figure 
2.38A).  
 
 
 
 
 
 
 
 
 
Figure 2.38: Two distinct possibilities for mechanistic involvement of H115 residue as 
a general base polarized by E74. A) Activation of FGH to facilitate the nucleophilic 
substitution. B) Promoting elimination of the sulfated FGH intermediate. 
 
This forms a catalytic triad that is reminiscent to the charge relay system seen in 
seine proteases 41 with FGH as the catalytic nucleophile in PaS. However, this activation 
is indirect as the hydroxyl group directly activated by H115 is the one further from the 
A) B) 
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sulfate. The involvement of E74 residue in the catalytic cycle reflects the same 
transesterification-elimination mechanism proceeding via a different residue (H115) for 
the activation of the nucleophile (FGH) than that depicted in Figure 2.28.  
Alternatively, the polarized H115 may serve as a general base to promote 
elimination of the sulfated FGH intermediate, thus regenerating the enzyme (Figure 
2.38B). At first glance, the latter is the more likely occurrence as no examples are known 
for H-bonding between the geminal hydroxyl groups of FGH-like diols in small molecule 
crystals, examined in the Cambridge structural database (CSD) as implied by Figure 
2.38A. 
To test the hypothesis that the E74 residue is involved in catalysis, site directed 
mutagenesis was performed to produce three mutants at the 74 position: E74Q, E74D 
or E74A (Figure 2.39) as described in section 2.6.9.1. Glutamine would test the necessity 
of the negative charge functionality without changing the size drastically while aspartate 
reduces the bulk while maintaining the functionality whereas alanine removing both the 
charge and bulk.   
 
 
 
Figure 2.39: The mutations introduced at the 74 position with the wild-type residue 
(Glutamate), where R and R’ represent the linked peptide chains. 
 
Kinetics for PNPS hydrolysis was studied with the purified E74 variants and WT-
PaS and the kinetic parameters were determined (Table 2.14) by fitting the data to the 
Michaelis-Menten model. 
 
 
 
 
 
 Glutamate(E)              Glutamine(Q)                 Aspartate(D)                  Alanine(A)              
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Table 2.14: Kinetic parameters of PNPS hydrolysis by WT-PaS and the E74 variants at 
pH 9 (50 mM Tris acetate), 37 °C. See section 2.6.9.2. 
 
 
In agreement with MSM 3 results, the study of PNPS kinetics (Table 2.14) of these 
mutants revealed that all mutants show detrimental effects on PNPS hydrolysis when 
compared to WT-PaS where the catalytic efficiency (Vmax/KM) is 300 fold lower. The KM 
of E74Q is 3.6 times greater than WT-PaS and that of E74D and E74A are >17 times 
greater than WT-PaS. The shape of E and Q are similar with just a terminal amide group 
replacing a carboxylate (Figure 2.39), hence substrate binding as seen in KM 
measurements is not dramatically perturbed, but Vmax is reduced approximately 83 
times indicating the importance of the carboxylate functionality. Out of the mutants, the 
E74D mutant has the highest Vmax (28% higher than E74A and 78% higher than E74Q) 
that supports the hypothesis that the negative charge functionality is important for 
turnover. This also indicates that not only the functionality, but the proximity of the 
charge to polarize the H115 residue is also important as observed by the significantly 
reduced Vmax of E74D mutant. 
Testing the kinetics of EAS/TS was attempted with the E74 variants. Due to 
impaired activity, assessing of the kinetic parameters was not possible. However, it 
would be an interesting residue to further investigate with an easier steroid sulfate such 
as EAS.  
 
 
 
 
 
 
Kinetic 
parameter 
WT-PaS E74Q E74D E74A 
Vmax /  105 
µmol min-1 g-1 
75 ± 2.0 0.9 ± 0.02 4.0 ± 0.07 2.9 ± 0.11 
KM / µM 8.12 ± 0.5 29.2 ± 3.1 143 ± 6.3 164 ± 24 
(Vmax/KM) / 
104 L g-1 min-1 
92 ± 6 0.31 ± 0.03 0.28 ± 0.01 0.18 ± 0.03 
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2.5 Conclusions and future directions 
 
In the course of engineering, a suitable sulfatase for the hydrolysis of steroid 
sulfates, PaS was selected as the candidate of choice. By investigation of the active site 
and the two proposed binding poses five residues were mutated in turn by SSM and the 
results indicated pose II as the preferred binding mode. This was supported by the 
results of the latter libraries that targeted multiple residues around the opening of the 
binding pocket of pose II. By the selection of 12 residues to improve for TS hydrolysis by 
mutagenesis in five SSM libraries and three MSM libraries and by shuffling the beneficial 
mutations three mutants (PVIV-, VVIV- and LEF-PaS) were identified with a catalytic 
efficiency (Vmax/KM) > 150 times than WT-PaS.  
The enzyme engineering also broadened the substrate scope for PaS. Observing 
hydrolysis of ECS and ETS, which are α-configured steroid sulfates, was an important 
breakthrough. The PVFV-PaS exhibited the greatest substrate range with an ability to 
hydrolyse ECS and ETS with rates two orders and an order of magnitude greater than 
WT-PaS, respectively. Although the substrate range improved at the early stages of 
enzyme engineering, continued screening for a single substrate was unfavourable for 
the substrate range in the latter rounds.  
The optimum pH for TS (an alkyl sulfate) lies approximately at pH 6 which is at 
least 2 pH units lower than the optimum for PNPS hydrolysis (an aryl sulfate). This is 
explained by the requirement of a general acid to protonate the leaving group of TS 
whereas it is not required for the leaving group of PNPS. In addition, the study of PaS in 
a range of buffers indicates that phosphate buffer is inhibitory to the enzyme, while bis-
tris propane with a broader pH range is recommended for future work. 
The studies on thermostability of the PaS variants indicated that PVFV-PaS 
possesses the greatest thermostability and is a moderate improvement of ~3 °C in 
melting temperature. In addition, the half-life of PVFV-PaS (5.8 hr) is significantly higher 
than WT-PaS (0.7 hr) at 50 °C. The improvements in thermostability would combine with 
catalytic improvement to give further benefit for PVFV-PaS. The level of post-
translational modification observed in all PaS variants range from 90-95% and the 
differences could be accountable for the systematic errors associated, hence the 
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improvements in activity observed in the PaS mutants are not due to differences in post-
translational modification.  
In addition, the importance of the E74 residue was discovered by the observed 
inactive MSM 3 library. It is proposed that the E74 is engaged in the catalytic mechanism 
by polarizing H115, which will activate FGH either for nucleophilic substitution or for the 
elimination of the sulfate group. This opens up an avenue for future investigation. 
Performing enzyme kinetics for the hydrolysis of a steroid sulfate by the produced E74 
mutants and molecular modelling simulations would provide further insights to the 
involvement of the E74 in the catalytic mechanism.  
Molecular modelling of the PaS variants with TS docked, or crystallization of the 
PaS variants with the substrate will be useful to further understand, how changes to the 
binding pocket influence enzyme stability and activity. This would also be helpful in 
further engineering the enzyme for an improved sulfatase.  
With the improved substrate scope, PVFV-PaS would be a good starting point to 
evolve for improved variants for ECS and ETS hydrolysis. The PVFV-PaS could be used as 
the template and introduce new mutations to the residues mutated in MSM 1 and MSM 
2 in small groups. Alternatively introduce mutations by error-prone PCR to discover 
improved variants for the hydrolysis of α-configured steroid sulfates. In addition, K158 
is an important residue that could be mutated by SSM to test the optimum residue at 
this position as this residue was mostly mutated in the beneficial mutants observed in 
the shuffled library (Table 2.6). With a version of PaS available for hydrolysis of TS and 
related steroid sulfates, addition of WT-PaS and subsequent versions would improve the 
range. Since one variant may not be the best for all substrates as discussed, a cocktail of 
enzymes could be used for steroid sulfate hydrolysis in anti-doping.  
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2.6 Experimental 
 
Unless otherwise specified, enzymes used for cloning and restriction digestion 
enzymes were purchased from New England Biolabs and chemicals were purchased 
from Sigma Aldrich. Phusion DNA polymerase was used for PCR throughout except in 
colony PCR. Dehydroepiandrosterone (DHEA) was obtained from BDH (Poole, UK) while 
the other free steroids were purchased from Steraloids (Rhode Island, USA). Steroid 
sulfates synthesised by Christopher Waller 42 from McLeod laboratory were used for 
experimental work. The AtsA gene for P. aeruginosa sulfatase was submitted to DNA 2.0 
(California) for E. coli codon optimization, synthesis and cloning into pJExpress404. 
Purification of PCR products and gel extractions were done using Promega® PCR 
purification kit. DNA extractions were done with QIAGEN® DNA miniprep purification kit. 
Sanger DNA sequencing was performed by the Biomolecular Resource Facility (BRF) in 
the John Curtin Medical School of Research, Australian National University. MilliQ water 
was used in all aqueous solutions and HPLC grade methanol was used for LC-MS related 
work. Unless otherwise stated, amounts and times used in the PCRs, digestions and 
ligations were according to the respective protocols from the enzyme supplier.  
 
2.6.1 DNA manipulations 
 
This section includes the general protocols for DNA manipulations performed 
during enzyme engineering.  
 
2.6.1.1 Oligonucleotides 
The primer design was facilitated by CLC sequence viewer (version 6.9) software 
that was used for sequence analysis and restriction site analysis, and was also assisted 
by Integrated DNA technologies (IDT) OligoAnalyzer 3.1 online tool 43 for estimation of 
melting temperatures and secondary structure analysis. The primers used for library 
creation were purchased from Integrated DNA Technologies, USA. The primers were 
dissolved in 10 mM Tris-Cl at pH 8.5 (Qiagen elution buffer) to yield a 100 µM 
concentration and stored at -20 °C.  
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2.6.1.2 Polymerase chain reaction (PCR) 
The PCRs were performed in either Veriti-96 well thermocycler or BioRad C1000TM 
thermocycler. All PCRs were performed in PCR microtubes with a typical reaction 
containing mini-prep DNA or a purified PCR product as the template (Table 2.15).  
 
Table 2.15: Sample preparation PCR 
Component Volume (µL) 
DNA template (50 – 100 ng) a 
Forward primer (10 µM)* 1.25 
Reverse primer (10 µM)* 1.25 
dNTPs (10 mM each) 0.5 
Phusion HF buffer (5 X) 5 
Phusion HF polymerase (2 U µL-1) 0.25 
Water 16.75 - a 
Total 25 
*Primers are listed in Table A1 (See Appendix). 
 
 
A typical thermocycle contained an initial denaturation step (98 °C, 1 min), 25 or 
30 cycles of amplification step (denaturation: 98 °C, 15s; annealing: 55 °C – 65 °C (Varied 
depending on the melt temperatures of the primers), 30 s; extension: 72 °C, 30 s – 2 
min) and a final extension step (72 °C, 5 – 10 min).  
 
2.6.1.3 DNA separation by gel electrophoresis 
The DNA gel electrophoresis was performed to check for the presence and the 
purity of the PCR products, digested products and ligated products. Most often 0.8 % 
agarose gels were used with a high range reference marker (0.5 – 10 kb) and less often 
1.5 % agarose gels were used with a low range reference marker (25 – 766 bp). The gels 
were prepared in 1x SB buffer (see Appendix) using RedSafeTM (iNtRON Biotechnology) 
nucleic acid staining solution (5 µL / 100 mL) and solidified on glass plates with a 
thickness of ~0.5 cm. the separation distance was ~6 cm. The wells contained a volume 
of approximately 0.5 x 0.1 x 0.5 cm3 that could load ~20 µL of sample.  
The samples were prepared by mixing the DNA sample (1 µL) with 6x loading dye 
(1 µL) followed by dilution with water (4 µL). The reference marker (New England 
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Biolabs) was prepared in a similar way and loaded with the samples. The gel 
electrophoresis was performed in a Wide mini sub™ gel tank with a voltage of 120 V 
supplied by BioRad 200/20 power supply. The run time was ~30 minutes and the bands 
were visualized under UV (254 nm) radiation or blue LED (when required to extract the 
DNA from the gel). 
 
2.6.1.4 Restriction enzyme digestion  
The DNA was digested with 10 units of the appropriate restriction enzyme (New 
England Biolabs) per 1 µg of DNA in a reaction volume of 50 µL with the manufacturer’s 
recommended buffer. Unless otherwise specified the digestion mixtures were incubated 
at 37 °C (Qualtex solidstat incubators) for 1 hour. If the digestion was carried out on a 
PCR product of an amplified gene, then the digested product was PCR purified, whereas 
if the digestion was carried out on vector DNA, then calf intestinal alkaline phosphatase 
(CIP, 10 units) treatment was performed along with digestion followed by gel 
purification.  
 
2.6.1.5 Ligation 
The calf intestinal alkaline phosphatase (CIP) treated pJExpress404 vector (0.025 
pmol) was ligated to insert in a 1:3 molar ratio unless otherwise specified. The ligation 
reaction was performed using T4 DNA ligase (1 µL) 10 x T4 ligase buffer (2 µL) diluted up 
to 20 µL with water. The reaction mixture was incubated at room temperature for 20 
minutes followed by DNA purification.  
 
2.6.1.6 DNA purification  
DNA purification was performed for several types of DNA. The DNA from PCR 
products, digested or ligated products were purified by the Promega® PCR purification 
kit. Gel purification was performed by first subjecting the DNA sample to gel 
electrophoresis (see 2.6.1.3). The band of the expected DNA was cut from the gel by 
visualizing under blue light with an orange filter followed by DNA extraction from the 
gel fragment according to the protocol of the Promega® purification kit. Plasmid DNA 
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was extracted and purified from overnight cultures (3 mL) using the Qiagen Miniprep ® 
kit. 
 
2.6.1.7 DNA quantification 
The DNA concentration was determined using NanoDrop ND-1000 (Thermo 
Scientific) spectrophotometer by measuring the absorption at 260 nm. The absorption 
at 280 nm was also measured as an indication of sample purity. A ratio of absorbance at 
260:280 nm greater than 1.8 indicates nucleic acid without protein contamination. 
 
2.6.1.8 Bacterial transformation  
Plasmid DNA was transformed into bacterial cells by electroporation using a 
BioRad MicroPulser according to the manufacturer’s instructions. Then 50-70 ng of 
construct DNA of the ligation product (in water) was transformed into 50 µL of electro-
competent E. coli DH5α cells. The cells were recovered in 0.5 mL LB medium and were 
incubated in 1.5 mL tubes at 37 °C, 180 rpm for 1 hour to develop ampicillin resistance. 
Transformants were plated on LB-agar 100 mg/L ampicillin (LBA) in 90 mm petri dishes 
and incubated overnight at 37 °C, for colony growth.  
 
2.6.1.9 Colony PCR 
Colony PCRs were performed to check for the presence and correct size of the 
inserts and for DNA amplification for sequencing purposes using the Taq DNA 
polymerase enzyme (New England Biolabs). First, a single colony was resuspended in 
water (5 µL). Then reaction components were mixed in two tubes: one with Taq DNA 
polymerase, the other with nucleic acid components (Table 2.16). 
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Table 2.16: Sample preparation for colony PCR 
Component Volume (µL) 
A) Polymerase buffer (10 x) without MgCl2 5 
       MgCl2 (25 mM) 3 
       Taq DNA polymerase (5 U µL-1) 0.25 
       Water 16.75 
B) dNTPs (10 mM each) 1 
       Forward primer, P30-f (10 µM)* 1 
       Reverse primer, P31-r (10 µM)* 1 
       Water 21 
       Colony resuspension 1 
Total 50 
*Primers are listed in Table A1 (See Appendix). 
 
The B) component was first pipetted into a PCR tube and mixed with 1 µL of the 
colony suspension followed by the mixing of 25 µL of A. The thermocycling conditions 
used were, 95 °C for 5 minutes followed by 25 cycles of 95 °C for 20 s, 55 °C for 30 s and 
68 °C for 1 minute and a final 5-minute extension at 68 °C.  
To check for the presence of the correct size of the insert, 1 µL of the colony PCR 
product was run on a 0.8 % agarose gel (see 2.6.1.3) with a band at ~2 kb confirming the 
correct size of the insert. The colony PCR product was purified and was used as the 
template for sequencing. 
 
2.6.1.10 DNA sequencing 
The DNA sequencing was performed by the Biomolecular Resource Facility (BRF) 
in the John Curtin School of Medical Research, Australian National University. 
Sequencing was performed on two different types of DNA templates; templates from 
plasmid purification (see 2.6.1.6) or templates from colony PCR (see 2.6.1.9). The DNA 
amplification was performed by PCR by using BigDye® terminator (Thermo Fisher 
Scientific) as recommended by the facility. The samples were prepared in a reaction 
volume of 20 µL (Table 2.17) 
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Table 2.17: Sample preparation for DNA sequencing 
Component Volume (µL) 
Plasmid DNA (150-300 ng) or Colony PCR DNA (20 – 50 ng) a 
BigDye® terminator version 3.1 0.5 
Sequencing buffer 400 mM Tris at pH 9 with 10 mM MgCl2 3.5 
Primer (3.2 µM)*  1 
Nuclease free water 15 - a 
Total  20 
*P6-f or P23-f or P24-r see Table A1, Appendix 
 
 
 
The thermocycling conditions used were, 96 °C for 5 minutes followed by 50 cycles 
of 96 °C for 10 s, 50 °C for 5 s and 60 °C for 4 minutes. The PCR amplified DNA samples 
were prepared for analysis by a clean-up protocol. First, the DNA was mixed with a 
precipitating solution containing ethanol (62.5 µL), sodium acetate (3M, pH 4.6, 3 µL) 
and water (14.5 µL). The mixture was incubated at room temperature for 15 minutes 
followed by centrifugation for 30 minutes at 3700 rpm (Eppendorf centrifuge 5804). The 
supernatant was removed by an inverted quick spin (300 rpm, 1 minute). The pellet was 
washed with 70 % (v/v) ethanol (200 µL) and centrifuged for a further 15 minutes (3700 
rpm). The supernatant was removed as above. Finally, the pellet was air dried for ~30 
minutes before submission for analysis.  
 
2.6.2 Preparation of E. coli electro-competent cells 
 
The E. coli strain of choice for all forms of this work was DH5α, which is known for 
its high transformation efficiency, relatively simple preparation and easy storage. All 
solutions, culture media, water, 1.5 mL tubes were pre-sterilized by autoclaving and the 
centrifuge bottles were sterilized by washing with 10% bleach, plenty of sterile water 
and 70% ethanol before drying in a sterile hood. All steps in the preparation was 
performed under sterile conditions. A single colony of an overnight grown DH5α strain 
streaked on a LB-agar plate was inoculated into 10 mL of YenB (yeast extract and 
nutrient broth) medium in a falcon tube. Following overnight growth of the starter 
culture at 37 °C it was inoculated into 990 mL of YenB medium and incubated at 37 °C 
shaking at 180 rpm until the OD reached ~0.8. Next, the culture was chilled on ice for 5 
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minutes and was transferred to the centrifuge bottles stored at 4 °C and centrifuged for 
10 minutes at 4000g, 4 °C. The supernatant was discarded and the cell pellet was washed 
with 100 mL ice-cold sterile 10% glycerol and centrifuged as before. This step was 
repeated. Next, the cells were resuspended in 20 mL of ice-cold 10% glycerol and 
centrifuged as before. The supernatant was discarded and the cells were resuspended 
with 200 µL of 10% glycerol for a final volume of ~ 2 mL. The cells were pipetted in 50 
µL aliquots into 1.5 mL Eppendorf tubes, snap frozen on dry ice and stored at -80 °C until 
required.  
 
2.6.3 Protein analysis  
 
This section describes the protocols for the visualization and quantification of the 
proteins required to validate the purity and the concentration before evaluation of the 
proteins. 
 
2.6.3.1 Protein visualization by SDS-PAGE 
Polyacrylamide gels were used to evaluate the purity of the fractions collected 
during enzyme purification. The gels were prepared based on a protocol by Laemmli et 
al. 44 by using 15 % separating region (w/v) at pH 8.8 and a 4.5 % stacking gel at pH 6.8 
both containing 37.5:1 ratio of acrylamide to N,N-methylenebisacrylamide (Amresco). 
The final concentrations of the separation gel are as follows: 0.375 M Tris.HCl (pH 8.8), 
0.1 % (w/v) SDS, 0.125 % (v/v) N,N,N′,N′-tetramethylethylenediamine (TEMED) and 
0.075 % (w/v) ammonium persulfate (APS, BioRad). The final solute concentrations in 
the stacking gel were similar to the separation gel except that 0.125 M Tris-HCl (pH 6.8) 
was employed. The gels were cast with a thickness of 0.75 mm and a height of 6 cm and 
2 cm for separation and stacking respectively using a multiple gel caster (Amersham 
Biosciences). The wells were 3.5 mm wide with 15 wells in the stacking region.  
The low molecular weight reference ladder (BioRad) was prepared by performing 
a 20 x dilution in cracking buffer (see Appendix), followed by heating at 95 °C for 5 
minutes, and was then stored at -20 °C until used. 
The protein samples were prepared by mixing a defined volume of protein solution 
(~2 µL) and making up to 10 µL with cracking buffer (see Appendix). Samples were 
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heated at 95 °C for 5 minutes before loading 5 µL of samples or standards into the wells. 
The gel electrophoresis was performed in a 1x running buffer using SE250 Mighty Small 
II gel tank (Hoefer) with a maximum current limited to 30 mA per gel and maximum 
potential difference limited to 200 V, supplied by Pharmacia LKB EP5 500/400 power 
supply. Electrophoresis was continued until the bromophenol blue solvent front reached 
the bottom of the gel (~45 minutes). The gel was then removed and washed three times 
in milliQ water to remove SDS before staining with BioSafe™ Coomassie blue G-250 stain 
(BioRad) according to manufacturer instructions.  
 
2.6.3.2 Determination of protein concentration 
The concentration of proteins was determined in two ways; by measuring UV 
absorbance or by Bradford assay.  
 
2.6.3.2.1 Bradford assay 
 The Bradford assay is a colorimetric based assay that is based on the change of 
the colour of the dye Coomassie Brilliant Blue G-250 under acidic conditions upon 
protein binding 45. Upon binding, the absorbance is shifted from 470 nm to 595 nm. The 
assay is based on the absorbance measurement at 595 nm that was measured using 
BioStrategy SpectraMax M2 plate reader.  
 The standards and samples were prepared in 0.9 g/L NaCl solution. Bovine serum 
albumin (BSA) was used as the standard for calibration. An initial standard of 1.4 g/L BSA 
(1.3 mL) was serially diluted in saline solution to produce the standard series with a 
range of BSA concentrations; 1.40, 1.08, 0.83, 0.64, 0.49, 0.38, 0.29, 0.22 g/L. The wells 
were set up by adding 100 µL water, 5 µL of protein and 250 µL of 20% Bradford reagent 
to give full wells with little or no meniscus. The absorbance was measured after 
incubating the wells for 10 minutes at room temperature. The standard curve was 
plotted with the absorbance at 595 nm against the BSA concentrations. The absorbance 
of the proteins was measured in a similar way to the standards by adding 100 µL of 
protein instead of the BSA standard and the concentrations of proteins were determined 
from the calibration plot.  
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2.6.3.2.2 UV absorbance 
Enzyme concentrations were also determined by UV absorbance at 280 nm on a 
NanoDrop 1000 (Thermo Scientific) using an extinction coefficient estimated by the 
ProtParam program on the ExPASy Proteomic Server 46. 
 
2.6.4 Enzyme purification 
 
The PaS mutants and WT-PaS expressed in E. coli were purified for enzyme kinetics 
and characterization using Ni-NTA His-trap column and further purified by size-exclusion 
chromatography when required. 
 
2.6.4.1 Affinity purification by Ni-NTA column 
 
Large-scale purification: 
The PaS enzyme purification was performed as described in Stevenson et al. (2015) 
with slight changes. Briefly, a starter culture was prepared by inoculating a single colony 
into 5 mL of Terrific Broth with 100 mg L-1 ampicillin (TBA) and was incubated overnight 
at 37 °C, 180 rpm (VWR IKA KS 4000 i control incubating shaker). The overnight starter 
culture was inoculated into 500 mL of TBA with 0.1 mM IPTG medium in a 2 L conical 
flask. The flask was incubated for ~30 hours at 30 °C or 48-50 hours at room temperature, 
shaking at 200 rpm. The cells were harvested by centrifuging at 8000g, for 30 minutes at 
4 °C. The supernatant was removed and the pellet was resuspended in buffer A (35 mL 
of Buffer A for 5 g of wet cell pellet). This cell suspension was lysed by 40 mg mL-1 
lysozyme (50 µL per 25 mL cell suspension) for 15 minutes at room temperature and was 
sonicated at 50% power and 50% pulse for 6-10 minutes by a Thermos Fisher omni sonic 
ruptor 400. Ammonium sulfate (0.2 g mL-1) was dissolved in the cell lysate, to precipitate 
unwanted protein, before centrifuging at 30000g for 30 minutes at 4 °C. The supernatant 
was recovered and additional ammonium sulfate was added for a final concentration of 
0.4 g mL-1 before overnight incubation on ice to precipitate PaS. The sample was then 
centrifuged at 30000g for 30 minutes at 4 °C. The supernatant was discarded and the 
pellet was resuspended in 20 mL of buffer A. This protein solution was loaded onto a 5 
mL Ni-NTA His-trap column (GE Healthcare) using a peristaltic pump (8 mL min-1) and 
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was eluted by an increasing gradient of buffer B with a flow rate of 1 mL min-1 (Figure 
2.40A). The collected fractions were tested for sulfatase activity using para-
nitrophenylsulfate (PNPS) and the purity of these fractions was evaluated by SDS-PAGE 
(Figure 2.40B). The fractions with > 90 % purity were pooled and extensively dialyzed 
against 50 mM Tris-HCl at pH 7.5 and stored at 4 °C. 
 
 
 
 
 
 
 
 
 
 
 
               *low molecular weight reference ladder 
 
 
Figure 2.40: Purification of WT-PaS by Ni NTA His-trap column. A) Elution profile 
(blue) with the increasing buffer B concentration (green). The second peak 
corresponds to sulfatase activity while the first peak corresponds to non-specific 
protein. B) Purity determined on SDS-PAGE 
 
Small-scale purification: 
Small-scale purification was performed for the enzyme characterization purposes. 
The overnight starter culture (0.5 mL) was inoculated to 50 mL of TB in a 200 mL culture 
flask. The same steps in the large-scale purification for expression, harvesting and cell 
lysis were followed. The lysed cell suspension was centrifuged for 10 minutes at 4000g. 
Next, the supernatant was loaded into 1 mL Ni-NTA His-trap column (GE Healthcare) and 
was washed with 10 mL of buffer A (see Appendix) containing 5% imidazole. The PaS 
enzyme was then eluted with 10 mL of buffer B (see Appendix) using a peristaltic pump 
where the first 0.5 mL was discarded. The eluted protein was mixed well with 5 g of 
ground ammonium sulfate and left overnight at 4 °C for precipitation. This was 
centrifuged for 15 minutes at 30000g and the supernatant was discarded. The protein 
pellet was resuspended in 0.5-1 mL of buffer A and was transferred to a 1.5 mL 
Eppendorf tube and centrifuged at 15000g for 15 minutes to precipitate any residual 
matter. The supernatant was then loaded to a 5 mL Hi-trap desalting column (GE 
 7  8  9 10 11 12 13 14 15 16 17 18 
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Healthcare) that was pre-conditioned with 25 mL buffer A. The protein was eluted with 
buffer A using a syringe (to avoid sample tailing) where the first 1.5 mL was discarded 
and 1.5-3.5 mL fraction was collected and was stored at 4 °C until further use. 
 
2.6.4.2 Gel purification 
The fractions containing sulfatase activity from the large scale purification of Ni 
His-trap column were further purified by Superdex 200 gel filtration column. The pooled 
fractions were concentrated to < 2 mL (4000g, 4 °C) using an Amicon ultra-centrifugal 
filter (Milipore, 30 kDa). The concentrated protein was injected to the AKTA protein 
purification system (GE healthcare) and was eluted in buffer A with a flow rate of 1 ml 
min-1 (Figure 2.41A). The purity of the fractions collected were assessed by SDS PAGE 
(Figure 2.43B). This protocol resulted in > 30 mg of protein with crystallization grade 
purity.  
 
 
 
 
 
 
 
 
 
 
*low molecular weight reference ladder 
 
 
Figure 2.41: Purification of His-trap purified WT-PaS by size exclusion 
chromatography. A) Elution profile (blue) in buffer A. B) Purity determined on SDS-
PAGE. 
 
 
2.6.5 Library generation 
 
2.6.5.1 SSM libraries (libraries 1-5) 
A mega-primer PCR method reported by Sanchis et al. 26 was used to create 
libraries for the single site saturation mutagenesis where a mutagenic primer and a 
flanking primer were used to generate a product of 300-1100 base pairs with the 
required mutation in the first PCR. This amplified sequence was then used as a mega-
    11 12 13 14 15 16 17 18 19 20 
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primer in the second PCR to anneal to the template at 60 °C with a second flanking 
primer in the vector, to generate the full length gene which was extracted by a gel 
purification. If the yield was low, then the gene was amplified in a third PCR with first 
and second flanking primers followed by PCR purification.  This was double digested by 
NdeI, EcoRI restriction enzymes (see 2.6.1.4) and was ligated to NdeI, EcoRI, CIP alkyl 
phosphatase treated pJExpress404 ampicillin resistant vector (see 2.6.1.5). 
 
2.6.5.2 Generating the combined mutants (PV-PaS and TV-PaS) 
 
The P-PaS, T-PaS and V-PaS mutants were double digested by PstI and EcoRI 
restriction enzymes. The   vector band (~4.5 kb) containing 155P/T mutation and the 
insert band (~1 kb) containing 330V mutation were isolated by electrophoresis (see 
2.6.1.3) in an 0.8% agarose gel, purified (see 2.6.1.6) and ligated (see 2.6.1.5) to generate 
the double mutants. 
 
2.6.5.3 MSM 1 library (library 6) 
An assembly method reported by Gibson et al. 47 was used to create the MSM 1 
library. Gibson assembly master mix purchased from New England Biolabs was used to 
anneal two fragments of overlapping DNA. The insert fragment containing the 
mutations and the vector fragment were generated in two separate PCRs and they were 
annealed at 50 °C for 15 minutes and 2 µL of this product was transformed into 50 µL 
electrocompetent E. coli DH5α (see 2.6.1.8). 
 
2.6.5.4 MSM 2 and MSM 3 libraries (libraries 7 and 8) 
Insert and vector DNA was spliced using an alternative method developed by Ruhu 
Qi at the Research School of Chemistry, Australian National University. Following vector 
amplification and purification 200 ng was added to a 20 µL reaction with an engineered 
E2 exonuclease with the provided buffer (engineered by Dr. Ruhu Qi, Astralian National 
University, not yet commercialized). DpnI was also included in the reaction to eliminate 
any parental DNA carried over from the PCR. The reaction mixture was incubated at 37 
°C (Qualtex solidstat incubators) for 1 hr, followed by enzyme inactivation at 75 °C for 
20 min. This resulted in vector DNA with about 15 bases of 5’ overhang. The insert 
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consisted of synthetic double-stranded oligonucleotides with 5’ overhangs 
complementary to those on the vector. The oligonucleotides were based on a short 
sequence from the PaS gene and included degenerate codons at mutation points. The 
coding and complementary oligonucleotides were annealed by heating a solution of 50 
nM of each at 72 °C for 5 minutes and then cooling to room temperature.  The purified 
vector DNA was mixed with the synthetic insert DNA in a 1:3 molar ratio at 65 °C for 10 
min before cooling to room temperature. The complementary 15 base-pair overhangs 
were sufficient to enable transformation of E. coli (see 2.6.1.8). 
 
2.6.5.5 Shuffled library (library 9) 
A similar protocol as described in section 2.6.5.1 was followed to generate the 
shuffling library. WT-PaS and PV-PaS were used as the templates for each half of the 
library to achieve K/V at 330 position in the library. A flanking primer with a tail end (see 
Tables A1 and A2) was used to avoid contamination from the starting template.  
 
2.6.6 Liquid chromatography mass spectrometry (LC-MS) 
 
The separation and detection of the steroids and their sulfate conjugates were 
performed on an Agilent 1260 Infinity UPLC system coupled to an Agilent 6120 
quadrupole mass spectrometer employing atmospheric pressure electrospray ionization 
(AP-ESI). An isocratic solvent system of 65% methanol in water with 10 mM ammonium 
acetate was used with an Agilent Poroshell 120 C18 column (30 mm with 5 mm guard, 
2.7 µm particles). Agilent 1290 infinity LC injector HTS sampler was used for screening 
experiments and the UPLC auto-sampler for kinetic experiments. The steroid sulfates 
were monitored in the negative mode as the proton loss species, [M-H]- and the free 
steroids were monitored in the positive mode as the proton adducts, [M+H]+. Capillary 
voltages and fragmentation voltages were adjusted according to published settings 38. 
 
2.6.7 Sulfatase activity screening 
 
The screens were designed to discover variants with beneficial activity for 
testosterone sulfate (TS) hydrolysis. Unless otherwise stated, the buffers used for 
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screening and assays are as follows. 50 mM Tris-acetate was used for buffering at pH 9, 
50 mM Tris-HCl for buffering at pH 7.5 and a triple buffer (TMA buffer) consisting of 50 
mM Tris, 25 mM MES and 25 mM acetic acid for buffering at pH 7. The pH of buffers was 
measured using pH 700 by Eutech Instruments. The buffers typically contained 1 µM of 
nandrolone (MSM 2, 3 and shuffled libraries) as the internal standard for quantification.  
 
2.6.7.1 Primary screen 
A 96-well plate based assay was performed as the primary screen. Single colonies 
from a SSM library were inoculated into separate wells containing 100 μL of LBA with 
0.1 mM IPTG in a round bottom 96-well plate. The sealed plates were incubated 
overnight at 37 °C shaking at 180 rpm. Then 40 µL of the culture from each well was 
transferred into a new flat bottom plate and the culture medium was removed by 
centrifuging (3700 rpm, 15 minutes) with 160 µL milliQ water and discarding the 
supernatant by inverting the plate with a gentle tap. The cell pellets were resuspended 
and lysed by 10 µL of 10 % BPER II (Thermo Fisher Scientific) for 10 minutes shaking at 
400 rpm. Then 40 µL of the reaction mixture containing 100 µM or 20 µM TS (final 
concentration) buffered at pH 9 or 7 (Table A3 see Appendix), was added to the wells, 
and the sealed plates were incubated at 37 °C (Qualtex solidstat incubators) for 4 hours. 
The reactions were then quenched with 50 µL methanol and the plates were sealed with 
sealing film (Axygen PlateMax ®). They were mixed and centrifuged at 3700 rpm for 15 
minutes using Eppendorf 5804 plate centrifuge. The supernatant was then injected into 
the LCMS. Data were evaluated by considering the T/TS (SSM libraries and MSM 1) or 
T/N (MSM 2, 3 and shuffled libraries) peak area. 
 
2.6.7.2 Secondary and tertiary screen 
The beneficial mutants from the primary or secondary screens were picked from 
the 96-well culture plates and streaked on LBA-agar plates before incubating at 37 °C, 
overnight. Isolated clones were then used for secondary or tertiary screening.  
The culture growth and reactions in the SSM libraries were performed in 500 μL 
of LBA with 0.1 mM IPTG in 1.5 mL Eppendorf tubes. The sealed tubes were incubated 
overnight at 37 °C shaking at 180 rpm. Then 100 µL of the culture volume was 
transferred to a new 1.5 mL tube and the culture medium was removed by centrifuging 
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(16000g, 5 minutes) with 400 µL milliQ water and discarding the supernatant. The cell 
pellet was resuspended in 10 µL milliQ water and lysed with 10 µL of 20 % BPER II 
(Thermo Fisher Scientific) for 10 minutes. Then 180 µL containing 100 µM TS (final 
concentration) buffered at pH 9, was added to the wells, and the sealed tubes were 
incubated at 37 °C (Qualtex solidstat incubators) for 4 hours. The reactions were 
quenched with 200 µL methanol, mixed, centrifuged (16000g, 5 minutes) and 350 µL of 
the supernatant was transferred to HPLC vials for LC-MS analysis. The culture growth, 
reaction and LC-MS analysis of the MSM libraries were performed in 96-well plates by 
the same protocol as described in section 2.6.7.1. These screens for SSM and MSM 
libraries were executed as independent biological triplicates. 
 
2.6.7.3 Comparison of TS and PNPS hydrolysis   
The TS and PNPS hydrolysis of a small library of randomly picked ten colonies from 
SSM 1 and SSM 4 were tested in singlicate. A wild type colony was used in both assays 
as a control. Ten randomly picked colonies from each library were expressed overnight 
at 37 °C in 500 µL LBA with 0.1 mM IPTG in 1.5 mL Eppendorf tubes. The PNPS assay was 
performed by lysing 10 µL of culture with 10 µL of 20 % BPER II (Thermo Fisher Scientific) 
for 5 minutes followed by adding 180 µL of 0.1 M PNPS (final) and measuring the initial 
rates at 405 nm. The TS assay was performed as described in section 2.6.7.1. 
 
2.6.8 Evaluation and characterization of PaS variants  
 
The concentrations of each enzyme preparation were tested by Bradford assay 
with bovine serum albumin as standards (see 2.6.3.2.1). 
 
2.6.8.1 Enzyme kinetics 
Enzyme activity as a function of substrate concentration (2.5, 5, 10, 20, 40, 80, 160, 
320 µM) was determined for purified proteins of WT PaS and the mutants for TS 
hydrolysis using LCMS. The concentration series of substrate was prepared by serial 
dilution of 320 µM TS in 50 mM Tris acetate at pH 9. The enzymes were prepared in the 
same buffer with a final concentration of 5 mg/L BSA and a final enzyme concentration 
of 0.4 µM for all enzymes except PVIV-, VVIV- and LEF-PaS that were at 0.08 µM. The 
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kinetics were monitored at 37 °C in triplicate. The substrates and the enzyme solution 
were centrifuged at 16000g for 5 minutes. Then, 360 µL of the substrate at each 
concentration was pipetted into separate HPLC vials and 400 µL of the enzyme solution 
was pipetted into a 1.5 mL tube. All were pre-incubated at 37 °C for 10 minutes in the 
LC-MS auto-sampler with the heater on. Next, 40 µL of the enzyme was pipetted to each 
vial, mixed, and the reaction rate was determined by measuring steroid concentration 
(T) at four time points, over which the rate was constant. Freshly prepared T standards 
(0.5, 1, 2, 5 µM T in 50 mM Tris acetate, pH 9) were used for quantification. The Michaelis 
Menten constant (KM) and maximum velocity for the reaction (Vmax) were calculated by 
fitting the data into the Michaelis Menten model using KaleidaGraph software. 
 
2.6.8.2 Effect of pH on PaS activity 
The optimum pH for the purified enzymes was assayed using WT-PaS and PVFV-
PaS with two different substrates: TS at 20 µM or 300 µM or PNPS at 20 µM or 50 µM. 
all substrates were prepared in TMA buffer containing 50 mM Tris, 25 mM MES and 25 
mM acetic acid 48, 49. The pH of the reactions ranged from 4 to 9 for TS hydrolysis or pH 
6 to 9 for PNPS hydrolysis. The TS hydrolysis was performed by mixing 10 µL of enzyme 
(0.4 µM final concentration) with 90 µL substrate and incubating at 37 °C for 1 hour. 
These reactions were quenched with 100 µL of MeOH (final concentration), centrifuged 
(16000g, 5 minutes), 150 µL of the supernatant was transferred to wells in 96-well plate 
and assayed by LC-MS (see 2.6.6). The PNPS hydrolysis was performed by pre-incubating 
the enzyme and substrate separately at 37 °C for 5 minutes, and mixing 20 µL of enzyme 
(10 nM final concentration) with 180 µL of substrate. After 1 minute or 3 minutes of 
reaction for WT-PaS and PVFV-PaS respectively, 100 µL of 1 M KOH was added to quench 
enzyme activity and ensure complete ionization of the para-nitrophenolate ion. The PNP 
was assayed at 405 nm using a SpectraMax M2 plate reader. The tests were performed 
in triplicate.  
 
2.6.8.2.1 PaS hydrolysis in a range of buffers 
The hydrolysis of WT-PaS and PVFV-PaS was tested in a range of buffers at two 
pHs representing each buffer. The reactions were performed at 37 °C or 50 °C. However, 
the same buffer preparation at 50 mM concentration was used at both temperatures 
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where the pH was adjusted only at 50 °C by HCl or NaOH(aq). The reactions were 
performed in 1.5 mL tubes in duplicates. First, 180 µL of the prepared buffers was 
pipetted to the 1.5 mL tubes. Then 10 µL of a mixture of 400 µM TS and 20 µM N was 
added followed by the addition of 10 µL of WT-PaS or PVFV-PaS at 0.4 µM final 
concentration. The reactions were incubated at 37 °C or 50 °C (Qualtex solidstat 
incubators) for half an hour followed by quenching the reactions with 400 µL of 75 % 
MeOH. The quenched reactions were centrifuged at 16000g for 5 minutes and 
transferred to HPLC vials for LC-MS analysis.  
 
2.6.8.3 Thermostability of PaS mutants 
PaS solutions were subjected to heat treatment in covered PCR strips using a PCR 
thermocycler (Bio-Rad C1000TM or Applied Biosystems Veriti). For analysis of the 
apparent melt temperature (Tmapp), PaS aliquots were incubated at defined 
temperatures for 5 min. The half-life (T1/2) was measured at 50 °C for defined times. 
Samples were kept on ice before and for 10 minutes after heat treatment, and untreated 
controls were kept on ice throughout. The PaS concentration for heat treatment was 
defined so that a ten-fold dilution would allow an accurate measurement of activity: 800 
nM for PVFV-PaS and 200 nM for all others. The activity of controls or samples (diluted 
10-fold) was assayed at 25 °C with 100 µM PNPS in 50 mM Tris acetate buffer at pH 9, 
or 50 mM Tris HCl buffer at pH 7.5 (enzymes diluted 10-fold in the reaction). The initial 
rate of PNP formation was measured at 405 nm over a period of 5 min using a 
BioStrategy SpectraMax M2 plate reader. Residual activity of treated samples was 
determined relative to controls and analysed by non-linear regression with 
KaleidaGraph 4.5. Observations for Tmapp were fitted to a modified Hill equation 49 
whereas those for T1/2 were to an exponential decay model. 
 
2.6.8.4 Testing the substrate scope 
Initial rates for hydrolysis of TS, EAS, ECS and ETS were tested with the purified 
proteins in triplicates. The tests were carried out in sealed 96-well plates. Two reaction 
conditions at pH 7.5 and 37 °C were used: i) α-configured steroid sulfates at 100 µM with 
4 µM enzyme incubated for 4 hours; or ii) β-configured steroid sulfates at 20 µM with 
0.08 µM enzyme incubated for 1 hour. Reaction were started by mixing 10 µL of enzyme 
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with 90 µL of substrate. Reactions were quenched with 100 µL of MeOH, centrifuged, 
and the amount of free steroid produced was measured by LCMS using the peak area 
ratio of the free steroid to internal standard (N). The results were quantified against the 
standards of free steroids prepared in a similar manner.  
 
2.6.8.5 Levels of post-translational modification of PaS mutants 
The levels of post-translational modification of cysteine to formylglycine was 
tested by the Ellman’s assay as described by Reiner et al. 50. All reagents and calibration 
standards required were freshly prepared. A 2 mM solution of Ellman’s reagent (5,5’-
dithiobis-(2-nitrobenzoic acid) or DTNB) was prepared in 50 mM sodium acetate. The 
reactions were conducted in 0.1 M Tris acetate at pH 8 and carried out in the wells of a 
96-well flat bottom plate with a 200 µL total volume.  
 
2.6.8.5.1 Determination of the molar extinction coefficient of TNB2- 
A standard series was prepared by using the reduced form of l-glutathione (GSH). 
The GSH stock solution for the standard series was prepared by diluting a 0.1 M GSH(aq) 
solution 200 times to make a 500 µM in water. A standard series of 5, 7.5, 10, 15, 20, 30, 
40 µM (calculated as the final concentrations in the reactions) GSH was prepared by 
diluting the 500 µM stock solution to produce 30 µM and 40 µM standards followed by 
a serial dilution. The reactions for the standard series were performed by adding 
guanidium chloride (8 M, 70 µL), Tris acetate buffer (1 M, 20 µL), GSH standard (100 µL) 
and DTNB2- (2 mM, 10 µL). The GSH blank was prepared by adding 100 µL of water 
instead of a GSH standard. The absorbance at 412 nm for the release of TNB2- was 
measured for 15 minutes at room temperature. The maximum absorbance was plotted 
against the GSH concentration to obtain the calibration plot and the molar extinction 
coefficient was determined by subtracting the blank and applying the parameters to 
Beer-Lambert law; A=ε*c*l where, A = absorbance, ε = molar extinction coefficient, c = 
concentration of the standards, l = path length. The reactions were performed in 
triplicate. 
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2.6.8.5.2 Determination of remaining cysteine of each PaS mutant and WT-PaS 
The enzymes were diluted to 100 µM concentration in water and the remaining 
amount of cysteine (thiol concentration) was tested according to the same protocol as 
for the standards. The reactions included the enzyme (100 µL), Tris acetate buffer (1 M, 
20 µL), guanidium chloride (8 M, 70 µL) and DTNB2- (2 mM, 10 µL). A protein blank was 
prepared similar to the GSH blank by adding 100 µL of water instead of protein. The thiol 
concentration was determined by applying the maximum absorbance observed to the 
equation of Beer-Lambert law. Each absorbance measurement was subtracted by the 
respective blank samples. The absorbance was measured in triplicate for each enzyme.  
 
2.6.9 Investigation of E74 residue 
 
2.6.9.1 Site directed mutagenesis of E74 residue 
Site directed mutagenesis was performed to create thee variants of PaS; E74Q, 
E74D and E74A. This included a single PCR amplification of the gene with a forward 
mutagenic primer (P27-f, P28-f and P29-f respectively for 74Q, 74D and 74A) and a 
reverse primer (P24-r) located at the end of the gene. The PCR product was purified from 
a gel extraction followed by double digestion with NcoI and EcoRI restriction enzymes. 
The purified digested product was ligated to NcoI, EcoRI, CIP alkyl phosphatase treated 
pJExpress404 ampicillin resistant vector (see 2.6.1.5). The ligated product was purified 
(see 2.6.1.6) followed by bacterial transformation (see 2.6.1.8).  
 
2.6.9.2 PNPS kinetics 
 
2.6.9.2.1 Determination of the molar extinction coefficient of para-nitrophenolate (PNP-) 
The standard series was prepared by serial dilution of an 80 µM PNP standard 
prepared from a freshly prepared 50 mM stock PNP solution in 50 mM Tris acetate at pH 
9, 37 °C. Then 200 µL of each standard was pipetted into wells of a 96-well flat bottom 
plate and the end point absorbance at 405 nm was read using a BioStrategy SpectraMax 
M2 plate reader. The standard curve was plotted with absorbance against PNP 
concentration and the molar extinction coefficient was calculated by the dividing the 
slope of the curve by the path length that was calculated by substituting the parameters 
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of the Beer-Lambert law. 
 
2.6.9.2.2  Kinetics 
The enzyme kinetics with PNPS was performed for the PaS E74 mutants and WT-
PaS. Enzyme activity as a function of substrate concentration (2.5, 5, 10, 20, 40, 80, 160, 
320 µM) was determined for purified proteins of WT PaS and the E74 mutants using 
BioStrategy SpectraMax M2 plate reader. The concentration series of substrate was 
prepared by serial dilution of 320 µM PNPS in 50 mM Tris acetate at pH 9. The enzymes 
too were prepared in the same buffer with a final enzyme concentration of 2 nM for 
WT-PaS and 200 nM for the E74 variants. The kinetics were monitored at 37 °C in 
triplicate.  The substrate was pipetted to the wells of a 96-well flat bottom plate with 
180 µL from each substrate concentration with the lids on and incubated in the plate 
compartment of the plate reader with the incubator turned on at 37 °C for 5 minutes. 
The enzymes (1 mL) at 10 times greater concentration were incubated in a 37 °C water 
bath for 5 minutes in sealed 1.5 mL Eppendorf tubes. After incubation, 20 µL of the 
enzyme was pipetted into the wells of the substrate by multi-channel pipetting and the 
plate was shaken for 5 seconds by the shaker option on the plate reader prior to reading 
absorbance. The initial rates for PNP- release was measured from 50-300 seconds at 37 
°C and the rate with related to concentration terms was calculated by applying the 
absorbance measurement to Beer-Lambert law by substituting the pre-determined 
extinction coefficient. The Michaelis constant (KM) and maximum velocity for the 
reaction (Vmax) were calculated by fitting the data into the Michaelis Menten model 
using KaleidaGraph software.   
 
2.6.10 Optimizing PaS expression in E. coli 
 
Different growth conditions were tested to optimize the expression of PaS. A 
single colony was inoculated in 0.5 mL of LBA or TBA and incubated overnight at 37 °C. 
The overnight starter culture was used to inoculate 50 mL of LBA or TBA with or without 
IPTG (100 µM) for induction in 125 mL culture flasks. The cultures were incubated at 30 
°C or 37 °C shaking at 180 rpm (VWR IKA KS 4000 i control incubating shaker). The 
cultures without added IPTG were incubated until the OD reached 0.8 at 595 nm 
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followed by addition of 100 mM IPTG to give a final concentration of 100 µM. The PNPS 
activity for all cultures was tested every hour between 24 and 32 hours by pipetting out 
10 µL of culture into a wells of a 96-well flat bottom plate followed by lysis with 10 µL of 
20 % BPER II (Thermo Fisher Scientific) for 5 minutes and measuring the initial rate of 
PNPS hydrolysis.  
1. Culture medium – LBA (Lauria Bertani- 100 mg L-1 ampicillin) and TBA (Terrific 
Broth - 100 mg L-1 ampicillin) were used for comparison 
2. Expression temperature – was varied between 30 °C and 37 °C under shaking 
conditions 
3. Induction time – was varied on which time IPTG induction was carried out 
a. Early induction – the overnight starter culture was added to the medium 
with IPTG. 
b. Late induction – the overnight starter culture was added to the medium 
without IPTG and then it was later induced with IPTG when the OD 
reached 0.8 at 595 nm.  
 
Figure 2.42: Different incubation conditions tested to optimize PaS expression 
 
The PNPS activity over an incubation time of 24-32 hours was measured and the 
maximum activity was plotted as in Figure 2.41. These results suggest that TBA medium, 
containing more nutrients than LBA, resulted in ~2 times better expression than in LBA. 
Additionally, longer incubation at lower temperatures yielded better results. Expressing 
the protein at 30 °C by inoculating the starter culture straight to IPTG induction in TBA 
resulted in the best expression for PaS. Therefore, a similar condition was employed for 
the expression of PaS for purification purposes.  
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Figure 2.43: PNPS hydrolysis activity in crude cell lysate for cultures under different 
conditions over an incubation time of 24-32 hours 
 
 
2.6.11 Minimal media selection 
 
2.6.11.1 Preparation of MMTS plates 
The MMTS was prepared according to the recipe developed in the McLeod 
laboratory adapted from Sambrook et al. 51 that uses the trace element recipe described 
by EMBL (obtained online in 2012). The MMTS medium was poured into petri dishes to 
achieve similar depth among the dishes in a sterile lamina-flow cabinet. The medium 
was allowed to solidify by drying for 10 minutes and were used immediately.  
 
2.6.11.2 Preparation of library cultures 
An E. coli transformation and recovery was performed that was followed by 
incubation as described in 2.6.1.10. Next, the cells were centrifuged at 6000g for 1 
minute and 400 µL of the supernatant was removed. The cell pellet was resuspended in 
the remaining media and was plated on a LBA-agar plate and was incubated overnight 
at 37 °C (Qualtex solidstat incubators). The cells were recovered by agitating about 10 
sterile glass beads and 2 mL of sterile water so that the beads displace the colonies over 
the entire surface. Then 1 mL of the resuspended cells were transferred to a sterile 1.5 
mL tube that was centrifuged at 6000g for 1 minute. The supernatant was removed and 
the cells were resuspended in 1 mL of no sulfur storage media and 100 µL aliquots were 
prepared in 1.5 mL tubes and stored at -80 °C. One aliquot was thawed and diluted 100-
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1000 times in water and 50 µL was plated on LBA-agar to estimate the dilution needed 
to obtain approximately 300 colonies per plate.  
 
2.6.11.3 Selection on MMTS 
An aliquot was thawed and 10 g L-1 thiamine was added to give a final 
concentration of 0.4 mg mL-1 in the diluted culture (DH5α is deficient in thiamine 
biosynthesis). Then 50 µL was plated on MMTS plates and the culture was uniformly 
distributed by agitating 10-15 sterile glass beads until the culture was absorbed. The 
glass beads were removed by collecting the beads to the lid by inversion of the plate. 
The plates were incubated at 30 °C until the colonies were visible and were transferred 
to 37 °C for faster growth.  
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Chapter 3:                    Application of PaS 
enzyme for urine samples 
 
3.1 Introduction 
 
With new developments in the analytical techniques such as mass spectrometry 
and chromatography, untargeted or metabolomic approaches are attracting attention in 
the anti-doping arena and becoming a promising strategy for the identification of new 
markers or metabolites. These methods have resulted in identification of new steroid 
sulfate metabolites 1-3 that extend detection windows for exogenous steroids or serve as 
markers for exogenous administration of endogenous steroids. With the growing 
importance of steroid sulfate markers in anti-doping screens, the demonstration that 
WT-PaS or its engineered variants can hydrolyse sulfate esters in real-world samples 
would be useful. 
The monitoring of the illicit use of steroids in the anti-doping laboratories is 
typically conducted by testing urinary steroids 4, as urine can be acquired in large 
volumes. However, components within the urine matrix can interfere with enzyme 
activity and provide an additional barrier for the introduction of a new enzyme 5-7 aimed 
at improving sample processing. The PaS enzyme engineered in defined buffers will be 
of greater utility if it has a similar performance in a complex matrix like urine. This 
chapter aims to investigate the practical application of PaS enzyme in urine including an 
effort using an untargeted method to detect a broad range of sulfated urinary 
metabolites and determine whether these are PaS substrates.  
The studies in this chapter include the application of enzyme hydrolysis of steroid 
sulfates either spiked into urine, present in urine as metabolites of endogenous steroids 
or exogenous administration. The enzyme hydrolysis was performed by PaS mutants 
produced in the course of enzyme engineering alongside with WT-PaS for comparison. 
This chapter consists of three studies; 3.2.1: quantification of d3-testosterone sulfate 
(d3TS) in a spiked urine sample, 3.2.2: hydrolysis of endogenous 
dehydroepiandrosterone sulfate (DHEAS) in human urine and 3.2.3: untargeted 
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screening of urinary sulfate metabolites and their enzyme hydrolysis in both humans and 
horses (section 3.2.3).  
 
3.2 Results and Discussion 
 
3.2.1 Quantification of d3-TS hydrolysis in a spiked urine sample 
  
In this thesis, protein engineering of PaS has been performed to improve TS 
hydrolysis. For this reason, the PaS variant with the highest Vmax for TS hydrolysis, LEF-
PaS, was tested in comparison with wild-type PaS. These tests were performed by using 
a female urine sample. The reaction conditions employed were analogous to those used 
for glucuronide hydrolysis with β-glucuronidase in a typical anti-doping screen. The tests 
were performed in duplicate and d3-TS (Figure 3.1) was used as the substrate instead of 
TS to avoid any endogenous TS complicating the results. Urine was spiked with 100, 200, 
or 300 ng/mL of d3-TS (61.6, 123.3, 185.0 ng mL-1 d3-T equivalent respectively) and 
incubated overnight at pH 7.5 and 37 °C with 100 µg/ mL or 10 µg/mL of either version 
of PaS as described in section 3.4.2.  
 
 
 
 
 
Figure 3.1: Structure of d3-testosterone sulfate 
 
First, the hydrolysis was performed with 100 µg/mL enzyme concentration (Figure 
3.2A) and LEF-PaS showed complete conversion at all concentrations while WT 
conversion was lower (35-60%). Within this experiment, the hydrolysis at 100 ng/mL d3-
TS by WT-PaS is exceptional with a large error observed.  Since the observed extent of 
hydrolysis between WT-PaS and LEF-PaS were not as dramatically discernible as 
expected, the enzyme concentration was reduced by one order of a magnitude allowing 
greater differentiation between the rates after overnight incubation (Figure 3.2B). 
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Figure 3.2: The percentage of d3TS hydrolysed by WT-PaS and LEF-PaS at A) 100 
µg/mL B) 10 µg/mL enzyme concentration at pH 7.5. The error bars represent the 
standard error of the duplicates. 
 
These results show that 10 µg/mL of LEF-PaS can completely hydrolyse the d3-TS 
at all substrate concentrations whereas WT-PaS conversion was estimated as < 2% at all 
concentrations (Figure 3.2B), that was below the lower limit of quantification (Table 
3.13). The lowest enzyme concentration at which LEF-PaS can completely hydrolyse d3-
TS under these conditions was not determined and could be lower than 10 µg/mL.  In 
addition, the LEF-PaS mutant has proven to show good hydrolytic activity compared to 
WT-Pas in the presence of a urine matrix despite the potential for inhibitory substances.  
 
3.2.2 Testing endogenous DHEAS hydrolysis in human urine 
 
Dehydroepiandrosterone (DHEA) is the most abundant circulating steroid in 
humans 8 and is a metabolic intermediate on the biosynthetic pathway to testosterone. 
It is reversibly converted to its sulfate conjugate (DHEAS) that exists in a greater 
concentration than the free steroid 9, 10. The amount of urinary DHEAS hydrolysis was 
tested with WT-PaS in comparison with PVFV-PaS as described in section 3.4.3. The 
PVFV-PaS mutant was selected because it has the broadest substrate range (section 
2.3.3). The DHEAS hydrolysis was performed with 100 µg/mL enzyme concentration and 
an overnight reaction at 37 °C at two different pHs (Figure 3.3). 
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Figure 3.3: The amount of DHEA detected after enzyme hydrolysis at pH 7 and pH 9 
 
The amount of free DHEA in a urine sample was analysed with no enzyme 
treatment and was estimated as less than 1 ng/mL and so considered negligible. Hence, 
the amount of DHEA detected from the enzyme treated samples is the DHEA produced 
from the hydrolysis of endogenous DHEAS. The hydrolysis at pH 9 compared to pH 7 was 
greater with both versions of PaS. At pH 9, both WT-PaS and PVFV-PaS showed levels of 
hydrolysis that were identical within error.  However, the absolute values of DHEA 
produced by PVFV-PaS at pH 7 were masked by an additional peak with the same mass 
as DHEA that had a retention time difference of < 7% that eluted after DHEA resulting in 
a lower integrated peak area. The amount hydrolysed by WT-PaS at pH 7 is slightly lower 
than that at pH 9 but is identical within error. Slower hydrolysis at neutral pH could 
possibly reflect lower stability. The DHEA produced from hydrolysis is within the range 
of quantification (Table 3.13). However, quantification of the amount of DHEAS present 
was not carried out to determine the percentage hydrolysed. A better discrimination of 
the amounts hydrolysed between enzymes could have observed if a shorter reaction 
time and a lower enzyme concentration was used.  
 
3.2.3 Untargeted screening of urinary metabolites 
 
The main aim of this section of work was to more broadly study the hydrolysis 
patterns of WT-PaS in comparison with PVFV-PaS. To achieve this, an untargeted 
detection method for urinary steroid sulfates was developed and employed to samples 
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pre- and post-enzyme hydrolysis. In addition, another aim of the study was to provide 
some structural information about the steroid sulfates observed. Furthermore, the 
equine urine study aims to identify metabolites of testosterone propionate 
administration by comparison of pre- and post-administration urine samples that could 
lead to the identification of potential markers.  
This study was performed as a part of a prize (Charles Hocart Award, ACT Mass 
Spectrometry Symposium, 2015) awarded to the candidate. The sample analysis on a Q-
Exactive plus LC-MS/MS (see section 3.4.5.2) was conducted by Mr Alex Chen of Thermo 
Fisher, Scoresby, Victoria. The methods were developed through consultation between 
the two parties.  
The Q-Exactive plus employs an orbitrap mass analyser that offers high resolution 
accurate mass (HRAM) performance. This can analyse a mass range of m/z 50-6000 and 
can be used for untargeted metabolomics. However, the mass range analysed in this 
study was limited to m/z 200-800. This study included the analysis on full scan mode (at 
70000 resolution, FWHM) that includes continuous acquisition and has the potential of 
detecting any compound if it is ionisable. Also data dependent tandem mass 
spectrometry (ddMS/MS) acquisition was employed (at 17500 resolution, FWHM) which 
selects prominent precursor ions 11 (top 10 per duty cycle in this study) to be fragmented 
and analysed by MS/MS. Therefore, this approach detects only the analytes selected for 
ddMS/MS that are later identified by applying the required filters. This technique is 
limited by the duty cycle rate as a faster duty cycle enables more acquisitions 11.  This 
ddMS/MS scan (17500, FWHM) and the high-resolution full MS scan (70000, FWHM) 
were acquired in parallel. This study targeted the identification of steroid sulfate 
metabolites although a range of putative sulfate metabolites were observed that did not 
appear to be steroidal in nature (Figure 3.4). 
Figure 3.4: A schematic representation of a duty cycle. 
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The study encompassed four urine samples; (1) human – female urine (female); 
(2) human – male urine (male); (3) horse – 0 hr blank urine (horse 0 hr); (4) horse – 12 
hr post administration of testosterone propionate (horse 12 hr). Each sample had three 
different treatments; i) control sample with no enzyme treatment; ii) treatment with 
WT-PaS; iii) treatment with PVFV-PaS. The enzyme hydrolysis was performed overnight 
at 37 °C, pH 7.5 in 75 mM (final concentration) Tris-HCl buffer (see section 3.4.5.1). The 
metabolites were extracted by solid phase extraction (SPE) with a weak anion exchange 
(WAX) cartridge and eluted with a mixture of ethyl acetate : methanol : diethylamine 
(25:25:1, by volume). All samples contained nandrolone and nandrolone sulfate as 
internal standards and were treated identically. Due to limited availability of the urine 
samples and analysis time, this study was performed as technical duplicates. 
 
3.2.3.1 Data analysis of ddMS/MS spectra and assignment of putative structures 
 
The data analysis included five major steps: 1) Analysis of ddMS/MS data with 
sulfate filters; 2) Integration of the peak areas for all sulfate metabolite precursor ions; 
3) Determination of the possible molecular formulae for selected precursor ions; 4) 
Attempted correlation of observed metabolites with the possible structures of 
previously reported compounds; 5) Integration of the calculated positive mode ion 
assuming hydrolysis to a sulfate free metabolite.  
First, filters for sulfates within a 10 ppm mass tolerance considering the loss of m/z 
= 97 or 80 corresponding to HSO4- and ·SO3- respectively 12 were applied on the ddMS/MS 
data. All the precursor ions corresponding to ≥ 20% of the relative abundance in the 
sulfate filters applied (Figure 3.5) were selected for further evaluation. As an example, 
from approximately 1050 data dependent acquisitions in the female control sample, 15 
precursor ions were selected for data analysis. 
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By applying sulfate filters to all samples analysed in duplicate, a range of putative sulfate 
metabolites were identified (Table 3.1). Similar profiles were observed for duplicates. 
 
Table 3.1: The number of peaks selected by applying the sulfate filters 
* Number of precursor ions selected with a relative abundance ≥ 20% of the most abundant peak  
 
Then the fragmentation patterns and the product ions for each of the precursor 
ions were analysed by inspection of the ddMS/MS scans. In the majority instances, this 
allowed the precursor ions to be identified, and in some instances some assignment of 
metabolite structure. The typical fragmentation patterns expected for the mono-
sulfates and bis-sulfates based on previous studies 12, 13 are exemplified in Figure 3.6. 
The previous studies report that mono-sulfates and bis-sulfates lose HSO4-, ·SO3- or SO3 
of m/z 97, m/z 80 and 80 Da respectively. 
 
Mono-sulfate ion loss fragmentation for testosterone sulfate 
 
 
 
 
Sample no. Sample name 
Number of precursor ions 
selected from the sulfate filters* 
(1) i) female _control 15 
(1) ii) female_ WT 19 
(1) iii) female_ PVFV 8 
(2) i) male _control 6 
(2) ii) male_ WT 12 
(2) iii) male_ PVFV 6 
(3) i) horse 0 hr _control 11 
(3) ii) horse 0 hr _ WT 16 
(3) iii) horse 0 hr _ PVFV 14 
(4) i) horse 12 hr _control 10 
(4) ii) horse 12 hr _ WT 14 
(4) iii) horse 12 hr _ PVFV 12 
        m/z = 367                          neutral 270 Da              m/z = 97 
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Mono-sulfate neutral loss of SO3 
 
 
 
 
Bis-sulfate ion loss fragmentation for estradiol bis-sulfate 
 
 
 
 
 
 
 
 
 
 
 
Bis-sulfate neutral loss of SO3 for estradiol bis-sulfate 
 
 
 
 
 
 
 
 
Figure 3.6: Typical fragmentation patterns observed for bis-sulfates and mono-
sulfates 
        m/z = 215     m/z = 333    m/z = 97 
 
m/z = 215    m/z = 350  m/z = 80 
 
        m/z = 367     neutral  287 Da                      m/z = 80 
 
        m/z = 351          m/z = 271                      neutral  80 Da 
 
m/z = 215    m/z = 175  neutral  80  Da 
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In the ddMS/MS data, fragmentation patterns of the mono-sulfates 
predominantly consisted of a single product ion: the loss of a sulfate ion; or two product 
ions: loss of a ·SO3- ion and the ion derived from of the neutral loss of SO3. Despite the 
scans targeting only the ion loss of the sulfate moieties, a neutral loss of SO3 was 
occasionally observed in the product ion spectra due to ion loss of ·SO3- in addition to 
the neutral loss of SO3. This provided a second ion with which to confirm the identity of 
the precursor ion. Due to this, metabolites that only lost SO3 (neutral loss) would not be 
observed by this method. Similarly, a product ion derived from the loss of 95 Da was 
observed in mono-sulfates that could be due to the consecutive neutral losses of SO3 
(80 Da) and ·CH3 (15 Da). Again, such cases would only be observed when accompanied 
by an ion loss of the sulfate derived ion at m/z 80 or m/z 97 leading to the mono-sulfate 
being observed as a precursor ion (Figure 3.7).  
 
 
 
 
 
 
 
 
 
Figure 3.7: The proposed pathway for the loss of 95 Da in a mono-sulfate.  
 
Furthermore, a product ion of m/z 81 was often observed that corresponds to an 
ion loss of a HSO3- 12 which provides potential for an additional filter.  
The identification of bis-sulfates was achieved with much less ambiguity due to 
the additional product ions typically afforded by fragmentation including observation of 
a mono-sulfate with a greater m/z value than that of the precursor ion. The 
fragmentation pattern of bis-sulfates therefore typically consisted of two product ions: 
the loss of a sulfate ion and the ion corresponding to the resulting mono-sulfate. 
In addition to a loss of m/z = 97 or 80, an apparent loss of m/z = 95 was 
infrequently observed in the bis-sulfates that could be due to a loss of ·SO3- followed by 
a loss of ·CH3 12 that could occur in a reaction scheme as shown in Figure 3.8.  
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Figure 3.8: The proposed pathway for the loss of m/z = 95 in a bis-sulfate. Figure 
adapted from reference article 12. 
   
Figure 3.9 shows two exemplary product ion spectra. The MS behaviour of the 
precursor ion (m/z = 224) in Figure 3.9A corresponds to that of a bis-sulfate. The loss of 
a HSO4- ion (m/z = 97) from the precursor ion resulted in a product ion of m/z = 351. 
Whereas the MS behaviour of the precursor ion (m/z = 243) in Figure 3.9B corresponds 
to a mono-sulfate that shows product ions at m/z = 163 that corresponds to the neutral 
loss of SO3 and m/z = 148 that corresponds to the succeeding loss of and ·CH3 (15 Da). A 
complemented ion loss of ·SO3- (m/z = 80) is also observed indicating why this mono-
sulfate was observed in the filtered ddMS/MS data. 
The m/z values are shown to one decimal point 
and the fragments with < 5% relative abundance are not shown for clarity. 
 
Figure 3.9: Exemplary product ion spectra observed in negative mode ddMS/MS 
corresponding to A) bis-sulfate loss of m/z 97 and B) mono-sulfate loss of 95 Da and 
m/z 80. The precursor ions are marked (*).  
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This study targeted steroidal sulfate analytes. Potential analytes range from 
estrone (270 Da) to cholesterol (386 Da) leading to notional mono-sulfates ([M-H]-) from 
m/z = 349 to m/z = 465 and bis-sulfates ([M-2H]2-) from m/z = 215 to m/z = 272 were 
considered. The free steroids ([M+H]+) range from m/z = 271 to m/z = 388. However, the 
scans employed in the analysis range from m/z = 200 to m/z = 800 in both polarities. 
This allowed other classes of sulfate metabolites to be detected by this approach, which 
may or may not fall within the range of steroids.  
 
3.2.3.1.1 Analysis of the female urine samples 
 
1) Application of sulfate filters to ddMS/MS scans 
The scan for the sulfate ion fragments in the female samples with ≥ 20% relative 
abundance of the most abundant peak in each sample resulted in metabolites that were 
only observed either in one sample or as common to more than one sample. In total, 33 
distinct metabolites were observed with limited overlap of six metabolites between the 
different samples (Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Venn diagram representing the number of precursor ions observed for 
each treatment of female urine. 
 
These metabolites were classified as mono-sulfates (mono) or bis-sulfates (bis) 
according to the fragmentation patterns observed. They were also classified as steroidal 
or non-steroidal (NS) based on the steroidal mass range (section 3.2.3.1) and to 
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observation of even ions when considering mono-sulfates within the mass range (Table 
3.2).  
 
Table 3.2: The precursor ions selected by applying the sulfate filters, the retention 
times, the product ions observed and the prediction as a bis-sulfate or a mono-sulfate. 
 
Precursor 
ion 
Ret. 
time  
(min) 
Product ions Bis 
/mono 
sulfate 
Non-
steroid 
sulfate 
Other ions 
97 80 
All samples 
A1 224 (40) 8.91 x  351 (12)   bis  
A2 383 (20) 9.89 x     mono  
A3 265 (80) 14.71 x     mono ns 
WT and PVFV treated samples 
E1 222 (100) 0.88  x 178 (12) 109 (12) 91 (10) mono ns 
     107 (10) 148 (8) 81 (5)   
E2 224 (25) 1.21 x x 124 (15) 351 (8) 312 (5) bis  
E3 248 (100) 1.84  x 124 (12) 107 (10) 81 (5) mono ns 
Control only 
C1 203 (45) 0.74  x 123 (100) 108 (15)  mono ns 
C2 212 (80) 0.86  x 132 (20) 81 (100)  mono ns 
C3 243 (19) 3.32  x 163 (100) 148 (54)  mono ns 
C4 232 (80) 5.97 x  367 (15)   bis  
C5 370 (10) 6.41  x 290 (100) 291 (25)  mono ns 
C6 231 (35) 6.58 x x 367 (15) 365 (5) 81 (60) bis  
     381 (5)     
C7 224 (70) 8.27 x  351 (25)   bis  
C8 354 (10) 9.26  x 274 (100)   mono ns 
C9 352 (5) 9.66  x 272 (100)   mono ns 
C10 238 (30) 10.35 x  379 (8)   bis  
C11 367 (25) 11.59 x     mono  
C12 601 (100) 12.58 x     mono ns 
WT treated sample only 
N1 229 (100) 0.69  x 107 (30) 147 (25) 150 (12) mono ns 
     121 (6) 81 (20)    
N2 309 (5) 0.75 x  129 (8)   mono ns 
N3 201 (5) 1.01 x  100 (5) 59 (8) 142 (5) mono ns 
N4 232 (100) 2.33 x x 367 (15) 59 (20) 215 (8) bis  
N5 305 (10) 2.36 x     mono ns 
N6 232 (50) 7.38 x x 215 (50) 155 (40) 59 (100) mono ns 
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     173 (20) 234 (30) 233 (20)   
     129 (8) 81 (42)    
N7 385 (50) 8.95 x  386 (10)   mono  
N8 383 (50) 9.07 x  384 (10)   mono  
N9 385 (30) 9.12 x  386 (10)   mono  
N10 383 (20) 10 x  384 (5)   mono  
N11 369 (100) 12.14 x  370 (15)   mono  
N12 369 (100) 12.3 x  370 (25)   mono  
N13 277 (100) 15.36  x    mono ns 
PVFV treated sample only 
M1 357 (15) 4.26  x 243 (5) 67 (20)  mono  
M2 246 (35) 8.16 x  395 (8)   bis  
The relative ion abundance observed in the MS/MS spectrum is shown within brackets. 
x denotes identified by filters for m/z 80 and/or m/z 97. 
mono: mono-sulfates; bis: bis-sulfates; NS: non-steroids 
Blue highlights: Putative steroids. 
Grey highlights: Even mass mono-sulfates within the steroidal mass range. 
 
From the 33 metabolites filtered in the three female samples, 17 metabolites 
(52%) could possibly be steroids (highlighted in blue). The remaining 16 metabolites are 
considered non-steroidal (NS) either because they do not fall within the steroidal range 
or due to the mono-sulfates containing an even-mass ion. In many instances, the sulfate 
fragment was observed as the base peak.  
Eight bis-sulfates were identified (A1, E2, C4, C6, C7, C10, N4 and M2). The loss of 
a HSO4- (m/z 97) was common to all the bis sulfates and the resulting mono-sulfate was 
observed as a minor product ion ranging from 5% - 25% relative intensity. The ion loss 
of ·SO3- (m/z 80) was observed by three precursor ions (E2, C6 and N4), however, the 
resultant mono-sulfate fragment was observed with < 1% relative abundance and was 
absent for N4.  This indicates that the loss of m/z 97 is favoured with the bis-sulfates 
when compared to the loss of m/z 80. For C6 there was a prominent loss of m/z 80 and 
15 Da to result in m/z 367 ion.  
The loss of m/z 97 and/or m/z 80 was observed in the mono-sulfates. Typically, 
the loss of m/z 97 did not result in other fragment ions. However, six mono-sulfates (C1, 
C2, C3, C5, C8 and C9) with the loss of m/z 80 contained two product ions: one 
corresponding to the loss of 80 Da and the second at m/z 80. This could be due to 
differences in fragmentation resulting in a mono-anionic product from a neutral loss of 
SO3 (80 Da) accompanied by the ion loss of m/z 80 as explained previously. Two mono-
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sulfates (C1 and C3) fragmented to give sequential loss of 80 Da SO3 and 15 Da ·CH3 
(Figure 3.6). In addition, an ion loss of HSO3- was observed at m/z 81 in seven product 
ion spectra (E1, E3, C2, C6, N1, N2 (< 2%) and N6) both in bis-sulfates and mono-sulfates 
indicating the applicability of using m/z 81 as an additional filter for sulfate derived ions.  
 
2) Peak integration of the precursor ions 
Peak integration was performed on the control and enzyme treated samples in the 
full scan data, for all the precursor ions selected from any sample regardless of their 
steroidal nature, and normalized with respect to the internal standard in each sample 
and presented as a fraction of the respective peak area of the control sample (Table 3.3).  
 
 Table 3.3: The integrated peak areas for each precursor ion normalized to the internal 
standard and presented as a fraction of the respective peak area of the control sample. 
 m/z Ret. time (min) WT/control PVFV/control 
A1 224 8.91 0.173 0.766 
A2 383 9.89 0.591 0.664 
A3 265 14.71 0.550 1.520 
E1 222 0.88 1.519 2.016 
E2 224 1.21 0.823 1.054 
E3 248 1.84 1.072 1.176 
C1 203 0.74 0.000 0.000 
C2 212 0.86 0.000 0.001 
C3 243 3.32 0.000 0.000 
C4 232 5.97 0.135 0.558 
C5 370 6.41 0.000 0.000 
C6 231 6.58 0.000 0.000 
C7 224 8.27 0.000 0.000 
C8 354 9.15 0.000 0.000 
C9 352 9.66 0.000 0.000 
C10 238 10.35 0.000 0.000 
C11 367 11.59 0.044 0.040 
C12 601 12.58 0.000 0.000 
N1 229 0.69 N/A N/A 
N2 309 0.75 3.674 4.880 
N3 201 1.01 1.380 1.572 
N4 232 2.33 0.615 0.885 
N5 305 2.36 0.705 0.960 
N6 232 7.38 0.291 0.205 
N7 385 8.95 0.514 0.630 
N8 383 9.07 0.239 0.286 
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N9 385 9.12 0.341 0.573 
N10 383 10 0.898 1.119 
N11 369 12.14 0.740 0.787 
N12 369 12.3 0.723 0.783 
N13 277 15.36 0.082 1.262 
M1 357 4.26 0.000 0.348 
M2 246 8.16 0.000 0.295 
Blue and grey highlights: Selected for molecular formula determination. 
N/A: Not applicable as the peak was absent in the control sample.  
 
Despite some ions not being selected as common to all samples from the 
ddMS/MS scan due to the criteria set (≥ 20% relative abundance), in most instances they 
were found in lower abundance in all samples. The absence of some signals when 
applying the sulfate mass filters for m/z 97 and m/z 80 may also reflect the data-
dependent acquisition that only selects the most prominent ions observed in the full-
scan data for subsequent MS/MS or product ion scan. Importantly, many sulfates 
selected in the control sample were absent or diminished considerably in the enzyme 
treated samples indicating significant hydrolysis of those sulfates (C1-C12). From the 33 
metabolites, the WT-PaS and PVFV-PaS treated samples exhibit significant changes of < 
33% or > 300% compared to the control samples in 20 and 16 metabolites respectively. 
From those, twelve metabolites (A1, C4-C11, N8, M1 and M2) fall within the mass range 
of steroids, and nine metabolites (E1, C1, C2, C3, C12, N1, N2, N6 and N13) are non-
steroidal. The two metabolites that the enzyme treated samples show a change of > 
300% than the control sample (N1 and N2) could be mono sulfates resulting from partial 
hydrolysis of bis-sulfates. However, all metabolites that fall within the mass range of 
steroids (Table 3.3 highlighted in blue and grey) regardless of the amounts hydrolysed 
are of interest and were selected for molecular formula determination. 
 
3) Molecular formulae determination 
As the next step, the possible molecular formulae were determined on the 20 
metabolites highlighted from Table 3.3. This included all the putative steroids and the 
three non-steroids within the steroidal range. The elements C, H, O, S, N and P were 
considered for this determination. Despite the fact that steroid sulfates are unlikely to 
contain nitrogen and phosphorus, these elements were included in the determination 
as some metabolites investigated were non-steroidal and it was possible that the masses 
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that potentially matched steroids were in fact non-steroidal in nature. The molecular 
formulae were determined as described in section 3.4.5.3. The search encompassed a 
criterion to contain at least one S and four O atoms in mono-sulfates and two S and eight 
O atoms in the putative bis-sulfates. Provided that the selected metabolites are sulfates, 
this criterion agrees well with the mono-sulfates. However, with the bis-sulfates it was 
assumed that the two anionic charges are derived from two sulfate groups.  The possible 
molecular formulae within a mass tolerance of 3 ppm were compared with that of the 
product ions and the only formulae that were comparable are reported (Table 3.4).  
 
Table 3.4: The possibilities of molecular formula for selected precursor ions. 
 Precursor ion Product ions 
A1 224.0614 (-2) 351.1637 (-1)  
i C15 H31 O8 N P S2 C15 H30 O4 N P S  
ii C19 H28 O8 S2 C19 H27 O4 S  
A2 383.1534 (-1)   
i C12 H27 O4 N6 S2   
ii C15 H30 O6 N P S   
iii C19 H27 O6 S   
E2 224.0433 (-2)   
i C14 H27 O9 N P S2 C14 H26 O5 N P S  
C4 232.0590 (-2) 367.1587 (-1)  
i C15 H31 O9 N P S2 C15 H30 O5 N P S  
ii C19 H28 O9 S2 C19 H27 O5 S  
C5 370.0966 (-1) 290.1398 (-1)  
i C6 H24 O6 N6 P2 S C6 H24 O3 N6 P2  
ii C7 H18 O4 N10 S2 C7 H18 O N10 S  
iii C9 H20 O5 N7 S2 C9 H20 O2 N7 S  
iv C12 H23 O7 N2 P S C12 H23 O4 N2 P  
v C16 H20 O7 N S C16 H20 O4 N  
C6 231.0511 (-2) 367.1218 (-1) 365.1419 (-1) 
i C17 H24 O8 N3 S2 C16 H21 O5 N3 S C17 H23 O4 N3 S 
ii C19 H26 O9 S2 C18 H23 O6 S C19 H25 O5 S 
C7 224.0614 (-2) 351.1637 (-1)  
i C15 H31 O8 N P S2 C15 H30 O4 N P S  
ii C19 H28 O8 S2 C19 H27 O4 S  
C8 354.1011 (-1) 274.1452 (-1)  
i C12 H23 O6 N2 P S C12 H23 O3 N2 P  
ii C16 H20 O6 N S C16 H20 O3 N  
C9 352.0883 (-1) 272.1295 (-1)  
i C5 H21 O4 N8 P S2 C5 H21 O N8 P S  
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ii C8 H24 O6 N3 P2 S C8 H24 O3 N3 P2  
iii C9 H18 O4 N7 S2 C9 H18 O N7 S  
iv C10 H24 O9 S2 C10 H24 O6 S  
C10 238.0773 (-2) 379.1949 (-1)  
i C17 H35 O8 N P S2 C17 H34 O4 N P S  
ii C21 H32 O8 S2 C21 H31 O4 S  
C11 367.1588 (-1)   
i C13 H28 O4 N4 P S   
ii C15 H30 O5 N P S   
iii C17 H25 O4 N3 S   
iv C19 H27 O5 S   
N4 232.0590 (-2) 367.1586 (-1)  
i C15 H31 O9 N P S2 C15 H30 O5 N P S  
ii C19 H28 O9 S2 C19 H27 O5 S  
N7 385.1696 (-1)   
i C12 H29 O4 N6 S2   
ii C15 H32 O6 N P S   
iii C19 H29 O6 S   
N8 383.1538 (-1)   
i C12 H27 O4 N6 S2   
ii C15 H30 O6 N P S   
iii C19 H27 O6 S   
N9 385.1694 (-1)   
i C12 H29 O4 N6 S2   
ii C15 H32 O6 N P S   
iii C19 H29 O6 S   
N10 383.1539 (-1)   
i C12 H27 O4 N6 S2   
ii C15 H30 O6 N P S   
iii C19 H27 O6 S   
N11 369.1745 (-1)   
i C15 H32 O5 N P S   
ii C19 H29 O5 S   
N12 369.1744 (-1)   
i C15 H32 O5 N P S   
ii C19 H29 O5 S   
M1 357.1016 (-1)   
i C7 H19 O4 N9 S2   
ii C10 H22 O6 N4 P S   
iii C14 H19 O6 N3 S   
iv C16 H21 O7 S   
M2 246.0749 (-2) 395.1898 (-1)  
i C17 H35 O9 N P S2 C17 H34 O5 N P S  
ii C21 H32 O9 S2 C21 H31 O5 S  
Blue highlights: Steroidal molecular formula 
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Most of the ions resulted in more than one possibility for the molecular formulae 
and some were determined as non-steroids. As expected, the even mass mono-sulfates 
(C5, C8, and C9) did not result in steroidal molecular formulae. From the 17 metabolites 
that were assumed as steroids from their m/z values (Table 3.2), only 15 metabolites 
resulted in a possible steroidal molecular formula with a number of carbon atoms ≥ 18 
(number of carbon atoms in estrone is 18) and are highlighted in blue. The E2 and M1 
metabolites did not result in a steroidal molecular formula. Interestingly all these 15 
metabolites contain a loss of m/z 97 out of which only two metabolites exhibited a loss 
of m/z 80 (C6 and N4). Some metabolites possessing the same m/z value with different 
retention times (A1 and C7; A2, N8 and N10; C4 and N4; N7 and N9; N11 and N12) will 
be considered together for the structure determination. Only the metabolites with a 
steroidal formula will be considered for structure determination.  
 
4) Steroid structure determination 
The metabolites with a steroidal formula (A1, A2, C4, C6, C7, C10, C11, N4, N7-
N12, and M2) were selected for structure determination. The structures were elucidated 
from the derived molecular formulae and the fragmentation patterns for the ions that 
could possibly possess a steroidal structure. The structure search was based on the 
reported structures on SciFinder molecular formula search tool. The structures for all 
derived molecular formulae (steroidal or non-steroidal) in these 15 metabolites were 
investigated. All the structures that resulted from this tool were filtered based on the 
following criteria: 1) should contain at least one -OSO3- group; 2) no heterocyclic steroids 
(as endogenous steroids with a heterocyclic structure are not reported); 3) no heavy-
atom isotopes.  Interestingly the non-steroidal formulae for the metabolites (e.g.: (C17 
H35 O9 N P S2)2- of M2) did not result in any structures and the steroidal molecular 
formulae resulted only in steroidal structures but no non-steroidal structures. The 
results of the structure search are shown in Table A6 (see Appendix). From these 15 
putative steroid sulfates, eight were significantly hydrolysed by either enzyme or both 
(Table 3.3) out of which six are bis-sulfates and three are mono-sulfates. 
However, this structural search has limitations as some of the published structures 
have inadequate evidence, as they are not compared with reference standards. Given 
many possibilities that exist for the structures of a single ion, they could be confirmed 
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by comparison with synthesized standards. However, a confirmation step was not 
carried due to limited time and the off-site analysis conducted as part of this study.  
 
5) Integration of the positive mode derivatives 
The expected masses of the complete hydrolysed products in the positive mode 
were calculated to the fourth decimal point by subtracting the mass of the lost sulfate 
group(s) from the sulfate metabolite precursor ion. The calculated m/z for [M+H]+ were 
then filtered from the positive polarity data in the full scan mode, for the 15 metabolites 
having a steroidal molecular formula (Table 3.5).  
 
Table 3.5: Peak integration of corresponding positive derivatives normalized to the 
internal standard and determination of molecular formulae. 
 
negative derivative positive derivative: mass tolerance=5 ppm  
m/z* molecular formula calculated 
m/z 
ret 
time 
(min) 
average area x 10-3 molecular 
formula# 
     control WT PVFV 
A1 224.0614 C15 H31 O8 N P S2 291.2319 11.9 18.388 16.763 16.677 C15 H34 O2 N P 
C7 (-2) C19 H28 O8 S2           C19 H31 O2 
N11 369.1744  C15 H32 O5 N P S       
N12 (-1) C19 H29 O5 S       
C4 232.059 C15 H31 O9 N P S2 307.2268 8.24 0.561 0.774 4.744 C15 H34 O3 N P 
N4 (-2) C19 H28 O9 S2  12.25 0.000 0.068 0.077 C19 H31 O3 
N7 385.1696 C15 H32 O6 N P S  17.71 1.526 1.238 1.174  
N9 (-1) C19 H29 O6 S       
  C12 H29 O4 N6 S2       
C6 231.0511 C17 H24 O8 N3 S2 305.2111 8.93 2.085 0.958 2.296 C17 H27 O2 N3 
 (-2) C19 H26 O9 S2  9.3 0.000 2.090 0.728 C19 H29 O3 
    10.19 6.065 1.354 1.612  
A2 383.1538 C12 H27 O4 N6 S2  12.65 0.028 2.648 3.861  
N8 (-1) C15 H30 O6 N P S  13.38 0.218 4.668 3.671  
N10  C19 H27 O6 S  13.6 2.053 3.552 3.770  
      16.66 0.904 1.705 1.571  
C10 238.0773 C17 H35 O8 N P S2 319.2632 - N/D   N/D  N/D    Not determined 
   (-2) C21 H32 O8 S2         
C11 367.1588 C13 H28 O4 N4 P S  289.2162 8.24 1.536 3.501 3.914 C19 H29 O2 
 (-1) C17 H25 O4 N3 S          
  C19 H27 O5 S          
   C15 H30 O5 N P S            
M2 246.0749 C17 H35 O9 N P S2 335.2581 12.96 1.232 1.302 1.262 C17 H38 O3 N P 
 (-2) C21 H32 O9 S2   16.72 0.080 1.746 2.256 C21 H35 O3 
N/D: Not detected. 
*The charge is specified in brackets. 
#Derived from observed precursors with 3 ppm mass tolerance. 
Grey highlights: enzyme treated samples > 3 times than control. 
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In some cases, the mono-sulfates and bis-sulfates give rise to the same completely 
hydrolysed product and so are shown together in Table 3.5. This suggests that these 
mono-sulfates could be the partially hydrolysed products of the respective bis-sulfates. 
Despite the partially hydrolysed products of bis-sulfates C10 and M2 that result in mono-
sulfates at m/z 397 and m/z 413 respectively being observed when the sulfate filters 
were applied in the ddMS/MS (Table 3.2), they were not reported as the relative 
abundance was < 2%. 
The presence of a single prominent peak was observed for the hydrolysed 
derivatives of A1/C7/N11/N12 and C11 metabolites whereas multiple peaks for the 
same m/z value were observed in some instances (C4/N4/N7 and N9, C6/A2/N8 and 
N10, and M2). No peaks in the positive mode were detected for the calculated m/z value 
for the hydrolysed derivative of C10.  
Integration of the peak areas in the positive mode resulted in three ions with peaks 
that integrate to more than 3 times the peak area in the enzyme treated sample over 
the control sample (highlighted in grey). However, the analysis of the positive mode 
derivatives is challenging for a few reasons; there lies some uncertainty regarding the 
functionality of the free steroids. Those without functionality such as a carbonyl group 
to be protonated would not be detected in the positive mode.  Furthermore, the extent 
of hydrolysis for the bis-sulfates is unknown as whether they result in completely 
hydrolysed free steroids or partially hydrolysed mono-sulfated products.  
The putative molecular formulae of the positive mode derivatives were 
determined in a similar way to step 3, and only the formulae that match with the 
formulae derived from negative mode data are reported. From these 15 putative steroid 
sulfates, eight showed significant hydrolysis in the negative mode data (A1, C4, C6, C7, 
C10, C11, N8, M1 and M2) by both WT-PaS and PVFV-PaS except for A1 and C4 that 
showed significant hydrolysis only by WT-PaS. The amount of hydrolysis shown in the 
negative mode data do not correlate well with that of the positive mode data for A1, C7 
and C10 metabolites, which showed significant hydrolysis in the negative mode data but 
not in the positive mode data. However, the other metabolites contained peaks that 
show significant hydrolysis in both negative and positive mode data.  
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Analysis of the C6 metabolite 
By proceeding through all the steps explained above, the C6 metabolite serves as 
suitable case for further discussion. The C6 metabolite was identified as a bis-sulfate 
(m/z 231) and the absence of this metabolite in the enzyme treated samples indicates 
hydrolysis by the enzymes (Table 3.3). The bis-sulfate suggests the possible presence of 
two mono-sulfates by partial hydrolysis of either sulfate group. The enzyme hydrolysed 
mono-sulfate product of C6 is calculated as m/z 383. This value corresponds to that of 
the A2, N8 or N10 metabolites that were all observed to some extent in the controls. 
The enzyme treated samples containing reduced amounts of the three mono-sulfate 
metabolites compared to the control sample (except for the PVFV treated N10 
metabolite) and no additional mono-sulfate peaks at m/z 383 in the enzyme treated 
samples suggests extensive hydrolysis of the bis-sulfate to the free steroid rather than 
the predominance of partial hydrolysis (Table 3.3).  
The scan in the positive mode for the calculated mass (m/z 305) of the complete 
hydrolysed product resulted in seven peaks out of which three resulted in peak areas > 
10 times compared to the control (highlighted in grey). This observation is consistent 
with the number of peaks expected from the complete hydrolysis of the three mono-
sulfates (two of which could be derived from the bis-sulfate) and/or one bis-sulfate 
metabolite that should give a number between two to four hydrolysed products.  
The C6 metabolite identified as a bis-sulfate shows a fragmentation pattern with 
product ions for the loss of m/z 97 (corresponding to the loss of HSO4-) and m/z 95 
(corresponding to the loss of ·SO3- followed by the loss of ·CH3). The respective 
fragmentations could occur as depicted in Figure 3.7. Previous studies of bis-sulfates 
suggest the loss of m/z 95 is associated with a sulfate adjacent to ketone or alkene 12. 
Taken these points into consideration with the structure search results (Table A6, see 
Appendix), the following structure or a stereoisomer (Figure 3.11) can be proposed for 
the C6 metabolite. Confirmation of this proposed structure would require access to 
reference materials that would allow comparisons of LC retention times and MS 
behaviour.  
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Figure 3.11: The proposed structure for the C6 metabolite and the enzyme 
hydrolysed products. Candidates for the mono-sulfates and the free steroid were 
observed in the negative and positive mode data respectively. 
 
3.2.3.1.2 Analysis of the male urine samples 
 
The number of metabolites selected from the application of sulfate filters was 
comparatively lower for all the male samples than for the female samples (Table 3.1). 
Most of the metabolites observed in the male samples were present in the female 
samples; control sample: C2, C7, A1, C10, C11 and M2; WT treated sample: N1, E2, A2, 
N11, A3 and N13; PVFV treated sample: E2, M1, M2, A1 and A2. In contrast, E1, E3, C1, 
C3-C6, C8, C9, C12, N2-N10 and N12 metabolites were not identified in the male samples 
with ≥ 20% relative abundance.  
The male samples identified five bis-sulfates, which were also observed in the 
female samples (A1, E2, C7, C11 and M2). The control, WT treated and PVFV treated 
samples contained zero, six and one new sulfate metabolites respectively, that were not 
observed in the female samples (Table 3.6). 
 
 
 
 
 
 
      bis-sulfate (C6)  hydrolysed mono-sulfate   hydrolysed free steroid 
           m/z 231                m/z 383    m/z 305 
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Table 3.6: The additional precursor ions observed in the male samples, the retention 
times, the product ions observed and the prediction as a bis-sulfate or a mono-sulfate 
 
Precursor 
ion 
Ret. 
time 
(min) 
Product ions 
Bis/mono 
sulfate 
Non-
steroid 
sulfate 
other ions 
 
97 80  
 WT treated sample only  
 
N14 309 (100) 15.18 x    mono ns 
N15 277 (100) 15.56  x   mono ns 
N16 353 (100) 15.59 x    mono  
N17 291 (100) 15.75  x   mono ns 
N18 291 (100) 16.47  x   mono ns 
N19 305 (100) 16.6  x   mono ns 
PVFV treated sample only 
 
M3 214 (100) 0.42  x 178 (55) 134 (35) mono ns 
The relative ion abundance observed in the MS/MS spectrum is shown within brackets. 
x denotes identified by filters for m/z 80 and/or m/z 97. 
mono: mono-sulfates; bis: bis-sulfates; ns: non-steroids 
Blue highlights: Putative steroids;  
 
The analysis of the male urine samples contained some uncertainty due to the 
incompatibility of the retention times between samples possibly due to slight changes 
in column temperature. The WADA chromatographic criterion specify the difference in 
retention time (∆RT) between the chromatographic peaks of the same analyte should 
not exceed 1% or ± 0.1 minutes. Complying this criterion was challenging when selecting 
the peaks for integration in the male samples. The corresponding analytes between 
samples were selected to the best ability by considering similar peak patterns and the 
shifts in the NS internal standard.  
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Table 3.7: The integrated peak areas for each precursor ion normalized to the internal 
standard and presented as a fraction of the respective peak area of the control sample  
 
 
Blue highlights: Putative steroids 
 
Comparison of the peak areas (Table 3.3 and Table 3.7) of the metabolites 
common to the female samples reveals that some metabolites (C2, C7, C10 and C11) are 
absent or reduced in the enzyme treated samples indicating considerable hydrolysis. 
Knowing the presence of DHEAS in high abundance 14 and observing DHEAS in human 
urine in a study performed to target sulfate metabolites in human urine 13, the C11 
metabolite present in both female and male samples could be DHEAS. In contrast, A1, 
A2, A3, E2, N1, N11, N13 M1 and M2 metabolites show different levels of hydrolysis 
compared to the female samples. The N14-N19 metabolites show an interesting pattern 
of integrated peak areas as these metabolites in the WT treated sample are 5-23 times 
greater than that of the control sample, whereas the PVFV treated sample contains 
comparable amounts of these metabolites to the control sample. From the 20 
metabolites identified, the WT-PaS and PVFV-PaS treated samples exhibit significant 
changes of < 33% or > 300% compared to the control samples in 17 and 5 metabolites 
respectively. 
 m/z Ret. time  (min) WT/control PVFV/control 
A1 224 8.88 0.106 1.075 
A2 383 9.77 0.294 0.524 
A3 265 14.38 1.796 0.820 
E2 224 1.21 1.389 1.602 
C2 212 0.80 0.000 0.000 
C7 224 8.09 0.000 0.000 
C10 238 10.13 0.000 0.000 
C11 367 11.53 0.016 0.020 
N1 229 0.40 12.858 1.496 
N11 369 11.16 0.171 0.019 
N13 277 15.11 12.472 1.050 
N14 309 15.18 6.378 0.425 
N15 277 15.56 15.849 1.029 
N16 353 15.59 5.354 0.433 
N17 291 15.75 22.564 1.179 
N18 291 16.47 18.599 0.864 
N19 305 16.45 18.973 1.434 
M1 357 4.09 0.000 0.734 
M2 246 7.85 0.000 0.418 
M3 214 0.42 0.827 2.026 
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The N16 metabolite is the only additional metabolite observed in the male 
samples that falls within the steroidal mass range and was selected for molecular 
formula determination. However, it resulted in a single formula, (C16 H33 O6 S)1- that is 
non-steroidal and will not be discussed further. 
 
3.2.3.1.3 Analysis of the horse urine samples 
 
This portion of the study focussed on identifying metabolites of testosterone 
propionate (TP) (Figure 3.12). This was based on comparing thoroughbred gelding urine 
samples collected at 0 and 12 hours post-administration of intramuscularly injected TP 
(see 3.1.1). In a recent study 15 the administration of TP to thoroughbred gelding was 
performed to test the T/ET ratio, however, studies on TP administration for untargeted 
steroidomics was not found on literature.  Further, the enzyme hydrolysis of the sulfate 
metabolites was tested by performing the same treatment as in the human urine 
samples. In this text, the pre-administration and post-administration samples are 
referred to as 0 hr and 12 hr samples respectively. 
 
 
 
 
 
Figure 3.12: Structure of testosterone propionate 
 
In the filtered ddMS/MS data, the peaks with ≥ 20% relative abundance compared 
to the most abundant peak of three samples each (one control and two enzyme treated) 
of 0 hr and 12 hr post-administration urine were selected.  The analysis of these samples 
resulted in a number of sulfate metabolites (Table 3.1) out of which only a single 
metabolite (P27) in the 12 hr sample was identified as a bis-sulfate. The peak areas of 
all these metabolites (40 unique metabolites) were integrated in all samples irrespective 
of which sample the metabolite was selected from. The peak integrated results of the 
controls of the 0 hr and 12 hr samples are reported in Table 3.8.  
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Table 3.8: The integrated peak areas in the 0 hr and 12 hr control samples for each 
precursor ion resulting from the sulfate filters in the ddMS/MS normalized to the 
internal standard.  
 
 Ret. time 
(min) 
m/z Average area 
0hr 12 hr 12hr/0hr 
P1 0.29 253 0.076 0.133 1.75 
P2 0.31 217 0.133 0.194 1.46 
P3 0.4 210 0.010 0.014 1.36 
P4 0.63 243 0.059 0.162 2.75 
P5 0.69 212 11.153 10.377 0.93 
P6 0.78 212 33.862 60.489 1.79 
P7 0.84 215 0.168 0.961 5.72 
P8 0.85 230 0.415 0.715 1.72 
P9 0.95 212 1.835 1.915 1.04 
P10 0.96 273 0.052 0.013 0.24 
P11 0.99 201 0.011 0.016 1.49 
P12 1.22 226 2.979 3.417 1.15 
P13 1.27 230 4.361 5.172 1.19 
P14 1.32 210 0.012 0.010 0.87 
P15 1.64 254 0.155 0.832 5.36 
P16 1.73 247 0.133 0.022 0.16 
P17 1.83 254 0.603 0.419 0.69 
P18 1.99 240 0.354 0.447 1.26 
P19 2.51 226 32.721 39.028 1.19 
P20 2.86 301 0.202 0.632 3.13 
P21 2.88 301 2.727 8.317 3.05 
P22 4.53 209 0.173 1.120 6.46 
P23 4.77 279 0.579 0.777 1.34 
P24 5.53 270 0.487 0.122 0.25 
P25 5.79 291 0.135 0.297 2.19 
P26 6.06 284 0.157 0.041 0.26 
P27 6.4 232 0.000 0.203 N/A 
P28 6.53 233 0.476 0.132 0.28 
P29 6.72 287 0.012 0.057 4.63 
P30 6.83 289 0.430 2.381 5.54 
P31 6.84 209 0.335 0.061 0.18 
P32 6.95 289 0.430 0.456 1.06 
P33 8.01 319 0.102 0.092 0.90 
P34 8.84 344 0.129 1.192 9.28 
P35 9.04 395 0.045 0.035 0.77 
P36 10.15 314 0.027 0.067 2.48 
P37 11.47 369 0.001 1.423 1998.33 
P38 14.11 265 0.631 0.724 1.15 
P39 15.26 353 0.031 0.034 1.10 
P40 15.66 293 0.263 0.299 1.14 
Blue highlights: Putative steroids 
Grey highlight: 12 hr area >3 times than 0 hr area 
N/A: not applicable 
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Within the defined criteria in the selection of metabolites, only three metabolites 
were found common to horse and human samples. The P6, P11 and P38 all non-steroidal 
metabolites were present in the human samples as C2, N3 and A3 respectively. The 
integrated peak areas of these metabolites in the controls of horse and human samples 
are presented in Table 3.13.  
 
Table 3.13: The integrated peak areas of the three common metabolites in horse and 
human control samples.  
 
m/z Horse control samples Human control samples  
Average area 
 
Average area 
0 hr 12 hr female male 
212 P6 33.862 60.489 C2 6.509 15.740 
201 P11 0.011 0.016 N3 0.009 0.000 
265 P38 0.631 0.724 A3 1.268 0.770 
 
The variation between the human and horse samples are not very significant for 
P11 and P38 metabolites. However, the P6 metabolite varies significantly in each sample 
with the horse samples containing 2-10 times greater amounts than that in the human 
samples. The enzyme hydrolysis of this metabolite reduced the amount of sulfate by 
more than 500 fold compared to the control sample in both horse (not shown) and 
human samples.  
From the 40 metabolites, ten metabolites had an average area that was three 
times higher in the 12 hr sample than in the 0 hr sample (grey highlights). Interestingly, 
six metabolites were observed to decrease > 3 times in the 12 hr sample compared to 
the 0 hr sample. Only four metabolites fell within the mass range of steroids (blue 
highlights: P27, P35, P37 and P39). The details of the MS/MS data of these metabolites 
are reported (Table 3.9). 
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Table 3.9: The product ions of the metabolites observed with > 5 times in the 12 hr 
post-administration sample than the 0 hr sample and/or metabolites within the 
steroidal mass range.  
The relative ion abundance observed in the MS/MS spectrum is shown within brackets. 
 
 
As shown in Table 3.9, the P27 metabolite exhibits the typical fragmentation 
pattern of a bis-sulfate showing fragmented product ions derived from the losses of  m/z 
97 (m/z 367), m/z 81 (m/z 383) and m/z 80 + 15 Da (m/z 369). From the four metabolites 
that fell within the range of steroids, P35 and P39 did not show significant changes in 
pre- and post- administration samples (Table 3.8) and will not be discussed. Of the non-
steroids that show a significant increase (P7, P15, P22, P30 and P34) in the 12 hr sample 
the increase was below 10-fold when compared to the 0 hr sample.  However, the 
putative steroidal P27 and P37 metabolites dramatically increased in the 12 hr post-
administration samples > 1000 times compared to the 0 hr sample and therefore could 
be potential metabolites that result from TP administration.  
The peak integration of P27 and P37 metabolites in the 12 hr enzyme treated 
samples did not result in significant changes (> 3 fold) relative to the control (Table 3.10). 
However, the amount of P37 metabolite in the enzyme treated samples indicates 
approximately half of this sulfate metabolite is hydrolysed. 
 
 
 
 Precursor Ret. time 
(min) 
Product ions Bis/mono 
sulfate 97 80 other ions 
P7 215 (20) 0.84  x 178 (100) 135 (8)  mono-sulfate 
P15 254 (3) 1.64 x x 174 (100)   mono-sulfate 
P22 209 (55) 4.53 x     mono-sulfate 
P27 232 (40) 6.4 x x 233 (40) 369 (20) 155 (35) bis-sulfate 
59 (80) 383 (16) 81 (70) 
367 (5) 
  
P30 289 (40) 6.83 x     mono-sulfate 
P34 344 (100) 8.84  x 124 (60) 59 (70) 67 (50) mono-sulfate 
P35 395 (12) 9.04 x  257 (20)   mono-sulfate 
P37 369 (100) 11.47 x 
 
370 (25) 
  
mono-sulfate 
P39 353 (90) 15.26 x     mono-sulfate 
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 Table 3.10: The integrated peak areas of the 12 hr samples of P27 and P37 normalized 
to the internal standard and presented as a fraction of the respective peak area of the 
control sample. 
 
 
 
 
The positive mode scan of the hydrolysed free steroid products of P27 and P37 
(hereafter named as X27 and X37 respectively) at m/z 307 and 291 respectively resulted 
in a single peak at each mass that could be integrated (Table 3.11) and a range of smaller 
peaks that were poorly resolved.  
 
Table 3.11: Peak integration of the corresponding hydrolysed free steroid products of 
P27 and P37 metabolites in the 12 hr samples normalized to the internal standard and 
presented as a fraction of the respective peak area of the control sample. 
 
negative derivative positive derivative: mass tolerance=5 ppm 
  m/z* molecular formula  calculated 
m/z 
Ret. 
time 
(min) 
average area 
normalized to 
control 
molecular 
formula# 
  
  
     WT/ 
control 
PVFV/ 
control 
  
P27 232.0590 
(-2) 
 
 
 
C13 H29 O8 N4 P S2 
C14 H30 O8 N3 S3 
C15 H31 O9 N P S2 
C17 H26 O8 N3 S2 
C19 H28 O9 S2 
X27 307.2268 15.14 1.18 1.30 - 
- 
C15 H34 O3 N P 
- 
C19 H31 O3 
P37 369.1743 
(-1) 
C13 H30 O4 N4 P S 
C14 H31 O4 N3 S2 
X37 291.2319 17.22 1.03 1.15 - 
- 
C15 H34 O2 N P  
- 
C19 H31 O2 
 
C15 H32 O5 N P S 
C17 H27 O4 N3 S 
C19 H29 O5 S 
         
*The charge is specified in brackets. 
#Derived from observed precursors with 3 ppm mass tolerance. 
 
The integration of the X27 and X37 peak areas in the positive mode resulted in 
lower values in the control compared to the enzyme treated samples. However, 
observing the respective peaks in the control sample indicates the presence of the free 
steroid in the initial sample in considerable amounts. When both metabolites are 
considered, the PVFV mutant shows greater hydrolysis by 10-12% than WT (Table 3.11).  
The peak integration of the positive mode derivatives X27 and X37 metabolites in 
the 0 hr control sample (Table 3.12) indicates the presence of these products prior to 
 m/z Ret. time (min) WT/control PVFV/control 
P27 232 6.4 1.038 1.514 
P37 369 11.47 0.551 0.527 
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administration. A similar amount of X27 derivative was observed in the control samples 
pre- and post-administration. This indicates the X27 is an endogenous metabolite that 
does not significantly change concentration upon TP administration. However, the 
concentration is slightly enhanced upon enzyme hydrolysis. The X37 metabolite on the 
other hand increases in concentration significantly upon TP administration and further 
increases upon enzyme hydrolysis. The molecular formulae derived for the positive 
derivatives further reduces the number of possibilities available for the negative 
derivatives. However, it should be noted that the positive mode peaks assigned for these 
metabolites are putative and may or may not be the accurate derivative of the 
respective metabolites.   
 
Table 3.12: Peak integration of corresponding positive derivatives of P27 (X27) and 
P37 (X37) metabolites in the 0 hr and 12 hr control samples. 
 
   
 
 
 
A steroidal structure search (on SciFinder molecular formula search tool) of the 
P27 and P37 metabolites was performed in a way similar to that of the female 
metabolites (section 3.2.3.1.1) and the structures for all derived molecular formulae are 
reported in Table A6 (see Appendix). Considering the fragmentation pattern of the P27 
bis-sulfate (with the product ions derived from the ion losses at m/z 97, m/z 81 and m/z 
95) which is similar to that of the C6 metabolite, the following structure or a 
stereoisomer can be proposed.  
 
 
 
 
Figure 3.13: The proposed structure for the P27metabolite. 
 
The P37 metabolite is consistent with AS, EAS, ECS or an isomer. However, AS, or 
ECS are unlikely due to considerable hydrolysis of P37 by both versions of PaS (Table 
 
average area * 10-3 
0 hr 12 hr 
X27 16.754 16.167 
X37 1.093 6.190 
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3.10).  Other structures are also found in SciFinder and are reported in Table A6 (see 
Appendix). Confirmation of structures by comparison with synthesized standards could 
further establish these metabolites (P27 and P37) to potential markers of TP 
administration. Furthermore, analysing urine samples for longer time-points to establish 
the detection window for P27 and P37 metabolites, and also performing a population 
study to test if similar patterns are observed broadly or in some individuals only, would 
be important work to be conducted in future.  
 
3.3 Conclusions and Future directions 
 
The initial studies on d3-TS and DHEAS hydrolysis of PaS enzyme has proven that 
PaS enzyme and its variants show good hydrolytic activity in the presence of a urine 
matrix despite the potential for inhibitory substances present such as phosphate. The 
LEF-PaS mutant at 10 µg mL-1 can completely hydrolyse 100, 200 and 300 ng mL-1 d3-TS 
in an overnight reaction at 37 °C, pH 7.5 analogous to the reaction conditions used by β-
glucuronidase enzyme in a typical anti-doping screen. Whereas, d3-TS hydrolysis by WT-
PaS under the same conditions was < 2% at all substrate concentrations. When DHEAS 
hydrolysis using 100 µg mL-1 of enzymes of either WT-PaS or PVFV-PaS, was performed 
in an overnight reaction at 37 °C, at pH 7 and pH 9, the amount of DHEA produced from 
hydrolysis was similar for both versions of PaS at pH 9. However, the production of DHEA 
at pH 7 was slightly lower than that at pH 9, which could be due to lower enzyme stability 
at pH 7.  
The untargeted screening of the urinary sulfate metabolites of the human urine 
samples discovered mono-sulfates as well as bis-sulfates. The treatment of PaS enzyme 
on the female urine samples resulted in a decrease in some metabolites compared to 
the untreated sample. Ten metabolites in the female samples were lowered at least a 2-
fold in both the enzyme treated samples. Despite the two versions of PaS showing 
considerable changes with respect to the control sample, the discrepancy between WT 
and PVFV treated samples was not significant except for a range of metabolites observed 
in the male samples (Table 3.7: N14-N19). This could be due to the high enzyme 
concentration (0.2 mg/mL) used in the reaction and the low concentrations of steroids 
present in the urine samples. When TS is concerned, WT-PaS has a slightly greater 
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affinity than PVFV-PaS at pH 9, however, the kinetic parameters closer to neutral pH 
were not determined.  The comparison of female and male samples resulted in 13 
common metabolites, 20 and 7 unique metabolites in the female and male samples 
respectively. From these, WT-PaS and PVFV-PaS treated samples exhibit significant 
changes of < 33% or > 300% compared to the control samples in 29 and 17 metabolites 
respectively in total out of which 12 and 7 are putative steroidal metabolites. 
The analysis of the 0 hr and 12 hr TP post-administration equine urine samples 
identified no bis-sulfates in the 0 hr sample and one bis-sulfate in the 12 hr sample. 
Interestingly, this study discovered two putative steroid sulfates, P27 and P37, in the 12 
hr sample with > 1000 fold increase over the 0 hr sample. The presence of the presumed 
hydrolysed products of these metabolites, X27 and X37 in the 0 hr control sample 
indicates the endogenous nature of the positive mode derivatives or the free urinary 
steroids. The level of X27 does not increase in the 12 hr control sample, but that of X37 
significantly increases in the 12 hr sample compared to the 0 hr sample. Further, X27 and 
X37 are slightly increased upon enzyme treatment. Therefore, P27, P37 and X37 could 
be used as potential markers to detect TP administration. This highlights the importance 
of sulfates as markers of drug administration as described in section 1.4 (Chapter 1). The 
elevated level of X27 and X37 metabolites upon enzyme hydrolysis shows the sulfatase 
could be of use in sample processing (e.g.: for GC-MS). 
Due to the limited resources, this study was performed as technical duplicates. 
Performing this study as biological replicates is one way the study could be extended and 
improved. Observing an ion loss of m/z 81 corresponding to HSO3- indicates that it could 
be used as an additional filter when filtering the precursor ions in the ddMS/MS that 
would make the selection more comprehensive. In addition, the neutral loss of SO3 (80 
Da) has not been investigated by this method. Further, the criterion followed when 
selecting the precursor ions in ddMS/MS of having ≥ 20% relative abundance would 
mask some potential markers. If faster techniques were available for data analysis, more 
metabolites would have been identified and more potential markers would have been 
discovered by considering a lower percentage of relative abundance for the selection.  
The future direction to continue this study is to confirm the elucidated structures 
of the identified metabolites with synthesized standards by comparison of retention 
times under the same conditions 
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3.4 Experimental  
 
Unless otherwise stated the chemicals were purchased from Sigma Aldrich. 
Dehydroepiandrosterone (DHEA) was purchased from BDH (Poole, UK) and DHEAS was 
synthesized according to a published method 16. The d3-T and d3-TS (NEt3 salt) were 
purchased from the National Measurement Institute (NSW, Australia). MilliQ water was 
used in all aqueous solutions and HPLC grade methanol was used for all LC-MS related 
work. The LC-MS system specifications are detailed in section 2.6.4 (see Chapter 2). 
 
3.4.1 Acquisition of urine samples 
 
A 14-year-old 635 kg thoroughbred gelding was recruited by Charles Sturt 
University (CSU) School of Animal and Veterinary Sciences for this study.  Testoprop® 
(testosterone propionate, 250 mg) was administered by intramuscular injection in the 
neck on the opposite side to the sampling jugular catheter.  Urine samples were 
collected at -72, -48, -24, 0, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours, then daily to 28 days 
post-administration. Urine samples were stored frozen at -20 °C before and after 
transportation to the Australian Racing Forensic Laboratory (ARFL) or Australian 
National University (ANU) until analysed. This study was approved by Charles Sturt 
University’s Animal Care and Ethics Committee and was in accordance with the 
Australian Code of Practice for the Care and Use of Experimental Animals for Scientific 
Purposes (Approval number 12/083).  In addition, the research proposal and approval 
was reviewed and supported by the Racing NSW Animal Care and Ethics Committee. The 
horse tolerated the drug well with no adverse effects reported. 
One male and one female were recruited for this study. Urine samples were 
collected within two days of analysis from a healthy male aged 23 years and a healthy 
female aged 31 years. The collected urine samples were stored at 4 °C until analysed. 
The study was approved by the ANU Human Research Ethics Committee and was in 
accordance with the 2007 National Statement on Ethical Conduct in Human Research 
(Approval number 2013/654). Volunteers gave written informed consent prior to 
participation.  
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3.4.2 Quantification of d3-TS hydrolysis in a spiked urine sample 
 
All reactions were performed in 1.5 mL of 0.2 M Tris-HCl buffer (pH 7.5 at 37 °C, 
1 µM N as the internal standard) with a 2.1 mL urine component and 0.4 mL of enzyme 
or enzyme storage buffer (0.1 mM Tris HCl, pH 7.5 in 50% glycerol) in 10 mL glass tubes. 
A series of d3-T calibrators at 0, 1, 5, 10, 50, 100, 200, and 400 ng mL-1 in human urine 
was prepared by serial dilution of 200 µg mL-1 d3-T in methanol. A 2.1 mL aliquot of each 
calibrator was added to 1.5 mL Tris-HCl buffer and 0.4 mL of enzyme storage buffer. A 
d3-TS spiked urine sample was prepared from a 200 µg mL-1 d3-TS in methanol to give 
final d3-TS concentrations of 100, 200 or 300 ng mL-1 (61.6, 123.3, 185.0 ng mL-1 d3-T 
equivalent respectively). A 2.1 mL aliquot of blank/d3-TS spiked urine in 1.5 mL Tris-HCl 
buffer was reacted with 0.4 mL of 1 mg mL-1 or 0.1 mg mL-1 WT-PaS or LEF-PaS. Control 
reactions with either blank or spiked urine were performed with enzyme storage buffer. 
Following overnight incubation at 37 °C, 4 mL of methyl tert-butyl ether was added to 
each tube and an end-over-end rotation was performed for 30 minutes. Next, these 
tubes were centrifuged for 15 minutes at 4000 rpm and the top layer was decanted into 
new glass tubes. These samples were evaporated to dryness with a flow of N2 at 60 °C. 
The dried samples were then reconstituted with 200 µL of 60% MeOH and were 
transferred into HPLC vials with inserts. Test samples and calibrators (10 µL) were 
injected into UPLC-MS system and signals for d3-T and N were detected in the positive 
mode as the proton adduct, [M+H]+ at m/z 292.4 and m/z 275.2 respectively. 
 
3.4.3 Testing endogenous DHEAS hydrolysis in human urine 
 
All reactions were performed in 1.5 mL of 0.2 M tris-acetate buffer (pH 7 or pH 9 
at 37 °C, 1 µM nandrolone as the internal standard) with a 2.1 mL urine component and 
0.4 mL of enzyme or enzyme storage buffer (0.1 mM tris HCl, pH 7.5 in 50% glycerol) in 
10 mL glass tubes. A series of DHEA calibrators of 0, 1, 5, 10, 50, 100, 500, 1000, 1500 
ng mL-1 was prepared in human urine by serial dilution of 150 µg mL-1  DHEA in methanol. 
Then 2.1 mL of each calibrator was added to 1.5 mL tris-acetate buffer and 0.4 mL of 
enzyme storage buffer. A 2.1 mL aliquot of blank urine was added to 1.5 mL tris-acetate 
buffer and was reacted with 0.4 mL of 1 mg mL-1 WT-PaS or PVFV-PaS. Control reactions 
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at both pHs were performed with enzyme storage buffer instead of enzyme. Following 
overnight incubation at 37 °C, 4 mL of methyl tert-butyl ether was added to each tube 
and an end-over-end rotation was performed for 30 minutes. Next, these tubes were 
centrifuged for 15 minutes at 4000 rpm and the top layer was decanted into new glass 
tubes. These samples were evaporated to dryness with a flow of N2 at 60 °C. The dried 
samples were then reconstituted with 200 µL of 60% MeOH and were transferred into 
HPLC vials with inserts. Finally, 20 µL of the test samples and calibrators were injected 
into LCMS system and signals for DHEA and nandrolone were detected in the positive 
mode as the proton adduct, [M+H]+ at m/z 289.2 and m/z 275.2 respectively.  
 
3.4.4 Calibration plots of the standards 
 
The LINEST function in Microsoft Excel was used to determine the detection limit 
of the tests carried out in this chapter. This function uses the least squares method to 
calculate a straight line that best fits the data (of the calibrators). A new set of y values 
were assigned by using the calculated slope and the intercept from the LINEST function. 
The lowest calibrator where the deviation of the observed and the calculated values are 
less than 20% was considered the lower limit of quantification (LLOQ).  
 
Table 3.13: The range and limit of quantification of each experiment. 
 
Section Experiment Range  
(ng mL-1) 
LLOQ  
(ng mL-1) 
3.2.1 Quantification of d3-TS hydrolysis in a spiked urine 
sample with 100 µg mL-1 enzyme 
10-400 10 
3.2.1 Quantification of d3-TS hydrolysis in a spiked urine 
sample with 10 µg mL-1 enzyme 
5-200 5 
3.2.2 Testing endogenous DHEAS in human urine at pH 7 10-500 10 
3.2.2 Testing endogenous DHEAS in human urine at pH 9 10-500 10 
 
 
3.4.5 Untargeted screening 
 
3.4.5.1 Sample treatment 
Four urine samples were subjected to untargeted screening; the two human urine 
samples, and two equine urine sample at 0 and 12 hours post-administration of 
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testosterone propionate (TP). Three reactions were performed for each sample in 
singlicates; a control reaction with the enzyme storage buffer, a WT-PaS (2 mg mL-1) 
reaction, and a PVFV-PaS (2 mg mL-1) reaction. All reactions were performed in 1.5 mL 
of 0.2 M Tris-HCl buffer (pH 7.5 at 37 °C, 1 µM nandrolone as the internal standard for 
positive mode detection) with 2.1 mL urine sample and 0.4 mL of enzyme storage buffer 
(0.1 mM Tris HCl, pH 7.5 in 50% glycerol for the control reaction) or enzyme (WT-PaS or 
PVFV-PaS) in 10 mL glass tubes. All samples were incubated overnight at 37 °C. Following 
incubation, the samples were centrifuged at 4000 rpm for 15 minutes (Rotofix 32 Hettich 
centrifuge). Next, solid phase extraction (SPE) was performed on each sample using 
Waters Oasis WAX SPE cartridges by a protocol described by Waller et al.17. Briefly, the 
cartridges were preconditioned with MeOH (1 mL) followed by water (2 mL). The 
supernatants of the centrifuged samples were loaded to the preconditioned cartridges 
and washed with 0.1 M NaOH (2 mL), 0.2 M Tris-HCl buffer (2 mL) and water (2 mL). The 
metabolites and the hydrolysed products were eluted into new 10 mL glass tubes with 
a mixture of ethyl acetate : methanol : diethylamine (25:25:1 v/v/v, 2 mL). Next 1.5 µL 
of 1 mM nandrolone sulfate (NS) was added to each tube as an internal standard for the 
negative mode detection. All samples were evaporated to dryness with a flow of N2 at 
60 °C. The dried samples were stored at -20 °C until analysis. The samples were 
reconstituted in 200 µL of 60% MeOH before the analysis. 
 
3.4.5.2 Analytical method 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis was 
performed on ThermoFisher QExactive Plus ™ (Thermo Fisher, Scoresby, Victoria) 
Orbitrap mass spectrometer equipped with a Thermo Accucore C18 AQ column (2.1 mm 
x 100 mm x 2.6 µm). The HPLC method consisted of a flow rate of 0.4 mL/min with a 
gradient elution of the following mobile phases; A: 10 mM ammonium formate in 100% 
water, B: 10 mM ammonium formate in 99% methanol:water, gradient: 0-3 min A:B 
(99:1, v/v), 3-15 min A:B (40:60, v/v), 15-18 A:B (0:100, v/v), 18-20 (0:100, v/v), 20-20.1 
min A:B (99:1, v/v) and 2.9 min equilibration time. The column oven temperature was 
set to 40 °C, and the injection volume was 1 µL. The samples were analysed as two 
injections each, in both polarities in full scan mode at a resolution of 70000 and the top 
10 precursor ions per duty cycle on ddMS/MS at a resolution of 17500 and a normalized 
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collision energy of 35%. The scan range targeted was m/z 200-800 in full scan and 50-
800 in ddMS/MS.   
 
3.4.5.3 Data analysis 
 Data analysis was performed using XCalibur 4.0 software that involved several 
key steps; applying filters to identify metabolites corresponding to a loss of a sulfate 
moiety on ddMS/MS data; integration of the areas under the peaks of the selected 
analytes in full scan mode; identifying the possibilities of molecular formulae; 
determination of the possible structures from the reported compounds and identifying 
and integrating the corresponding hydrolysis products in positive mode.    
The previously reported characteristic mass spectrometric behaviour (Figure 3.6) 
of the sulfated metabolites 12 was considered in the data dependent acquisition. A 
precursor ion scan was performed in ddMS/MS negative mode by considering the 
common ion loss of m/z 97 corresponding to HSO4- and m/z 80 corresponding to ·SO3- 
with a mass tolerance of 10 ppm. The product ion spectra of all precursor ions 
corresponding to ≥ 20% of the relative abundance in the sulfate filters applied were 
analysed. The m/z value of the precursor ion and the other ions with more than 5% 
relative abundance present in the product ion spectra were recorded with their relative 
abundance. The data analysis targeted the identification of mono-sulfated and bis-
sulfated steroid metabolites. Therefore, based on the fragmentation patterns and the 
previously reported data, the precursor ions were predicted as mono-sulfates or bis-
sulfates. These metabolites were also classified according to the calculated mass range 
for steroids; the metabolites out of the steroidal mass range and the mono-sulfates 
within the mass range but with an even mass ion as non-steroids.  
Next, the amount of steroid sulfate detected was evaluated by the integration of 
the chromatographic peaks of the selected precursor ions with a mass tolerance of 5 
ppm in the full scan mode. The integrated peak areas were normalized with respect to 
the nandrolone sulfate internal standard ([M-H]-) in the corresponding run. The 
averages of the normalized peak areas of the two technical replicates of the enzyme 
treated samples were compared with the corresponding average of the control sample. 
All the metabolites that fell within the calculated steroidal mass range were selected for 
further investigation. The possibilities for the molecular formulae of the selected 
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analytes were determined by including C, H, O, S, N and P as the expected elements 
composing the metabolites with the appropriate charge and constraining the search to 
a mass tolerance of 3 ppm. The search encompassed limits for the mono-sulfates to 
contain a minimum of one S and four O atoms and for the bis-sulfates to contain two S 
and eight O atoms.  
Based on the calculated masses of the completely hydrolysed products (Figure 
3.11), the positive derivatives were determined. These masses were scanned in the 
positive polarity of full scan data with a mass tolerance of 5 ppm for the metabolites 
that resulted in a steroidal molecular formula with the minimum number of C atoms ≥ 
18. The probable peaks were integrated and were normalized with respect to the 
nandrolone internal standard ([M+H]+). They were compared with the respective control 
sample for evaluation of the enzyme hydrolytic activity. The presence of the correlated 
molecular formulae of the hydrolysed products were determined by a similar approach 
to the formulae determination of the analytes in the negative mode. Finally, the 
structures were proposed from the derived molecular formulae and the fragmentation 
patterns based on the reported structure on SciFinder molecular formula search tool. 
All the structures that resulted from this tool were filtered based on the following 
criteria: 1) should contain at least one -OSO3- group; 2) no heterocyclic steroids (as 
endogenous steroids with a heterocyclic structure are not reported); 3) no heavy-atom 
isotopes.   
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Chapter 4                Concluding remarks        
         and Future Directions 
 
Exploitation of steroids by athletes is an ongoing concern in the sporting arena 
that demands improved doping control solutions. With the growing importance of 
detecting the sulfate metabolites of steroids, the significance of a suitable sulfatase 
enzyme was discussed. Therefore, the primary objective of this study was to engineer 
an enzyme for improved steroid sulfate hydrolysis. From a range of sulfatases previously 
reported for the hydrolysis of steroid sulfates 1, the arylsulfatase from Pseudomonas 
aeruginosa (PaS) was selected as the potential candidate. However, it required 
improvements on substrate scope and activity to be used for anti-doping applications. 
The PaS enzyme was engineered by a semi-rational approach to discover mutants with 
improved catalytic activity for testosterone sulfate (TS) hydrolysis and to improve the 
steroid sulfate substrate scope. This included mutating five residues in turn by SSM, 
three small groups of neighbouring residues simultaneously and finally shuffling all the 
beneficial mutations found in the pathway of enzyme engineering. 
The substrate binding mode for PaS was unknown. With the structural data in 
hand, two poses for PaS binding were proposed by molecular modelling in collaboration 
with Dr. Thomas Balle at the Faculty of Pharmacy, University of Sydney. Therefore, as a 
first step, the residues around the two poses proposed for substrate binding were 
explored in turn by SSM. The results of these SSM libraries strongly implicated that pose 
II is the preferred pose for substrate binding where R155 and K330 residues are located 
at the opening of the pocket (Figure 4.1).  
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Figure 4.1: Pose II with the substrate, DHEAS, (dark blue) docked into the 
model derived from the crystal structure (1HDH) 2. The R155 and K330 residues 
mutated by SSM are shown in pink. 
 
Employing LC-MS technique for screening, limited the size of the MSM libraries to 
a few thousand. Hence the library size was restricted by reducing the amino acid 
alphabets 3-5 that the targeted residues were mutated to. Though this strategy resulted 
in significantly improved mutants it nevertheless had the disadvantage of potentially 
missing some positive mutants. However, as a high throughput colourimetric assay was 
thought unlikely to lead to improved mutants for TS hydrolysis, the coverage had to be 
compromised to minimise the library size.  
After screening eight libraries for TS hydrolysis by cautious selection of twelve 
residues and one shuffled library of the beneficial mutants from the previous rounds, 
mutants were achieved with significant improvements in catalytic activity, substrate 
scope or both. Lowering the substrate concentration used for screening from MSM 2 
library onwards, to mimic the conditions expected for real-world samples helped in 
identifying beneficial mutants with a remarkably favourable KM that would be more 
suitable with the samples encountered in anti-doping screens. The LEF-PaS mutant 
exhibits the highest catalytic activity (Vmax) for TS hydrolysis with a catalytic efficiency 
(Vmax/KM) more than 150 times than WT-PaS. In addition to LEF-PaS mutant, PVIV-PaS 
and VVIV-PaS mutants also exhibited a catalytic efficiency of more than 150 times than 
WT-PaS and significant improvement in substrate affinity. However, PVFV-PaS identified 
in an earlier round shows the broadest substrate range. Importantly, the detection of 
significant hydrolytic activity with PVFV-PaS for the α-configured steroid sulfates derived 
from etiocholanolone and epitestosterone was a breakthrough. The PVFV-PaS mutant 
K330 
R155 
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hydrolyses ECS in a rate of two orders of magnitude higher than WT-PaS. This revealed 
that although the substrate scope improved at the early stages of screening, continued 
screening for a single substrate was detrimental for the substrate scope. The PVFV-PaS 
mutant now serves as the starting point for further research targeting improved mutants 
for the hydrolysis of α-configured steroid sulfates. Optimising the screening process for 
simultaneous evolution for multiple substrates that consist of α-configured or β-
configured steroid sulfates, would be useful to greatly minimize the screening efforts. 
With improved variants for different substrates, a cocktail of enzymes could be used for 
steroid sulfate hydrolysis in anti-doping. The PVFV-PaS and LEF-PaS mutants also show 
modest improvements in thermostability. 
It was also found that the optimum pH of PaS for the hydrolysis of alkyl steroid 
sulfates such as testosterone sulfate lies towards a slightly acidic pH. This indicates the 
importance of a general acid for the protonation of the leaving group of such substrates 
whereas aryl sulfates such as PNPS do not essentially require a general acid for the 
protonation of the leaving group 6 and hence the alkaline pHs would be best suitable for 
PNPS hydrolysis. Further, phosphate buffer was found to inactivate PaS and should not 
be used for PaS related experiments or application.  
The importance of E74 residue in the hydrolysis of steroid sulfates was uncovered 
by the inactive MSM 3 library that resulted upon mutagenesis of this residue. Targeted 
mutagenesis of E74 confirmed the necessity of this residue. This result has led to the 
hypothesis that PaS requires a catalytic triad where E74 polarises H115 that then 
activates the FGH for the nucleophilic substitution on the sulfate ester or elimination of 
the sulfate group. Future study of this previously unrecognized catalytic residue could 
shed light on mechanism of PaS and related enzymes.  
For further improvements of PaS, understanding the interactions of the catalytic 
residues with substrates of different orientations and steriochemistry will also be 
important. Performing molecular modelling or crystallization would provide useful 
information on this. A comprehensive modelling of PaS enzyme is currently being carried 
out to further characterize enzyme-substrate interactions. 
Hydrolysis of steroids by PaS in real world samples indicated that the enzyme has 
good catalytic activity in a urine matrix and can be efficiently used in the conditions 
analogous to β-glucuronidase used in a typical anti-doping screen. The untargeted 
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screen of pre- and post-administration of testosterone propionate (TP) horse urine 
samples identified three metabolites that could be potential markers for TP 
administration. The untargeted screen would provide more important information if the 
predicted structures can be confirmed by comparing with synthesized reference 
materials. Specially confirming the identified potential markers of TP administration 
would be very important to be useful in anti-doping.  
The PaS enzyme has already received international interest from the anti-doping 
community and WT-PaS and PVFV-PaS have been sent to WADA accredited laboratories 
in Barcelona, Cologne and Rome for testing. The outcome of these investigations are 
eagerly awaited.  
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Appendix 
Recipes and reagents 
 
Unless otherwise specified the reagents were purchased from Sigma Alrich and 
solutions are made in miliQ water. 
 
LB (Lysogeny Broth also known as Luria Burtani media) 
Dissolve 5 g of yeast extract (Difco), 10 g of tryptone (Difco), 10 g of NaCl in 900 mL of 
water and adjust the pH to pH 7 with NaOH(aq) and top up to 1 L with water. Sterilize by 
autoclaving.   
 
LBA (Lysogeny Broth with ampicillin) 
Prepare LB as above and when cooled after autoclaving add filter sterilized ampicillin 
(Astral) at 100 g/L to give a final concentration of 100 mg/L. 
 
LB-agar 
Add 15 g/L of agar (Difco) to LB prepared as above. Sterilize by autoclaving.  
 
LBA-agar 
Prepare LB-agar as above and when cooled add filter sterilized ampicillin (Astral) at 100 
g/L to give a final concentration of 100 mg/L. 
 
TBA (Terrific Broth with ampicilin) 
Dissolve 12 g of tryptone, 24 g of yeast extract and 4 mL of glycerol in 900 mL of water. 
Separately dissolve 2.31 g of KH2PO4 and 12.54 g of K2HPO4 in 100 mL of water and 
sterilize the two solutions separately by autoclaving. Once cooled down mix the two 
solutions and add filter sterilized ampicillin at 100 g/L to give a final concentration of 
100 mg/L. 
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YENB (Yeast Extract-Nutrient Broth) 
Dissolve 7.5 g/L of yeast extract and 8 g/L of nutrient broth (Difco) in water and sterilize 
by autoclaving. 
 
5 X M9 salts 
Dissolve 64 g of Na2HPO4.7H2O (or 34 g of the anhydrous salt), 15 g of KH2PO4, 2.5 g of 
NaCl and 5 g of NH4Cl in 1 L of water and sterilize by autoclaving. 
 
EMBL trace elements  
Dissolve 5 g of EDTA, 0.83 g of FeCl3.6H2O, 84 mg of ZnCl2, 13 mg of CuCl2.2H2O, 10 mg 
of CoCl2.6H2O, 10 mg of H3BO3 ,1.6 mg of MnCl2.6H2O in 1 L of water and filter sterilize. 
 
MMTS  
Add 1.6 g of agarose (molecular biology grade) in a thoroughly rinsed autoclaved bottle 
and mix with 156 mL of water and bring the mixture to boil using a microwave oven to 
prepare the molten agarose solution. Next cool to about 60 °C and add 40 mL of 5 X M9 
salts, 2 mL of 100 X EMBL trace elements, 1.27 mL of 50 % (v/v) glycerol (autoclaved 
sterilized), 400 µL of 1 M MgCl2 & 50 mM CaCl2 (prepared in 70 % ethanol), 200 µL of 
100 g/L ampicillin (prepared in 70 % ethanol), 0.2 mM final concentration of TS 
(prepared in 70 % ethanol) 20 µL of 0.1 M IPTG (prepared in 70 % ethanol). Mix the 
solution gently but thoroughly by tipping end over end to avoid bubbles and to ensure 
uniform distribution. 
 
No sulfur storage media 
Filter sterilize 20 mL of 50 % (v/v) glycerol, 10 mL of 5 X M9 salts, 500 µL of EMBL trace 
elements and 100 µL of 1M MgCl2 and 50 mM CaCl2 dissolved in 19.4 mL of water.  
 
Cracking buffer (include β-mercaptoethanol) 
Add 120 µL of 0.1 % (w/v) bromophenol blue (Merck), 1.12 mL of 80 % (v/v) glycerol 
(Merck), 800 µL of 2 M Tris (pH 6.8), 2 mL of 10 % (w/v) SDS, 31 mg/mL dithiothreitol 
and volume up to 10 mL with water. Prior to use, β-mercaptoethanol is added to give a 
final amount of 5 % (v/v). 
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1x Running buffer (for SDS-PAGE) 
Dissolve 14.4 g of glycine (Merck), 3 g Tris and 1 g of SDS (Merck) in 1 L of water.  
 
1x SB (Sodium borate) buffer 
Prepare 0.01 M NaOH  (Ajax) in water at pH 8, pH adjusted by boric acid.  
 
Buffer A 
Prepare 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, and 0.1 mM CaCl2. The pH is adjusted 
by HCl. 
 
Buffer B 
Prepare 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.1 mM CaCl2 and 200 mM imidazole. 
The pH is adjusted by HCl. 
 
TMA buffer 
Prepare a 2X concentrated buffer by dissolving 100 mM Tris, 50 mM MES and 50 mM 
acetic acid and adjusting the pH by HCl or NaOH(aq). 
 
Steroid stock solutions 
The 10 mM, 5 mM  or 1 mM stock solutions of steroids were prepared in HPLC grade 
MeOH. 
 
Steroid sulfate stock solutions 
The 20 mM, 10 mM or 5 mM stock solutions of steroid sulfates were prepared in milliQ 
water. 
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Oligonucleotides 
 
Table A1: Oligonucleotide primers used for mutagenesis 
Primer 
No. 
Primer sequence 
P1-f GAACTG(NNS)GGTATGCGTGCTATCCG 
P2-r CCTTTCAGAAT(SNN)CGGGGTAGACTC 
P3-r GAATTTCGG(SNN)CGCCTCCAGC 
P4-r CCGGACCGAA(SNN)CGGGAACGCC 
P5-r GATCCGGACC(SNN)TTTCGGGAAC 
P6-f CTGACCCGTGAGTGGGAGG 
P7-f GACGAGTCTACCCCGCCC(NYS)CTGAAAGGTACCC 
P8-r GATCCGGACC(SRN)CACCGGGAACGCCTC(SRN)CAGCGCACCCTC 
P9-f CGCTG(NYS)GAGGCGTTCCCGGTG(NYS)GGTCCGGATC 
P10-r CTTTCAG(SRN)GGGCGGGGTAG 
P11-f TATGTGGAGGACGAACGCTATCTGGATACT 
P12-r GGGTAGACTCGTCGTACGG 
P13-f GAGCCGCCGTACGACGAGTCTACCCCGCCC(VTT)(NYS)(NYS)GGT(NYS)CCGGCTCTG 
P14-r CCAGATAGCGTTCGTCCTCCACATACAGAGCCGG(SRN)ACC(SRN)(SRN)(AAB)GGGCG 
P15-f GGCACCGACCACCATATCGCGGGTATTGGTACC(NYS)GCA(NYS)GCCTTGAC 
P16-r CGTAACCCGGCTTACCCTCCAATTCTGGGGTCAAGGC(SRN)TGC(SRN)GGTACCAA 
P17-f CCCAGAATTGGAGGGTAAGCC 
P18-r TACCCGCGATATGGTGGTC 
P19-f GTGCGCTG(TTS)GAGGCGTTC         
P20-f CTACCCCG(CST)(VTT)(STG)(RWA)GGT(WCC)CCGGCTCTGTATG 
P21-f CACAATTCCACAACGGTTTC 
P22-r CGAAAGGCTCAGTCGAAAG 
P23-f CACAACGGTTTCCCTCTAGAAATAATTTTG 
P24-r CTGCCAGGCATCAAATAAAACGAAAG 
P25-r GAGAGAGAGAGAGAGAGAGAGAGAGGCCGATGGTAGTGTGGGGAC 
P26-r GAGAGAGAGAGAGAGAGAGAGAGAGG 
P27-f ATTGGTACCATGGCA(CAA)GCCTTGAC 
P28-f ATTGGTACCATGGCA(GAT)GCCTTGAC 
P29-f ATTGGTACCATGGCA(GCA)GCCTTGAC 
P30-f CTCGAAAATAATAAAGGGAAAATCAG 
P31-r TGGTAGTGTGGGGACTC 
The mutated codons are in bold text within brackets. 
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Table A2: Randomized positions, methods of mutagenesis and oligomers used in each 
library. Library name abbreviations are specified in the main text. 
 
Table A3: The library template and the screening conditions of each library 
 
 
Library 
Index 
Library 
name 
amino acid positions 
mutated 
Mutagenesis 
method 
Oligomers used 
1 SSM 1 F328 
Megaprimer 
method 
PCR 1: P21-f / P3-r 
PCR 2: PCR 1 / P22-r 
2 SSM 2 F463 
Megaprimer 
method 
PCR 1: P1-f / P24-r 
PCR 2: P23-f / PCR 1 
3 SSM 3 F331 
Megaprimer 
method 
PCR 1: P6-f / P5-r 
PCR 2: P21-f / PCR 1 
PCR 3: PCR 1 / P22-r 
PCR 4: P21-f / PCR 2 + PCR 3 / P22-r 
4 SSM 4 K330 
Megaprimer 
method 
PCR 1: P6-f / P4-r 
PCR 2: P21-f / PCR 1 
PCR 3: PCR 1 / P22-r 
PCR 4: P21-f / PCR 2 + PCR 3 / P22-r 
5 SSM 5 R155 
Megaprimer 
method 
PCR 1: P21-f / P2-r 
PCR 2: PCR 1 / P22-r 
6 MSM 1 I156/L325/F331 
Gibson 
Assembly 
method 
PCR 1: P7-f / P8-r 
PCR 2: P9-f / P10-r 
7 MSM 2 I156/L157/K158/T160 RQ method 
PCR 1: P11-f / P12-r 
Insert: P13-f / P14-r 
8 MSM 3 M72/E74 RQ method 
PCR 1: P17-f / P18-r 
Insert: P15-f / P16-r 
9 Shuffled 
R155/I156/L158/K158/ 
T160/L325/K330 
Megaprimer 
method 
PCR 1: P19-f / P25-r 
PCR 2: P20-f / PCR 1 / P26-r 
PCR 3: P23-f / PCR 2 / P26-r 
Library 
Index 
Library 
name 
Template Screening conditions 
1 SSM 1 WT-PaS 100 μM TS, pH 9, 37 °C 
2 SSM 2 WT-PaS 100 μM TS, pH 9, 37 °C 
3 SSM 3 WT-PaS 100 μM TS, pH 9, 37 °C 
4 SSM 4 WT-PaS 100 μM TS, pH 9, 37 °C 
5 SSM 5 WT-PaS 100 μM TS, pH 9, 37 °C 
6 MSM 1 PV-PaS 100 μM TS, pH 9, 37 °C, 
7 MSM 2 PV-PaS 20 μM TS, pH 7, 37 °C, Nandrolone-IS 
8 MSM 3 PVFV-PaS 20 μM TS, pH 7, 37 °C, Nandrolone-IS 
9 Shuffled WT-PaS/PV-PaS 20 μM TS, pH 7, 37 °C, Nandrolone-IS 
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AtsA sequence 
 
Amino acid sequence of native PaS with the additional hexa-histidine tag at the C-
terminus The residues subjected to mutagenesis are highlighted in green.  
 
        10         20         30         40         50         60  
MSKRPNFLVI VADDLGFSDI GAFGGEIATP NLDALAIAGL RLTDFHTAST CSPTRSMLLT  
 
        70         80         90        100        110        120  
GTDHHIAGIG TMAEALTPEL EGKPGYEGHL NERVVALPEL LREAGYQTLM AGKWHLGLKP  
 
       130        140        150        160        170        180  
EQTPHARGFE RSFSLLPGAA NHYGFEPPYD ESTPRILKGT PALYVEDERY LDTLPEGFYS  
 
       190        200        210        220        230        240  
SDAFGDKLLQ YLKERDQSRP FFAYLPFSAP HWPLQAPREI VEKYRGRYDA GPEALRQERL  
 
       250        260        270        280        290        300  
ARLKELGLVE ADVEAHPVLA LTREWEALED EERAKSARAM EVYAAMVERM DWNIGRVVDY  
 
 
       310        320        330        340        350        360  
LRRQGELDNT FVLFMSDNGA EGALLEAFPK FGPDLLGFLD RHYDNSLENI GRANSYVWYG  
 
       370        380        390        400        410        420  
PRWAQAATAP SRLYKAFTTQ GGIRVPALVR YPRLSRQGAI SHAFATVMDV TPTLLDLAGV  
 
       430        440        450        460        470        480  
RHPGKRWRGR EIAEPRGRSW LGWLSGETEA AHDENTVTGW ELFGMRAIRQ GDWKAVYLPA  
 
       490        500        510        520        530        540  
PVGPATWQLY DLARDPGEIH DLADSQPGKL AELIEHWKRY VSETGVVEGA SPFLVRHHHH  
 
 
HH 
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PaS enzyme parameters 
 
Important enzyme (native) parameters of WT-PaS 
 Number of amino acids: 536 
 Theoretical pI: 5.50 
 Extinction coefficient: 102790 M-1 cm-1 
Beneficial mutations 
Table A4: Molecular weight of the beneficial PaS mutants and WT-PaS 
 
 
 
 
 
 
 
 
 
 
 
 
Grey highlights: Mutations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mutational residue Molecular weight with the 
hexa-histidine tag (Da) PaS enzyme 155 156 157 158 160 325 330 
WT-PaS R I L K T L K 60768 
P-PaS P I L K T L K 60709 
T-PaS T I L K T L K 60713 
V-PaS R I L K T L V 60739 
TV-PaS T I L K T L V 60684 
PV-PaS P I L K T L V 60680 
PVFV-PaS P V L K T F V 60700 
PVIV-PaS P I V I T L V 60651 
VVIV-PaS R V V I T L V 60696 
LEF-PaS R L L E T F K 60803 
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LC-MS parameters 
 
Table A5: Parameters for analyte detection by LC-MS using ESI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte Abbr. Ion m/z Capillary 
V 
Frag. V 
androsterone A [M+H]+ 291.2 3000 120 
androsterone 3-sulfate AS [M-H]- 369.2 3000 200 
boldenone B [M+H]+ 287.2 1500 100 
boldenone 17-sulfate BS [M-H]- 365.1 3000 200 
dehydroepiandrosterone DHEA [M+H]+ 289.2 4000 100 
dehydroepiandrosterone 3-sulfate DHEAS [M-H]- 367.2 3000 200 
epiandrosterone EA [M+H]+ 291.2 5000 110 
epiandrosterone 3-sulfate EAS [M-H]- 369.2 3000 200 
epitestosterone ET [M+H]+ 289.2 1500 120 
epitestosterone 17-sulfate ETS [M-H]- 367.2 3000 200 
estrone E [M-H]- 269.2 4000 180 
estrone 3-sulfate ES [M-H]- 349.1 4000 180 
etiocholanolone EC [M+H]+ 291.2 4000 120 
etiocholanolone 3-sulfate ECS [M-H]- 369.2 3000 200 
nandrolone N [M+H]+ 275.2 1500 100 
nandrolone 17-sulfate NS [M-H]- 353.1 3000 200 
testosterone T [M+H]+ 289.2 1500 120 
testosterone 17-sulfate TS [M-H]- 367.2 3000 200 
d3-testosterone  d3-T [M+H]+ 292.4 1500 120 
d3-testosterone  d3-TS [M+H]+ 370.4 3000 200 
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Steroidal structure search 
 
Table A6: The resulted steroidal structures for each possible chemical formula in the 
female and horse samples of interest 
 m/z Steroidal structure 
A1 
C7 
  
  
  
224.0614 
(-2) 
(C15 H31 O8 N P S2)2- 
No matches 
 
 
(C19 H28 O8 S2)2- 
  
  
A2 
N8 
N10 
383.1538 
(-1) 
(C12 H27 O4 N6 S2) 1- 
No matches 
 
 
(C15 H30 O6 N P S) 1- 
No matches 
 
 
(C19 H27 O6 S) 1- 
 
 
 
 
 
 
C4 232.059 (C15 H31 O9 N P S2)2- 
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N4 
  
  
  
  
  
(-2) 
  
No matches 
 
 
(C19 H28 O9 S2) 2- 
  
  
C6 231.0511 
(-2) 
C17 H24 O8 N3 S2 
No matches 
 
 
(C19 H26 O9 S2) 2- 
 
 
 
 
 
 
 
 
 
 
C10 238.0773 
(-2) 
(C17 H35 O8 N P S2) 2- 
No matches 
 
 
(C21 H32 O8 S2) 2- 
 
C11 367.1588 
(-1) 
(C13 H28 O4 N4 P S) 1- 
No matches 
 
 
(C15 H30 O5 N P S) 1- 
No matches 
 
 
(C17 H25 O4 N3 S) 1- 
No matches 
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(C19 H27 O5 S) 1- 
 
 
N7 
N9 
 
384.1475 
(-1) 
(C12 H29 O4 N6 S2) 1- 
No matches 
 
 
(C15 H32 O6 N P S) 1- 
No matches 
 
 
(C19 H29 O6 S) 1- 
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N11 
N12 
369.1745 
(-1) 
(C15 H32 O5 N P S) 1- 
No matches 
 
(C19 H29 O5 S) 1- 
 
M2 246.0749 
(-2) 
(C17 H35 O9 N P S2) 2- 
No matches  
 
(C21 H32 O9 S2) 2- 
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P27 232.0590 
(-2) 
 
(C13 H29 O8 N4 P S2) 2- 
No matches 
 
 
(C14 H30 O8 N3 S3) 2- 
No matches 
 
 
(C15 H31 O9 N P S2) 2- 
No matches 
 
 
(C17 H26 O8 N3 S2) 2- 
No matches 
 
 
(C19 H28 O9 S2) 2- 
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P37 369.1743 
(-1) 
(C13 H30 O4 N4 P S) 1- 
No matches 
 
 
(C14 H31 O4 N3 S2) 1- 
No matches 
 
 
(C15 H32 O5 N P S) 1- 
No matches 
 
 
(C17 H27 O4 N3 S) 1- 
No matches 
 
 
(C19 H29 O5 S) 1- 
 
 
 
 
 
 
 
 
 
 
 
 
*The structures containing 35S, 14C, D and T isotopes are disregarded 
 
 
  
 
